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Summary 
Background: Schistosomiasis, accounted among the neglected tropical diseases (NTDs), 
represents a major public health problem, particularly in Africa, where more than 95% of all 
the cases of the world are currently concentrated. The health consequences of Schistosoma 
infection are considerable. Apart from the known long-term complications of a chronic 
infection (e.g. portal hypertension, kidney failure, bladder cancer and sterility), 
schistosomiasis is a debilitating disease leading to anaemia, malnutrition, chronic abdominal 
and pelvic pain, and diarrhoea. 
In 2001, the World Health Assembly (WHA) adopted resolution 54.19, which urged 
member states to regularly treat at least 75% and up to 100% of all school-aged children at 
risk of schistosomiasis and other high-risk groups. Moreover, in 2006, the World Health 
Organization (WHO) launched the “preventive chemotherapy” (PCT) strategy, which relies 
on the regular administration of anthelminthic drugs to at-risk populations in an integrated 
manner. Following these international calls for action against NTDs, several African 
countries, including Niger, launched national control programmes based on PCT with support 
from partners. 
The aims of the present PhD thesis in epidemiology were (i) to assess the morbidity of 
schistosomiasis in infants and preschool-aged children currently not included in PCT; (ii) to 
evaluate praziquantel (PZQ) efficacy using different treatment schemes, including a detailed 
analysis of cost; and (iii) to enhance the control of schistosomiasis and other NTDs in Niger. 
Methods and principal findings: First, achievements and remaining challenges of 
schistosomiasis and soil-transmitted helminthiasis (STH) control in three countries of West 
Africa (i.e. Burkina Faso, Mali and Niger) that benefited from support of the Schistosomiasis 
Control Initiative (SCI) have been analysed. In the first 3 years of the control programmes, 
nearly 13.5 million doses of PZQ have been administrated against schistosomiasis and 
albendazole against STH with coverage rates varying between 67% and 94%. The PZQ 
treatments have resulted in a reduction of the prevalence and intensity of Schistosoma 
infection in sentinel cohorts that were set up to monitor and evaluate the national control 
programmes. Key challenges these national control programmes are currently facing include 
the ability to maintain the reduction in morbidity achieved so far and ensuring sustainability. 
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Second, we assessed morbidity due to schistosomiasis in infants and preschool-aged 
children who are currently not included in PCT according to WHO guidelines, including risk 
factors for infection in early childhood. We carried out a cross-sectional epidemiological 
survey in two villages in Niger: Falmado that is endemic for Schistosoma haematobium only, 
and Diambala that is a mixed S. haematobium-S. mansoni focus. A total of 282 children were 
examined (149 girls, 133 boys; average age, 2.6 years) and 224 mothers (average age, 30.1 
years). For S. haematobium diagnosis, two urine samples obtained over consecutive days 
were subjected to a standard filtration method, while the diagnosis of S. mansoni was based 
on a single stool sample using duplicate Kato-Katz thick smears. Additionally, in Diambala, a 
pre-tested questionnaire was administered to mothers, which recorded demographic data, 
recent treatment history with anthelminthic drugs, household sanitation and water supply and 
bathing practices for their children. Prevalence of egg-patent S. haematobium infection among 
young children and their mothers was, respectively, 51% and 56% in Falmado, and 61% and 
72% in Diambala. The prevalence of S. mansoni infection in Diambala was 44% among 
children and 52% in mothers. Mixed egg-patent infections of S. haematobium and S. mansoni 
were revealed in 29% of the children and 37% of the mothers. Results from the questionnaire 
survey showed that 70% of the children were accompanied by their mothers to 
schistosomiasis transmission sites before reaching their first birthday, and that three-quarter of 
the mothers used water directly drawn from the irrigation canals to wash their children. 
Third, we evaluated the efficacy and safety of two closely spaced doses of PZQ against 
S. haematobium and S. mansoni in school-aged children, and characterised re-infection 
patterns over a 1-year period. The study was carried out in five villages in western Niger: 
Falmado, Seberi, Diambala, Namarigoungou and Libore. Parasitological examinations 
consisted of triplicate urine filtrations and triplicate Kato-Katz thick smears at each visit. Two 
40 mg/kg oral doses of PZQ were administered 3 weeks apart. Follow-up visits were 
conducted 6 weeks, 6 months and 12 months after the first dose of PZQ. Adverse events were 
monitored within 4 hours after dosing by the survey team and 24 hours after treatment using a 
questionnaire. Our final study cohort comprised 877 children who were infected with either 
S. haematobium, or S. mansoni, or both species concurrently and received both doses of PZQ. 
At baseline, the geometric mean (GM) infection intensity of S. haematobium ranged from 3.6 
(Diambala) to 30.3 eggs/10 ml of urine (Falmado). The GM infection intensity of S. mansoni 
ranged from 86.7 (Diambala) to 151.4 eggs/gram of stool (EPG) (Namarigoungou). Adverse 
events were reported by 33% and 1.5% of the children after the first and second dose of PZQ, 
Summary 
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respectively. We found cure rates in S. haematobium-infected children 3 weeks after the 
second dose of PZQ ranging between 49% (Falmado) and 98% (Namarigoungou) and high 
egg reduction rates (92-100%). Regarding S. mansoni, only moderate cure and egg reduction 
rates were found (52-59% in Diambala, 55-60% in Namarigoungou). 
Fourth, in order to generate additional evidence regarding the safety and efficacy of PZQ 
for schistosomiasis in infants and preschool-aged children, we pursued a drug efficacy trial 
using PZQ syrup (Epiquantel®) in children aged below 72 months. The study was carried out 
between May and August 2010 in three villages. Overall, 243 children infected with 
S. haematobium and/or S. mansoni were treated with PZQ syrup at a dose of 40 mg/kg after 
they had received a meal of millet porridge. Children were observed during 4 hours post-
treatment and a questionnaire was administered to the mothers the following day to determine 
adverse events. Follow-up visits consisting of three urine filtrations and triplicate Kato-Katz 
thick smears were conducted 3 and 6 weeks post-treatment. The proportion of children having 
presented early adverse events during the 4-hour period post-treatment was 33% and the 
proportion of adverse events occurring within 24 hours after treatment was 6.2%. No serious 
adverse events were recorded. The most frequent symptoms were abdominal pains (31%), 
bloody diarrhoea (16.2%) and sleepiness (15.3%). Before treatment, 165 children were 
infected with S. haematobium among whom 87% presented a light infection (1-49 eggs/10 ml 
of urine) and 13% a heavy infection (≥50 eggs/10 ml of urine). The overall cure rate against 
S. haematobium was 86% and 95% after 3 and 6 weeks post-treatment, respectively. Three 
and 6 months after treatment, the GM egg reduction rate for S. haematobium was 69% and 
71%, respectively. With regard to S. mansoni, 96 infected children, were treated with PZQ. 
Among them, 39% had moderated to heavy infection intensities (≥100 EPG). Observed cure 
rates were 75% and 50%, respectively, 3 and 6 weeks after treatment. The respective GM egg 
reduction rates were 67% and 19%. 
Fifth, in order to help countries in finding viable strategies that are financially acceptable 
to sustain schistosomiasis control activities, we conducted a cost-effectiveness study 
comparing a school-based and a community-based mass drug administration strategy for 
schistosomiasis and STH control in Niger. In 2006, we undertook a survey in four districts to 
estimate the economic cost per district, per treatment and per Schistosoma infection averted. 
The study compared the costs of treatment at start-up and in a subsequent year and identified 
the allocation of costs by activity, input and organization. The total economic cost of the 
Summary 
xiv 
programme, including programme-specific expenditures, national and local government costs 
and international technical support and programme co-ordination in four study districts, over 
a 2-year period, was US$ 456,718, which translates to an economic cost per treatment of US$ 
0.58. The full economic delivery cost of school-based treatment in 2005/2006 was US$ 0.76, 
while a somewhat lower cost was observed for community distribution (US$ 0.46). If only 
costs to the programme were included, the respective figures were US$ 0.47 and US$ 0.41. In 
the study district over a 2-year period, the average cost per Schistosoma infection averted was 
US$ 0.76 for children with one treatment and the cost was US$ 6.7 for adults. 
Conclusions: Sustainability of schistosomiasis and STH control programmes in sub-
Saharan Africa remains a grand challenge. Integration with other existing health 
interventions, particularly those targeting NTDs and strengthening of health systems is a way 
to ensure continued distribution of anthelminthic drugs and other interventions. At an average 
cost per treatment of US$ 0.58, control could be handled by the countries. 
A substantive proportion of preschool-aged children had egg-patent Schistosoma 
infection, inclusive of co-infection with S. haematobium and S. mansoni. Hence, in highly 
endemic areas, more attention should be paid on preschool-aged children and women of 
childbearing age, so that they can benefit from PCT, thus, increasing effective coverage of 
those infected. PZQ syrup is well tolerated in infants and preschool-aged children. The cure 
and eggs reduction rates were high against S. haematobium infection, but additional studies 
are warranted to determine the efficacy against S. mansoni. 
In school-aged children, PZQ given in two closely spaced doses is efficacious against 
S. haematobium. However, low egg reduction rate observed against S. mansoni raises concern 
about mounting PZQ tolerance. 
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Zusammenfassung 
Hintergrund: Schistosomiasis ist eine vernachlässigte tropische Krankheit, welche ein 
bedeutendes Problem für die öffentliche Gesundheit darstellt, vor allem in Afrika, wo aktuell 
mehr als 95% aller weltweit auftretenden Fälle konzentriert sind. Die gesundheitlichen 
Auswirkungen der Schistosomiasis sind beträchtlich. Abgesehen von den bekannten Langzeit 
Komplikationen einer chronischen Infektion (wie Pfortaderhochdruck, Leberversagen, 
Blasenkrebs und Unfruchtbarkeit) ist Schistosomiasis eine kräftezehrende Erkrankung welche 
zu Anämie, Mangelernährung, chronischen Unterleibsschmerzen sowie Diarrhö führen kann. 
Im Mai 2001 wurde an der ‘‘World Health Assembly“ (WHA) die Resolution Nummer 
54.19 ins Leben gerufen. Diese Resolution hält Mitgliederstaaten dazu an regelmässig 
mindestens 75% und bis 100% aller Kinder im Schulalter, welche dem Risiko einer 
Schistosomen Infektion ausgesetzt sind, sowie andere Gruppen mit hohem Risiko, 
regelmässig mit Praziquantel zu behandeln. Desweiteren führte die 
Weltgesundheitsorganisation (WHO) eine Strategie der „präventiven Chemotherapie“ (PCT) 
ein, welche sich auf eine regelmässige, integrative Verabreichung von Entwurmungsmitteln 
stützt. Diesen internationalen Aufrufen für die Bekämpfung der Schistosomiasis und anderer 
vernachlässigter Tropenkrankheiten folgend, lancierten einige afrikanische Länder, 
einschliesslich Niger, mit Hilfe von Partnern, PCT-basierte, nationale Kontrollprogramme. 
Die Ziele dieser Dissertation in Epidemiologie waren (i) die Morbidität durch 
Schistosomiasis in Klein- und Vorschulkindern, welche derzeit nicht in die PCT Strategie 
eingeschlossen sind, zu ermessen; (ii) die Wirksamkeit und Verträglichkeit von Praziquantel 
bei verschiedenen Behandlungsschemata zu evaluieren, einschliesslich einer detaillierten 
Kostenanalyse; und (iii) die Kontrolle der Schistosomiasis und anderer vernachlässigter 
Tropenkrankheiten in Niger zu stärken. 
Methoden und wichtigste Ergebnisse: Zuerst wurden die bisherigen Leistungen und 
verbleibenden Herausforderungen der Schistosomiasis und der vom Boden-übertragenen 
Wurminfektionen in drei Ländern Westafrikas (nämlich Burkina Faso, Mali und Niger), 
welche von der Unterstützung der “Schistosomiasis Control Initiative“ (SCI) profitierten, 
analysiert. In den ersten drei Jahren des Kontrollprogramms wurden annähernd 13.5 
Millionen Dosen Praziquantel gegen Schistosomiasis, und Alendazole gegen von Boden-
übertragenen Wurminfektionen verabreicht mit einer Deckungsrate zwischen 67% und 94%. 
Zusammenfassung 
xvi 
Die Praziquantel Behandlungen führten zu einer Reduktion der Prävalenz und Intensität von 
Schistosomen Infektionen in den Beobachtungskohorten welche zur Überwachung und 
Bewertung der nationalen Kontrollprogramme etabliert worden waren. Die 
Schlüsselherausvorderungen welchen diese nationalen Kontrollprogramme derzeit gegenüber 
stehen, sind das Vermögen, diesen Rückgang der Morbidität welcher bisher erreicht wurde 
beizubehalten sowie die Sicherung der Nachhaltigkeit. 
Zweitens ermassen wir die Morbidität von Schistosomiasis in Klein- und 
Vorschulkindern, welche zur Zeit nicht in der PCT wie von der WHO empfohlen 
eingeschlossen sind, einschliesslich der Risikofaktoren einer Infektion in der frühen Kindheit. 
Wir führten eine Querschnittsstudie in zwei Dörfern in Niger durch: Falmado welches 
endemisch nur für Schistosoma haematobium ist und Diambala welches ein Brennpunkt 
sowohl für S. haematobium wie auch S. mansoni ist. Insgesamt wurden 282 Kinder (149 
Mädchen, 133 Jungen; durchschnittliches Alter: 2.6 Jahre) und 224 Mütter (durchschnittliches 
Alter: 30.1 Jahre) untersucht. Für die Diagnose von S. haematobium wurden zwei Urinproben 
an zwei aufeinanderfolgenden Tagen mit der Standard Filtrationsmethode untersucht, 
während die Diagnose von S. mansoni auf der Untersuchung einer einzelnen Stuhlprobe 
mittels zweier Kato-Katz Ausstriche beruhte. Desweiteren wurden vorgetestete Fragebögen, 
welche demographische Daten, kürzliche Behandlungsgeschichten mit Entwurmungsmitteln, 
die sanitäre Situation des Haushalts und Wasserversorgung sowie Badepraktiken für die 
Kinder aufnahmen, mit den Müttern in Diambala durchgeführt. Die Prävalenz von Ei-
patenten S. haematobium Infektionen bei jungen Kindern und deren Mütter war 51% und 56% 
in Falmado, sowie 61% und 72% und Diambala. Die Prävalenz von S. mansoni in Diambala 
war 44% unter den Kindern und 72% unter den Müttern. Gemischte, Ei-patente Infektionen 
von S. haematobium und S. mansoni zeigten sich in 29% der Kinder und 37% der Mütter. Die 
Auswertung der Fragebogenstudie zeigte, dass 70% aller Kinder von ihren Müttern zu 
Schistosomiasis Übertragungsstellen begleitet wurden, bevor sie ein Jahr alt waren und dass 
drei-Viertel der Mütter Wasser welches sie direkt aus den Bewässerungskanälen bezogen 
benutzten um ihre Kinder zu waschen. 
Drittens evaluierten wir die Wirksamkeit und Sicherheit zweier eng aufeinanderfolgender 
Dosen Praziquantel gegen S. haematobium und S. mansoni bei Kindern im Schulalter und 
charaktisierten die Re-infektionsmuster über einen Zeitraum von einem Jahr. Die Studie 
wurde in den folgenden fünf Dörfern im Westen Nigers durchgeführt: Falmado, Seberi, 
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Diambala, Namarigoungou und Libore. Parasitologische Untersuchungen bestanden aus drei 
Urinfiltrationen und drei Kato-Katz Ausstrichen bei jedem Besuch. Zwei 40 mg/kg 
Praziquantel Dosen wurden in einem Abstand von drei Wochen verabreicht. Folgebesuche 
wurden 6 Wochen, 6 Monate und 12 Monate nach der ersten Praziquantel Dosis durchgeführt. 
Nebenwirkungen wurden während vier Stunden nach der Medikamentenverabreichung vom 
Studienteam, und 24 Stunden danach mittels eines Fragebogens überwacht. Unsere 
letztendliche Studienkohorte bestand aus 877 Kindern die entweder mit S. haematobium oder 
S. mansoni oder mit beiden parasitären Wurmarten zugleich infiziert waren und beide Dosen 
Praziquantel erhalten hatten. Bei der Basisstudie reichte der geometrische Mittelwert (GM) 
der Infektionsintensität von S. haematobium von 3.6 (Diambala) bis 30.3 Eier pro 10 ml Urin 
(Falmado). Der GM der Infektionsintensität von S. mansoni reichte von 86.7 (Diambala) bis 
151.4 Eier pro Gramm Stuhl (EPG) (Namarigoungou). Nebenwirkungen wurden bei 33% 
bzw. 1.5% der Kinder nach der ersten bzw. zweiten Dosis Praziquantel berichtet. Wir fanden 
Heilungsraten zwischen 49% (Falmado) und 98% (Namarigoungou) sowie hohe Ei 
Reduktionsraten (92-100%) bei S. haematobium-infizierten Kindern drei Wochen nach 
Verabreichung der zweiten Praziquantel Dosis. Für S. mansoni wurden lediglich 
mittelmässige Heilungs- und Ei Reduktionsraten gefunden (52-59% in Diambala, 55-60% in 
Namarigoungou). 
Viertens führten wir, um weitere Befunde bezüglich der Verträglichkeit und Wirksamkeit 
von Praziquantel gegen Schistosomiasis bei Klein- und Vorschulkindern zu erhalten, eine 
Wirksamkeitsstudie mit einem Praziquantel Sirup (Epiquantel® ) bei Kindern mit einem Alter 
von bis zu 72 Monaten durch. Die Studie wurde zwischen Mai und August 2010 in drei 
Dörfern in Niger durchgeführt. Insgesamt wurden 243 Kinder welche mit S. haematobium 
und/oder S. mansoni infiziert waren, mit einer Dosis von 40 mg/kg des Praziquantel Sirups 
behandelt, nachdem ihnen eine Mahlzeit aus Hirsebrei verabreicht worden war. Nach der 
Behandlung wurden die Kinder über 4 Stunden beobachtet und am darauffolgenden Tag ein 
Fragebogen mit den Müttern durchgeführt um Nebenwirkungen zu ermitteln. 
Folgeuntersuchungen bestehend aus 3 Urinfiltrationen und 3 Kato-Katz Ausstrichen wurden 3 
und 6 Wochen nach der Behandlung durchgeführt. Der Anteil Kinder, der frühe 
Nebenwirkungen während der ersten 4 Stunden nach Behandlung zeigte, lag bei 33% und der 
Anteil Nebenwirkungen welche innerhalb von 4-24 Stunden nach der Behandlung auftraten 
bei 6.1%. Es wurden keine ernsten Nebenwirkungen berichtet. Die am häufigsten 
auftretenden Symptome waren Unterleibsschmerzen (31%) sowie blutiger Durchfall und 
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Schläfrigkeit (16%). Vor der Behandlung waren 166 Kinder mit S. haematobium infiziert, von 
welchen 87% eine leichte Infektion (1-49 Eier pro 10 ml Urin) und 13% eine schwere 
Infektion (≥50 Eier pro 10 ml Urin) aufwiesen. Die Heilungsrate für S. haematobium betrug 
im Gesamten 86% drei Wochen, bzw. 95% sechs Wochen nach Behandlung. Der GM der Ei 
Reduktionsrate für S. haematobium betrug 71% drei, bzw. 77% sechs Wochen nach 
Behandlung. Gegen S. mansoni wurden 96 infizierte Kinder mit Praziquantel behandelt. Unter 
diesen hatten 39% eine mittlere bis schwere Infektion (≥100 EPG). Die beobachtete 
Heilungsrate lag bei 75% drei, bzw. 50% sechs Wochen nach Behandlung. Die 
entsprechenden GM der Ei Reduktionsraten waren 67% und 19%. 
Fünftens, um den Ländern dabei zu helfen durchführbare Strategien dafür zu finden 
die Schistosomiasis Kontrollstrategien langfristig zu gewährleisten, führten wir eine 
Kosteneffizienzstudie durch in welcher wir eine schulbasierte mit einer gemeindebasierten 
Massenbehandlungsstrategie gegen die Schistosomiasis und von Boden-übertragener 
Wurminfektionen verglichen. Unsere Studie wurde im Jahr 2006 durchgeführt in vier 
Distrikten von Niger um die wirtschaftlichen Kosten pro Distrikt, pro Behandlung und pro 
abgewendeter Schistosomen Infektion abzuschätzen. In der Studie wurden die 
Behandlungskosten beim Start und im darauffolgenden Jahr verglichen und die 
Kostenverteilung auf die Aktivitäten, den Einsatz und die Organisation identifiziert. Die 
gesamten wirtschaftlichen Kosten des Programms, einschliesslich programmspezifischer 
Ausgaben, nationaler und lokaler Regierungskosten und internationaler technischer 
Unterstützung sowie Programmkoordination von vier Distrikten betrugen 456,718 US$ über 
einen Zeitraum von zwei Jahren, was einem Kostenpunkt von 0.58 US$ pro Behandlung 
entspricht. Die vollen wirtschaftlichen Kosten für eine schulbasierte Behandlung in Jahr 
2005/2006 betrugen 0.76 US$ während für die gemeindebasierte Behandlung etwas 
niedrigere Kosten beobachtet wurden (0.46 US$). Wenn man für die jeweiligen Grafiken 
ausschliesslich die Kosten des Programms berücksichtigt, handelt es sich um 0.47 US$ bzw. 
0.41US$. Die durchschnittlichen Kosten pro abgewandter Schistosomen Infektion im 
Studiengebiet über den Zeitraum von zwei Jahren betrugen 0.76 US$ für Kinder mit einer 
Behandlung und 6.7 US$ für Erwachsene. 
Schlussfolgerungen: Die Nachhaltigkeit von Kontrollprogrammen gegen die 
Schistosomiasis und anderer vernachlässigter Tropenkrankeiten in Subsahara-Afrika bleibt 
eine gewaltige Herausforderung. Die Eingliederung in andere Gesundheitsinterventionen, vor 
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allem jener welche auf vernachlässigte Tropenkrankheiten und die Stärkung von 
Gesundheitssystemen abzielen, stellt einen Weg dar, um die kontinuierliche Verteilung von 
Entwurmungsmedikamenten und anderer Interventionen sicher zu stellen. Wir spekulieren, 
dass die durchschnittlichen Kosten von 0.58 US$ pro Behandlung von den Ländern 
gehandhabt werden können. 
Ein bedeutender Anteil Vorschulkinder hatte eine Ei-patente Schistosomen Infektion, 
inklusive Co-Infektion zwischen S. haematobium und S. mansoni. Daher sollte in 
hochendemischen Gebieten Vorschulkindern und Frauen im gebährfähigen Alter mehr 
Aufmerksamkeit geschenkt werden, damit sie von der PCT profitieren und so die effektive 
Abdeckung der Infizierten erhöht wird. Praziquantel Sirup wird von Klein- und 
Vorschulkindern gut vertragen. Gute Heilungsraten und hohe Ei Reduktionsraten wurden bei 
der S. haematobium gefunden, doch weitere Studien sind angebracht um die Wirksamkeit 
gegen S. mansoni zu bestimmen. 
Bei Kindern im Schulalter ist Praziquantel in zwei eng beieinanderliegenden Dosen 
verabreicht, wirksam gegen S. haematobium. Jedoch erweckt die niedrige Ei Reduktionsrate 
bei S. mansoni Besorgnis über eine steigende Praziquantel Toleranz. 
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Résumé 
Introduction et objectifs : Les schistosomoses qui maintenant appartiennent au groupe 
des maladies tropicales négligées représentent un problème de santé publique majeur 
particulièrement en Afrique où sont concentrés plus de 95 % de tous les cas estimés dans le 
monde. Les conséquences sanitaires des schistosomoses sont considérables. En plus des 
complications connues dues à l’infection chronique comme l’hypertension portale, 
l’insuffisance rénale, le cancer et la stérilité, la schistosomose est une maladie débilitante qui 
est aussi responsable d’anémie, de diarrhées, de malnutrition et de douleurs abdomino-
pelviennes chroniques. 
En 2001, l’Assemblée Mondiale de la Santé a adopté la résolution 54.19 qui 
demandait instamment aux états membres de traiter régulièrement 75 % et au delà de tous les 
enfants d’âge scolaire et les autres groupes à risque de schistosomose. Mieux, en 2006, 
l’Organisation Mondiale de la Santé (OMS) a lancé sa stratégie de chimio prévention qui 
repose sur l’administration régulière de médicaments anti helminthiques de manière intégrée. 
Suite à ces appels internationaux pour l’action contre les maladies tropicales négligées, 
plusieurs pays africains dont le Niger ont lancé des programmes nationaux de lutte basés sur 
la stratégie de chimio prévention avec le soutien des partenaires. 
Les objectifs de la présente thèse sont : (i) d’évaluer la morbidité de la schistosomose 
chez les nourrissons et les enfants d’âge préscolaire non encore inclus dans la stratégie de 
chimio prévention, (ii) d’évaluer la tolérance et l’efficacité du praziquantel (PZQ) selon 
plusieurs schémas thérapeutiques et (iii) de faire une analyse détaillée des coûts du traitement 
et de faire des propositions afin d’améliorer la lutte contre la schistosomose et les autres 
maladies tropicales négligées au Niger. 
Méthodes et principaux résultats : Nous avons premièrement analysé les résultats 
atteints et les défis auxquels sont confrontés les trois pays d’Afrique de l’ouest (Burkina Faso, 
Mali et Niger) soutenus par l’initiative de lutte contre la schistosomose (SCI) en matière de 
lutte contre la schistosomose et les géohelminthiases. En trois ans de mise en œuvre des 
programmes, près de 13,5 millions de doses de médicaments ont été administrées contre la 
schistosomose et les géohelminthiases avec des taux de couverture variant entre 67 % et 
94 %. Ces traitements au PZQ ont entrainé une réduction importante de la prévalence et de 
l’intensité des infections dans les sites sentinelles qui avaient été mis en place afin de suivre et 
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évaluer ces programmes. Les défis majeurs auxquels sont confrontés ces programmes sont 
leur habilité à maintenir le seuil de réduction de la morbidité obtenu et d’assurer la pérennité. 
Deuxièmement, nous avons évalué la morbidité due à la schistosomose chez les 
nourrissons et les enfants d’âge préscolaire non encore inclus dans la stratégie de chimio 
prévention recommandé par l’OMS et évaluer les risques d’infection à un âge précoce. Nous 
avons conduit une enquête transversale dans 2 villages du Niger : Falmado, qui est endémique 
pour Schistosoma haematobium et Diambala qui est un foyer d’infection mixte 
S. haematobium-S. mansoni. Au total 282 enfants avaient été examinés (149 filles, 133 
garçons, âge moyen 2,6 ans) et 224 mères (âge moyen 30,1 ans). Pour le diagnostic de 
S. haematobium deux échantillons d’urine obtenus sur 2 jours consécutifs ont été soumis à la 
technique de filtration urinaire standard, tandis que pour S. mansoni, un examen de selle selon 
la technique de Kato-Katz a été réalisé. A Diambala, un questionnaire a été administré aux 
mères afin de recueillir les données démographiques, la notion d’un traitement récent avec des 
antihelminthiques, l’approvisionnement en eau, l’assainissement et les pratiques de baignade 
de leurs enfants. La prévalence d’infection à S. haematobium chez les enfants et leurs mères 
était respectivement de 51 % et 56 % à Falmado ; et 61 % et 72 % à Diambala. La prévalence 
d’infection à S. mansoni à Diambala était de 44 % chez les enfants et 52 % chez les mères. La 
prévalence des infections mixtes S. haematobium-S. mansoni était de 29 % chez les enfants et 
37 % chez les mères. Les résultats du questionnaire ont montré que 70 % mères se font 
accompagner par leurs enfants aux sites de transmission avant qu’ils n’aient l’âge d’un an, et 
que 3 quarts des mères utilisent l’eau directement prélevée des canaux d’irrigation pour laver 
leurs enfants.  
Troisièment, nous avons évalué l’efficacité et la tolérance de deux doses de 40 mg / kg 
de PZQ administrées à trois semaines d’intervalle contre S. haematobium et S. mansoni chez 
les enfants d’âge scolaire, et la réinfection un an après. L’étude a été conduite dans 5 villages 
de l’ouest du Niger : Falmado, Seberi, Diambala, Namarigoungou et Libore. Nous avons 
procédé à trois examens parasitologiques après filtration urinaire et 3 examens de selle par 
Kato-Katz à chaque visite. Les enfants ont été suivis à 6 semaines, six mois et 12 mois après 
l’administration de la première dose de PZQ. Les réactions secondaires ont été suivies 
pendant un période de 4 heures suivant l’administration du PZQ par l’équipe et par 
questionnaire administré aux mères 24 heures après. Notre échantillon final comprenait 877 
enfants infectés par S. haematobium ou S. mansoni ou les deux simultanément et qui avaient 
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reçus les deux doses de PZQ. Avant traitement, l’oviurie géométrique moyenne de S. 
haematobium pour 10 ml d’urine variait de 3,6 à Diambala à 30,3 à Falmado, tandis que la 
moyenne géométrique d’œufs par gramme (EPG) de selles pour S. mansoni variait de 86,7 à 
Diambala à 151,4 à Namarigoungou. Des réactions secondaires ont été rapportées par 33 % et 
1,5 % des enfants respectivement après la première et la seconde dose de PZQ. Le taux de 
guérison de S. haematobium 3 semaines après la deuxième dose de PZQ variait entre 49 % à 
Falmado et 98 % à Namarigoungou avec des taux de réduction de l’oviurie allant de 92 % à 
100 %. Concernant S. mansoni, le taux de guérison et de réduction de l’excrétion ovulaire 
étaient modérés, respectivement 52 % et 59 % à Diambala, 55 % et 60 % à Namarigoungou. 
Quatrièmement, afin de générer plus d’évidence par rapport à la tolérance et à 
l’efficacité du PZQ pour la schistosomose chez les enfants d’âge préscolaire, nous avons 
conduit un autre essai clinique avec le PZQ sirop (Epiquantel®), chez les enfants âgés de 
moins de 72 mois. Cette étude a été conduite entre mai et août 2010 dans 3 villages du Niger. 
Au total 243 enfants infectés par S. haematobium et/ou S. mansoni avaient été traités avec du 
PZQ sirop à la dose de 40 mg / kg de poids après qu’un repas constitué d’une bouillie de mil 
leur ait été servi. Après traitement, les enfants ont été surveillés pendant une période de 4 
heures et un questionnaire a été administré aux mères le lendemain afin de recueillir les 
réactions secondaires. Des visites de suivi consistant en 3 examens de filtration urinaire et 3 
examens de Kato-Katz ont été conduites 3 et 6 semaines après le traitement. La proportion 
d’enfants ayant présenté des réactions secondaires précoces dans les 4 heures suivant 
l’administration du PQZ était de 33 % tandis que la proportion des réactions secondaires dans 
les 24 heures était de 6,2 %. Aucun effet indésirable grave n’a été observé. Les réactions 
secondaires les plus fréquentes étaient les douleurs abdominales (31 %), la diarrhée sanglante 
(16,2 %) et la somnolence (15,3 %). Avant traitement, 165 enfants étaient infectés par S. 
haematobium parmi lesquels 87 % avaient une infection légère (1-49 œufs pour 10 ml 
d’urine) et 13 % une infection sévère (≥50 œufs pour 10 ml d’urine). Le taux de guerison 
global à S. haematobium était respectivement de 86 % et 95 % trois et six semaines après 
traitement. Le taux de réduction de l’oviruie était quand à lui de 71 % et 77 %, respectivement 
3 et 6 semaines après traitement. En ce qui concerne S. mansoni, 96 enfants infectés avaient 
été traités au PZQ. Parmi eux, 39 % présentaient une infection modérée à forte (nombre 
d’œufs par gramme de selle >100). Le taux de guérison était de 75 % et 50 % respectivement 
3 et 6 semaines après traitement tandis que le taux de réduction de l’excrétion ovulaire était de 
67 % et 19 % respectivement. 
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Cinquièmement, afin de contribuer à la recherche de stratégies financièrement viables 
pour la pérennisation des activités de lutte contre la schistosomose, nous avons conduit une 
étude coût-efficacité comparant la distribution de médicaments à base-scolaire et la 
distribution à base communautaire. Nous avions conduit cette étude en 2006 dans quatre 
districts afin d’estimer le coût économique du programme, le coût par traitement et le coût par 
infection à S. haematobium évité. L’étude a comparé le coût au démarrage du programme et 
un an après et déterminé les coûts par activités, intrants et organisation. Le coût économique 
total du programme incluant les dépenses spécifiques du programme, les coûts locaux et les 
coûts de l’appui technique international et la coordination dans les 4 districts sur la période de 
2 ans était de 456 718 US$ tandis que le coût par traitement était de 0.58 US$. Le coût 
économique global par traitement de la stratégie à base scolaire en 2005/2006 était de 0,76 
US$ tandis que le coût de la distribution à base communautaire était de seulement 0.46 US$. 
Si seul les coûts supportés par le programme étaient considérés, les coûts par traitement 
seraient respectivement de 0,47 USD pour la stratégie à base scolaire et 0,41 USD pour la 
stratégie à base communautaire. Dans les districts enquêtés, sur la période de 2 ans, le coût 
moyen par cas de schistosomose évité était de 0,76 US$ par enfant et de 6,7 US$ par adulte. 
Conclusion : La pérennisation des programmes de lutte contre la schistosomose et les 
géohelminthiases demeure un défi important en Afrique. L’intégration avec les autres 
interventions de santé existantes et en particulier celles ciblant les maladies tropicales 
négligées et le renforcement du système de santé sont des voies pour continuer à assurer la 
distribution des médicaments antihelminthiques et les autres interventions. A un coût moyen 
de 0.58 US$ par traitement, les pays pourront l’assurer. 
Une proportion importante d’enfants d’âge préscolaire est infectée par la 
schistosomose y compris des infections mixtes à S. haematobium-S. mansoni. Par conséquent, 
dans les zones hyper endémiques, plus d’attention doit être accordée aux enfants d’âge 
préscolaire et à leurs mères afin qu’ils puissent bénéficier de la chimio prévention et ainsi 
augmenter la couverture thérapeutique effective des personnes traitées. Le PZQ sirop est bien 
toléré chez les nourrissons et les enfants d’âge préscolaire. Les taux de guérison et de 
réduction de l’oviurie sont élevés avec S. haematobium. Par contre, des études 
complémentaires sont nécessaires afin de mieux déterminer son efficacité contre S. mansoni. 
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Chez les enfants d’âge scolaire, le PZQ administré en 2 doses rapprochées est efficace 
contre S. haematobium. Cependant les faibles taux de réduction de l’excrétion ovulaire 
observés suscitent l’inquiétude quant à la montée de la tolérance de S. mansoni au PZQ. 
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1. Introduction
1.1.   Schistosomiasis: biology and life cycle 
Schistosomiasis is a water-related disease that is due to an infection with trematode 
worms, which live in the venous circulatory system of the definitive vertebrate hosts. An 
infection occurs through skin contact while a person is in contact with water polluted by 
faeces or urine of Schistosoma-infected individuals. An intermediate hosts (freshwater 
molluscs) is indispensable for the life cycle (Gryseels et al., 2006). 
There are at least 19 species of schistosomes from which five species are recognized 
pathogenic for human, namely Schistosoma haematobium, S. mansoni, S. intercalatum, 
S. japonicum and S. mekongi. In sub-Saharan Africa, S. haematobium, S. mansoni and 
S. intercalatum occur, with the former two being the predominant species (WHO, 1993a). 
Adult schistosome worms live inside the venous circulatory system. Their morphology is 
very similar from one species to the other. They measure 10-20 mm, the male shelters in a 
longitudinal gutter of a longer female worm. In the two sexes surface is roughcast 
protuberances. The egg contains a mobile miracidia ready to hatch. It measures 70-200 µm, 
depending on species. The cercariae, which measure approximately 50 µm, is characteristic 
by its form: the head (or body) is connected to a tail, which will enable to get rid during the 
penetration of the skin. 
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Figure 1.1. Schistosoma eggs: 1. S. mansoni 2. S. japonicum 3. S. intercalatum 4. S. mekongi 
5. S. haematobium (source: http://www.dpd.cdc.gov/dpdx; accessed: 15 August 2011) 
 
Common characteristics of intermediate hosts are that they are freshwater gastropod 
molluscs, hermaphrodites and oviparous. Four species are involved in the transmission of 
human schistosomiasis: Bulinus for S. haematobium and S. intercalatum, Biomphalaria for 
S. mansoni, Oncomelania for S. japonicum and Tricula for S. mekongi. With the exception of 
Oncomelania that are amphibious, snails live in freshwaters, not very deep, using watery 
vegetation for support and food. 
Bulinus species can tolerate high temperatures. A dozen species are likely to be 
intermediate hosts of S. haematobium, from which Bulinus truncatus is the most important 
African intermediate host. Bulinus forskalii is the usual intermediate host of S. intercalatum. 
Biomphalaria is the intermediate hosts of S. mansoni. These snails are more susceptible to 
desiccation and high temperatures compared to Bulinus. 
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Figure 1.2. Schistosoma life cycle (source: http://www.dpd.cdc.gov/dpdx; accessed: 15 August 2011) 
This Schistosoma life cycle is identical for the five human species with the only 
exception of the intermediate host snails. After having reached their sexual maturity in the 
venal system, the female worms lay their eggs in the capillaries. Eggs will have to leave the 
capillary and cross the organs before falling in the intestine or the bladder to be eliminated 
with the excreta. 
It is noteworthy that for S. japonicum, more than 40 species of reservoir hosts exist (e.g. 
water buffalo and pigs), which is renders transmission control particularly challenging (Wang 
et al., 2008). 
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1.2. Schistosomiasis distribution 
1.2.1. Schistosomiasis in the world 
Schistosomiasis, considered as a neglected tropical disease (NTD) (Hotez et al., 2006a; 
Molyneux, 2004) is the most prevalent tropical disease after malaria (WHO, 1993a). Indeed, 
schistosomiasis is endemic in 76 countries, although transmission appears to be interrupted in 
several countries (WHO, 2011). It is estimates that at least 800 million people are exposed to 
the risk of Schistosoma infection in the world; among them, more than 200 million people are 
infected (WHO, 2011). According to estimates put forth by the World Health Organization 
(WHO), the number of deaths associated with schistosomiasis are approximately 300,000 
people per year (WHO, 2002; van der Werf et al., 2003). Schistosomiasis is intimately 
connected with poverty (Hotez et al., 2006a; King, 2010). More than 90% of the people 
requiring preventive chemotherapy live in Africa (WHO, 2011), where 42 countries are 
endemic for schistosomiasis. 
 
Figure 1.3. Distribution of schistosomiasis in the world in 2009 (source: WHO, 2011) 
 
S. haematobium is distributed throughout Africa, in the valley of the Nile in Egypt, in the 
Maghreb region in small marshes (some remaining pockets in Algeria and perhaps in 
Morocco), in Madagascar and in the Middle East, Yemen (WHO, 1998b). S. mansoni is 
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widespread in Egypt, East and South Africa; in West Africa, in Latin America (Brazil and 
Venezuela), and in the Antilles. S. japonicum prevails in the People’s Republic of China, in 
Formosa, in Indonesia and the Philippines. S. mekongi is endemic in Cambodia, and in Lao 
People’s Democratic Republic. It has been eliminated in Japan and Korea. S. intercalatum is 
restricted to some parts of Central African, i.e. Gabon, Congo, Democratic Republic of the 
Congo and Cameroon, as well as in Angola. 
 
1.2.2. Schistosomiasis in Niger 
Schistosomiasis represents a major problem of public health in Niger. Considering the 
prevalence observed and the fact that the population of Niger are especially concentrated near 
water points, it is estimate that at least 4.5 million people are exposed to this affection on the 
extent of the country (Garba et al., 2006; Fenwick et al., 2009; Schur et al., 2011). The 
development of small dams to promote irrigation for food sufficiency in the country is the 
factor supporting the propagation of the disease (Ernould et al., 1999, 2004). 
 
Figure 1.4. Map showing the prevalence of S. haematobium in Niger in 2006 (source: Clements et al., 
2008) 
 
In Niger, two forms of Schistosoma exist: S. haematobium and S. mansoni with however 
a strong prevalence of the urinary form (Garba, 2000; Garba et al., 2006). 
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Urinary schistosomiasis is present in all the climatic zones of the country with a high 
prevalence around irrigated perimeters of the Niger River, Birni Konni, Maradi and Diffa and 
around the temporary and permanent ponds of Téra and Mirriah and oases of the Aïr 
Mountains. Intestinal schistosomiasis was initially limited to the department of Gaya 
(Doumenge and Mott, 1987; Mouchet et al., 1988; Ernould et al., 2000; Clements et al., 
2008). However, a new focus was discovered at Namarigoungou in 2002 (Labbo et al., 2003b; 
Garba et al., 2004b) upstream of Tillabéri on the Niger River. In the meantime, S. mansoni is 
progressing in this region replacing S. haematobium. The number of S. mansoni-endemic 
villages is increasing as well as the prevalence (Garba et al., 2010). 
Malacologic studies carried out in Niger found the existence of many intermediate hosts. 
Bulinus truncatus has been identified as the main species responsible for the transmission of 
urinary schistosomiasis. B. truncatus rothfsi is distributed in all the climatic zones of Niger 
(Labbo et al., 2003a, 2008; Ernould et al., 2004), while B. senegalensis, even if present in all 
the climatic zones of Niger, is involve in the transmission of urinary schistosomiasis mainly 
in temporary ponds (Vera et al., 1992). B. globosus is found in the Niger River, the Center 
and the East of the country, and this snail species mainly occurs in temporary ponds. 
B. forskalii, which is distributed across the country, was found to contribute to the 
transmission of urinary schistosomiasis in the Niger River Valley, but at a small scale (Labbo 
et al., 2007). B. jousseaumei is localized in the Niger River Valley and B. umbilicatus in the 
extreme south of the country, in the Niger River Valley and the Center of the country but they 
do not transmit schistosomiasis in Niger. 
Biomphalaria pfeifferi is found in the extreme south of the country (Gaya, Boboye), in 
Aïr mountains and recently in Tillaberi region in the Niger River Valley is responsible for the 
transmission of S. mansoni (Mouchet et al., 1988, 1990; Labbo et al., 2003b). 
 
1.3. Morbidity due to schistosomiasis 
In endemic areas, infection occurs at childhood. Infection increases in prevalence and 
intensity before reaching a peak around the age of 13-15 years (King et al., 1988; Verle et al., 
1994). The granulomatous response to parasite eggs is responsible of the constitution of the 
pathology in schistosomiasis (Gryseels et al., 2006). 
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The miracidia secretes and excrete proteolytic enzymes diffusing through the ovular wall. 
Later on these ovular antigens will involve the formation of a granuloma, the elementary 
lesion specific of schistosomiasis disease. The formation of the granuloma translates a 
defensive response of the host against the aggression induced by the eggs, which cross the 
walls of the urinary, genital or intestinal tracts creating an ignition and bleeding. The lesions, 
constitute of granuloma are mainly located in the mucous membrane and under mucous 
membrane of the bladder, the ureter and the genitals for S. haematobium; of the intestine for 
S. mansoni and S. intercalatum. These lesions are the cause of the hypertrophy of the walls. 
Moreover eggs of S. mansoni are pulled by the blood current and can reach the liver, the 
lungs, the nervous system and the skin. 
Clinical manifestations of schistosomiasis are classified into three phases namely (i) 
contamination, (ii) invasion and (iii) patent. The phase of contamination caused by the entry 
of cercariae into the skin begins with itching, and then appear erythematous spots, papular 
rash, possibly a fever and general fatigue. Most frequently this phase is quiet and 
unperceived. 
The phase of invasion occurs after a dumb period of 2-10 weeks following the 
contamination. It is characterized by immune-allergic signs, such as fever, cutaneous signs 
(pruritus, urticaria and oedema), muscular or articular pains, cough, abdominal pains or 
diarrhoea. 
At the patent phase, the signs cease to be univocal and depend on the territories of egg-
laying of each species. It’s clinically distinguishes: urogenital schistosomiasis due to 
S. haematobium, intestinal schistosomiasis due to S. mansoni and S. intercalatum, and arterio-
venous schistosomiasis due to S. japonicum and S. mekongi. 
 
1.3.1. Urogenital schistosomiasis 
Haematuria is the essential and the most frequent sign. Very often it is microscopic. In 
certain cases, it is insufficient to draw the attention of the subject. More significant, it is final, 
capricious and is then repeated. Often, it is possible to observe pubic pains, descending 
towards the purses, even in the absence of bacterial infection; they are often revived by pain 
when urinating. 
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Pollakiuria is chronic, sometimes accompanied with burns or itching at the end of the 
miction. Later on, bladder and ureter granulomas can cause an obstruction of the urinary 
tracts, which can induce hydroureter, hydronephrosis and a renal failure; and bladder 
calcifications (Gray et al., 2011). These chronic bladder lesions create favourable conditions 
for the development of the cancer of the bladder at adult age (WHO, 1993b). Studies have 
shown that squamous cell bladder carcinoma are more frequent in S. haematobium-endemic 
zones (Badawi et al., 1995; O'Connor et al., 1999). The successful control of schistosomiasis 
led to a decrease of the number of bladder cancer in Egypt (Barocas et al., 2011). 
Genital schistosomiasis, although neglected, is very frequent in the two genders. It can 
result, in the long-term, to sterility (Poggensee et al., 2006; Nayama et al., 2007). 
In women the main signs of the low genital organs are vulvo-vaginal and cervical lesions 
leading to external tumours of the vulva, pain and bleeding during sexual intercourse and 
menstruation disorders. The specific lesion at the colposcopy is the “sandy patches” 
(HellingGiese et al., 1996). In the upper genital organs, schistosomiasis can cause 
miscarriage, ectopic pregnancy, tubal obstruction and sterility. These bleedings due to 
schistosomiasis would create favourable situation for the transmission of HIV (Feldmeier et 
al., 1994, 1995; Hotez et al., 2009; Stoever et al., 2009). These genital lesions can sometimes 
also be found in S. mansoni infections (Lambertucci et al., 2009; Cavalcanti et al., 2011). In 
men, the main signs are epididymitis, funiculitisis, spermato-cystitis, prostatitis, 
haemospermia and painful erections (Feldmeier et al., 1999; Leutscher et al., 2000). 
1.3.2. Intestinal schistosomiasis 
Intestinal schistosomiasis is due to S. mansoni and S. intercalatum and S. japonicum. The 
eggs are mostly localized in the ramifications of the portal system, which explains the 
topography of the lesions: intestine, liver and spleen. 
The symptoms are not specific and not always present. Most of the time, the diagnosis is 
carried following a systematic parasitological examination of the stools. The most frequent 
signs are diarrhoea, sometimes bloody, dysenteries, alternating sometimes with the 
constipation, splenomegaly and hepatomegaly. 
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The hepatosplenic lesions are very frequent in S. mansoni infection and less in 
S. intercalatum. 
The main long-term complication is the liver fibrosis which induces a portal hypertension 
which can lead to ascitis, oesophageal varices, variceal bleeding and death (van der Werf et 
al., 2003; Gray et al., 2011). 
Anaemia, fatigue, low cognitive capacities are signs of the subtitle morbidity due to 
schistosomiasis (King and Dangerfield-Cha, 2008). 
Schistosomiasis lesions treated at a young age regress quickly and the clinical symptoms 
disappear (Boisier et al., 1998; Campagne et al., 2001; Vennervald et al., 2005). However, in 
case treatment is delayed until adulthood, it was shown that its effects are weak, especially on 
the portal fibrosis (Richter, 2003). Sandy patches the female genital schistosomiasis 
pathognomonic sign do not regress after treatment with praziquantel (Kjetland et al., 2006). 
These observations underscore that it is necessary to implement treatment of children before 
irreversible lesions have occurred. 
 
1.4. Diagnostic of schistosomiasis 
1.4.1. Clinical diagnostic 
In urinary schistosomiasis, the diagnosis is generally evoked in the presence of 
haematuria. In S. mansoni, the diagnosis is generally considered by the presence of bloody 
diarrhoea or dysentery. 
The clinical diagnosis remains useful and is more specific in the case of the urinary 
schistosomiasis than in the intestinal form. 
 
1.4.2. Parasitological diagnostics 
It is based on the presence Schistosoma eggs in the urine (S. haematobium) or in the stool 
(other Schistosoma species) by using parasitologic techniques. 
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Urine filtration technique on Nucleopore, Nytrel or paper allows a quantification of the 
results and appears the most interesting method in the field for the diagnostic of 
S. haematobium. 
The Kato-Katz technique of thick faecal smears under rectangle of cellophane (Katz et 
al., 1972) is recommended for the diagnosis of S. mansoni, S. japonicum and S. intercalatum. 
The sensitivity of these techniques can be improved by examining multiple samples 
(Campagne et al., 1999; Utzinger et al., 2001; Kosinski et al., 2011), which remedy day-to-
day variation of egg output (Engels et al., 1996). 
Formalin-based techniques for sedimentation or concentration can also be used. The 
Flotac (Knopp et al., 2009a, 2009b) is another technique which appeared interesting in the 
diagnosis of schistosomiasis and STH (Cringoli, 2006; Utzinger et al., 2008). However, the 
Flotac technique, although more sensitive to detect light infections (Glinz et al., 2010), 
appears to be more complex and costly (Speich et al., 2010). 
 
1.4.3. Immunological diagnosis 
The most promising technique is the circulating cathodic antigen (CCA) dipstick 
(Stothard et al., 2009) which detects antigens of Schistosoma in the urines. CCA is more 
sensitive and indicated in the screening for S. mansoni (Standley et al., 2010; Shane et al., 
2011). The sensitivity of CCA is low in detecting S. haematobium infection (Erko et al., 2008; 
Stothard et al., 2009). Other techniques using blood or of urines specimens exist, like blood 
soluble egg antigen-enzyme-linked immunosorbent assay (SEA-ELISA), eosinophil cationic 
protein (ECP), (Leutscher et al., 2008; Stothard et al., 2009; Webster et al., 2010), but they are 
not used in routine and sometime, they do not distinguish between active and past infection. 
 
1.4.4. Other diagnostic methods  
Radiological techniques can show the lesions induced by schistosomiasis. In addition to 
the traditional X-ray, ultrasonography since the beginning of the 1980s became the field most 
suitable technique for schistosomiasis-related morbidity assessment (Hatz et al., 1992a, 
1992b; Hatz, 2001; Koukounari et al., 2006). The availability of portable machines as well as 
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its reliability, its acceptance by the patients, and the possibility to examine many people are 
major features of this technique for morbidity studies. It has largely contributed to 
epidemiological research on the description of the lesions due to schistosomiasis and in the 
definition of the treatment strategies and periodicity (Devidas et al., 1989; Hatz et al., 1998; 
Wagatsuma et al., 1999; Campagne et al., 2001; Garba et al., 2004a). 
Biopsy of the rectal mucous membrane followed by the examination of the fresh 
specimen on the microscope has a great sensitivity but it does not allow any quantification 
and cannot be used in the field. 
 
Figure 1.5. Image showing some current diagnostic techniques. Macrohematuria, . Dipstick for 
microhematuria, . CCA test . SEA-ELISA test 
 
1.4.5. Community diagnostic 
It determines endemicity of schistosomiasis in a community and consequently the 
treatment strategy to apply in this community according to the prevalence. It consists in 
surveys using school-aged children samples. The prevalence found is used to classify the 
community in a level of endemicity according to WHO thresholds (WHO, 2006). The 
techniques used for the surveys are parasitology, but also methods known as rapid assessment 
techniques are used. 
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The three most widely used rapid assessment techniques for community diagnostic of 
urinary schistosomiasis are: (i) school-based questionnaires, (ii) visual haematuria and (iii) 
reagent strip testing for microhaematuria detection in the urine. 
Lengeler and colleagues developed and validated a simple school-based questionnaire 
approach, which proved useful in identifying high-risk communities of urinary 
schistosomiasis at the district level in Tanzania (Lengeler et al., 1991a, 1991b, 1991c). This 
method, initially developed in the Kilombero district, then successfully validated in the 
nearby Kilosa district, was subsequently validated in several African countries (N'Goran et 
al., 1998; Utzinger et al., 2000b; Lengeler et al., 2002). Good correlations were found 
between schoolchildren’s answers regarding the question “did you have blood in urine in the 
last 2 weeks” (Lwambo et al., 1997; Booth et al., 1998; Guyatt et al., 1999). In Côte d'Ivoire, 
N’Goran et al. showed that the use of questionnaire was rapid and cost-effective to identifiy 
schools at highest risk of urinary schistosomiasis (N'Goran et al., 1998). 
Visual haematuria technique is also easy to perform. Fresh urine specimens are examined 
in a transparent container. However, in adults and girls, this indicator can be less sensitive 
because of a higher frequency of urinary infections that are not related to schistosomiasis and 
menstruations. The use of reagent strips allows identifying the non visual haematuria. They 
have been used for the validation of the results obtained by questionnaire in Tanzania and in 
Côte d’Ivoire (N'Goran et al., 1989). However the diagnostic accuracy of urine dipsticks 
varied according to the brands used (Ugbomoiko et al., 2009). They are particularly 
interesting within the framework of the evaluation of schistosomiasis morbidity after a 
treatment campaign. However, they would be less useful in the zones of weak prevalence 
(Robinson et al., 2009; Kosinski et al., 2011). 
Considering the increasing needs for mapping in the new control programmes launched 
in sub-Saharan Africa (Brooker et al., 2009; Standley et al., 2009; Baker et al., 2010), at 
country level, and of the significant costs required, lot quality insurance sampling (LQAS) 
techniques (Brooker et al., 2005) seem an attractive alternative to reduce cost and save time. It 
has been used in S. mansoni survey in Uganda and shows a good applicability and speed in 
the survey. 
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1.5. Schistosomiasis control 
1.5.1. Preventive chemotherapy 
In highly endemic areas (e.g. sub-Saharan Africa), control of schistosomiasis rests on 
morbidity control, which is implemented through preventive chemotherapy (PCT) or mass 
drug administration (WHO, 2006). Other control strategies include health education for 
behaviour change, safe water, improved sanitation and snail control. PCT has been endorsed 
by WHO as the global strategy because of the safety, efficacy and low costs of praziquantel. 
Importantly, PCT has a rapid impact on morbidity (Molyneux, 2004; Molyneux et al., 2005; 
Hotez, 2009). In addition, this strategy advocate for co-implementation of neglected tropical 
diseases instead of single disease control because of the rapid impact of the treatments on 
health and cost-effectiveness considerations (Molyneux, 2004; Molyneux et al., 2005; Hotez 
et al., 2006b; Kolaczinski et al., 2007; Hotez, 2009). Monitoring surveys undertaken after 
large-scale implementation of this strategy confirms rapid and drastic reduction in the 
morbidity level of schistosomiasis (Kabatereine et al., 2007; Koukounari et al., 2007; Toure et 
al., 2008; Zhang et al., 2008). However, these programmes mainly depend on external funds 
in sub-Saharan Africa, and hence sustainability remains a great concern as well as increasing 
resistance of the population to repeated rounds of treatment (Parker et al., 2008; Allen and 
Parker, 2011). 
Several international initiatives have been put in place over the past several years 
demonstrating renewed interest in schistosomiasis research and control. The most important 
initiatives are summarized in Table 1.1. Moreover, funding for implementation of PCT has 
increased considerably, thanks to support by the World Bank for schistosomiasis control in 
Yemen and USAID. Drug manufacturers also contribute with free donation of medicine 
(http://www.who.int/neglected_diseases/pharma_contribution/en/index.html; accessed on 24 
August 2011). In addition to the well known mectizan and albendazole donation programme 
for lymphatic filariasis elimination and the zithromax donation for trachoma elimination, new 
initiatives of free drug donation have been recently launched, such as mebendazole (200 
millions tablets/year by Johnson & Johnson) and albendazole (400 million tablets/year by 
Merck) for STH control in school-aged children through Children Without Worms (CWW), 
and 200 million (20 million/year) tablets of praziquantel donation from Merck Serono by 
2017. 
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The World Health Assembly resolution 54.19, adopted in 2001, urges member states to 
treat at least 75% of all school-aged children who are at risk of schistosomiasis before 2010. 
Data assembled by WHO in 2009 show that this goal is far from being reached because of 
many constrains. In fact, only 19.6 million people were treated in the endemic regions, 
representing 8.2% of the estimate people infected, even if an increase of 116% was observed 
compared to 2006 (WHO, 2011). It should be noted, however that this report concern only 21 
endemic countries out of the 42 in Africa. The constrains in implementing the PCT strategy 
are the insufficient commitment of the countries and consequently low in-country funds 
allocated, and the availability of drugs (Fenwick, 2009; Savioli et al., 2009; Hotez et al., 
2010). 
 
Table 1.1. Major organizations supporting research and implementation of schistosomiasis control in 
sub-Saharan Africa 
Name (creation 
year) 
Countries of 
intervention 
Objectives Leading 
organizations 
Funding 
source 
SCI (2002) 
Schistosomiasis Control 
Initiative 
http://www3.imperial.ac.
uk/schisto 
Burkina Faso 
Mali 
Niger 
Tanzania 
Uganda Zambia 
 
-To encourage development of sustainable schistosomiasis and STH 
control programmes  
-To reach at least 75% of school-aged children and other high-risk groups 
with chemotherapy 
-To create a demand for sustained schistosomiasis and STH control. 
-To promote access to anthelminthic drugs and good case management in 
the regular health system. 
-To develop a rigorous monitoring and evaluation plan  
Imperial 
College of 
Science and 
Technology, 
London 
Bill & 
Melinda 
Gates 
Foundation 
CONTRAST (2006) 
A multi-disciplinary 
alliance to optimise 
schistosomiasis control 
and transmission 
surveillance in sub-
Saharan Africa 
http://www.eu-
contrast.eu/ 
Cameroon 
Kenya 
Uganda 
Niger 
Senegal 
Tanzania 
Zambia 
Research for control focused on: 
-molecular tools for new insight into snail-schistosome transmission 
biology; 
-characterisation of schistosome-snail relationships and transmission 
potential; 
-spatial epidemiology for schistosomiasis risk mapping and prediction; 
-social sciences approaches to better understand and encourage local 
control interventions; 
-outreach and dissemination facility established; 
University of 
Copenhagen 
 
Partners  
DBL 
NHM-UK 
ICL 
Swiss TPH 
Coris 
Bioconcept 
European 
Union 
SCORE (2008) 
Schistosomiasis 
Consortium for 
Operational Research 
and Evaluation 
http://score.uga.edu 
Côte d’Ivoire 
Ethiopia 
Kenya 
Mozambique 
Niger 
Tanzania 
Uganda 
-Evaluation of alternative approaches to mass drug administration (MDA) 
in communities with high and moderate prevalence rates of 
schistosomiasis; 
-Studies related to subtle morbidity, snail infections and schistosome 
population genetics; 
-Elimination of schistosomiasis in a defined geographic area and 
providing data and insights into effective strategies for moving large 
areas from having a low prevalence of infection to eliminating 
schistosomiasis. 
-Field evaluations of CCA urine assay for use as a screening tool for S. 
mansoni  
-Research and evaluation on human diagnostic tests for schistosomiasis 
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1.5.2. The move towards elimination 
Once morbidity control has been achieved, the next logical step is elimination of the 
disease as a public health problem. This can be envisaged in areas where sustainable control 
has led to low endemicity (WHO, 2002). Experiences in several countries and the disease 
infection indicators decrease in response to chemotherapy (Utzinger and de Savigny, 2006; 
Kabatereine et al., 2007; Koukounari et al., 2007) has shown that it is an achievable goal in 
sub-Saharan Africa (Laamrani et al., 2000; Knopp et al., 2011). A schistosomiasis elimination 
programme was launched on 28 July 2011 in Zanzibar. The objectives of this project, funded 
by the Bill & Melinda Gates Foundation through the University of Georgia project named 
SCORE are to eliminate schistosomiasis as a public health problem in Unguja Island in 3 
years and to eliminate transmission in 5 years in Pemba 
(http://score.uga.edu/Elimination.html). 
Mass drug administration and additional measures such as strengthening of the health 
system, improvement of sanitation, health education for behaviour change, safe water, 
(Curtale et al., 2010; Gray et al., 2010), snail control (Takougang et al., 2007) and 
reinforcement of the surveillance (Amarir et al., 2011) are necessary for sustainable 
schistosomiasis control. Indeed, investment in schistosomiasis control is a waster if benefits 
after successful PCT campaigns are not sustained after such rapid impact interventions. 
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2. Goals and objectives
2.1.   Aim of the study 
The goals of this PhD thesis in Epidemiology are (i) to deepen our understanding of the 
epidemiology of and morbidity due to schistosomiasis in young children; and (ii) to evaluate 
the efficacy of praziquantel and to assess the economic cost implication of mass drug 
administration strategies in order to enhance the control of schistosomiasis control in sub-
Saharan Africa. 
2.2 .   Specific objectives 
− To elucidate the objectives and the organisation of the schistosomiasis and soil-
transmitted helminthiasis control programmes in selected West African countries. 
− To present the results achieved and the impact of mass drug administration campaigns 
undertaken in selected West African countries in 3 years since the establishment of large-
scale schistosomiasis and soil-transmitted helminthiasis control programmes. 
− To discuss the challenges West African countries now face in ensuring sustainability of 
schistosomiasis control, and thus consolidating achievements made to date. 
− To determine the financial and economic costs of the national schistosomiasis and soil-
transmitted helminthiasis control programme in Niger, particularly the cost per person 
treated and the cost per Schistosoma infection averted. 
− To determine the cost-effectiveness of a school-based and community-based preventive 
chemotherapy strategy in Niger. 
− To determine the prevalence and intensity of schistosomiasis in children below the age of 
5 years and in their mothers in a village in Niger where only S. haematobium occurs, and 
in a village where S. haematobium and S. mansoni co-exist. 
− To enhance our understanding of the epidemiology of schistosomiasis and risk factors for 
an infection in early childhood. 
− To evaluate the safety and efficacy of praziquantel syrup (Epiquantel®) in Schistosoma 
infection in infants and preschool-aged children in three endemic villages of Niger. 
− To assess the efficacy and safety of two closely spaced doses of praziquantel against 
S. haematobium and S. mansoni infection among school-aged children in a highly 
endemic area of Niger and to describe reinfection patterns over a 1-year period after 
treatment.
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3.1.  Summary 
Since 2004 the West African countries of Burkina Faso, Mali and Niger are 
implementing national schistosomiasis and soil-transmitted helminthiasis (STH) control 
programmes with financial and technical support from the ‘Schistosomiasis Control Initiative’ 
(SCI). In the first three years of the control programmes, nearly 13.5 million of people have 
been treated with praziquantel against schistosomiasis and albendazole against STH with 
coverage rates varying between 67.0% and 93.9%. These treatments have resulted in a 
reduction of the prevalence and intensity of Schistosoma infection in the sentinel cohorts that 
were set up to monitor and evaluate the national control programmes. The challenges 
currently facing by these national control programmes are the ability to maintain the reduction 
in morbidity achieved thus far due to the mass treatment campaigns and ensuring 
sustainability. For reinforcement of surveillance monitoring the establishment of a 
geographical information system is suggested in order to contribute towards enhanced 
sustainability of these programmes. Our new working hypothesis is that targeted control 
accompanied by periodic mass treatment campaigns (every two to three years) can contribute 
to maintaining the low levels of morbidity achieved thus far. The implementation of 
integrated neglected tropical disease control programmes in these countries will provide 
means to ensure the financial sustainability of control activities for the years to come. 
Key words: schistosomiasis control, morbidity, integration, sustainability, Burkina Faso, 
Mali, Niger. 
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3.2.  Introduction 
Schistosomiasis represents a significant public health problem in tropical and sub-tropical 
areas. A recent analysis suggests that 779 million people are at risk of schistosomiasis, and 
207 million people were infected in mid-2003 throughout the world (Steinmann et al. 2006). 
Africa is the continent that is suffering the most with an estimated 85% of those currently 
exposed living on this continent (WHO, 1999; Chitsulo et al. 2000; Steinmann et al. 2006). 
Apart from the known long-term complications of a chronic Schistosoma infection (e.g. 
portal hypertension, kidney failure, bladder cancer and sterility), schistosomiasis is a 
debilitating disease leading to anaemia, malnutrition, chronic abdominal and pelvic pain, and 
diarrhoea; all which are underestimated with regards to schistosomiasis related morbidity 
(King et al. 2006). A recent re-assessment of the morbidity due to schistosomiasis (King et al. 
2005) emphasised that the true burden of the disease, as expressed in disability-adjusted life 
years (DALYs) lost, is between 2% and 15%, contrary to the former estimates of the World 
Health Organization, which quantified the burden due to schistosomiasis at only 0.5-0.6% 
(WHO, 2002). 
Following World Health Assembly (WHA) resolution 54.19, several African countries 
established national programmes to control morbidity due to schistosomiasis and soil-
transmitted helminthiasis (STH). Burkina Faso, Mali and Niger, in West Africa, were selected 
to benefit from financial and technical support of the ‘Schistosomiasis Control Initiative’ 
(SCI; http://www.sci-ntds.org) and large-scale schistosomiasis and STH control programmes 
have been established (Fenwick et al. 2006). The main strategies employed by these national 
control programmes are the organization of mass treatment campaigns and targeted health 
education in areas where prevalence rates justified the intervention using WHO (2002) 
criteria.  
This article summarizes some of the key results obtained in the three years since the 
establishment of these large-scale schistosomiasis and STH control programmes in 2004 in 
the three West African countries supported by SCI. Finally, the challenges the countries now 
face in ensuring sustainability and thus consolidating the achievements made will be 
discussed, including proposal for integrating multiple neglected tropical disease control 
programmes. 
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3.3 .  National schistosomiasis control programmes in Burkina Faso, Mali 
and Niger 
3.3.1. Distribution of the disease 
Schistosoma haematobium is the most widespread species in all three West African 
countries (Garba et al. 2006). The transmission areas are primarily irrigation schemes, along 
rivers, and near both temporary and permanent water ponds. Schistosoma mansoni is less 
prevalent compared to S. haematobium, and is limited to certain irrigated areas such as the 
Office of Niger, Bandiagara, Selingué and Baguinéda-Koulikoro in Mali (Koukounari et al. 
2006). In Mali, the prevalence of S. mansoni exceeds 50% in the Office of Niger. In Burkina 
Faso, S. mansoni is localised in the south-western part of the country; while in Niger 
transmission sites are primarily in the Niger River valley, but prevalence is increasing along 
the river where an emergent foci has been reported recently (Garba et al. 2004). 
3.3.2. Objectives, targets and strategies of control programmes 
In line with WHA resolution 54.19, the goal of the national control programmes is to 
reduce schistosomiasis morbidity to a level at which it will not constitute a public health 
problem. Hence, the three programmes have endorsed the WHO objective of reaching at least 
75% of the school-aged children, and have added the objective of targeting high-risk 
communities with the drug of choice, praziquantel (Doenhoff et al. 2009). Two drug 
distribution strategies have been used by the programmes. The first distribution strategy is 
through the schools where trained teachers or health workers distribute the drugs to school-
aged children. The second drug distribution strategy used is community-based, where trained 
drug distributors selected by the community, trained teachers or health workers treat 
community members. 
3.4.  Mass treatment and its impact 
In the three countries, nearly 13.5 million of people have been treated in a 3-year period 
starting in 2004. The coverage rates of the mass treatment in the different study areas varied 
between 67.0% and 93.9% (Table 3.1). The lack of accurate population statistics due to a high 
rate of migration in certain areas of Niger might explain the somewhat lower coverage rate 
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observed in Niger. Difficulties with the mass treatment campaigns were experienced mainly 
in large urban areas where populations were reluctant to comply with the treatment despite the 
significant number of people at risk in these towns such as the capital cities of Bamako and 
Niamey (Dabo et al. 2003; Labbo et al. 2003). Interestingly, this was observed particularly 
among more educated population strata. The regions were gradually integrated in the mass 
treatment campaigns. In both Burkina Faso and Niger the mass treatment campaigns have 
been scaled up to target all regions; however, in Mali, the endemic areas of the centre and 
eastern part of the country still remain to be covered by mass treatment.
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Table 3.1. Reported number of people treated with praziquantel and average coverage rates in the study regions during the first three years of schistosomiasis 
control activities implemented in Burkina Faso, Mali and Niger 
2004 2005 2006 Total 
No. of 
regions 
No. of 
people 
treated 
Coverage 
(%) 
No. of 
regions 
No. of 
people 
treated 
Coverage 
(%) 
No. of 
regions 
No. of 
people 
treated 
Coverage 
(%) 
No. of 
regions 
No. of people 
treated 
Coverage 
(%) 
Burkina 
Faso 4 1,027,007 92.1 9 2,278,615 89.6 4 2,818,578 93.9 13 6,124,200 93.0 
Mali 4 2,598,138 93.5 2 472,257 89.3 6 3,070,395 92.8 
Niger 3 671,670 68.0 5 2,034,510 67.0 5 1,540,556 84.9 8 4,246,736 72.8 
Total 1,698,677 6,911,263 4,831,391 13,441,331 
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For monitoring and evaluation purposes, cohorts of school-aged children in all three 
countries, and adolescent and adult cohorts in Niger were recruited and followed to monitor 
the impact of mass drug distribution campaigns. In Mali, repeated cross-sectional surveys of 
adolescent and adults were also carried out. In addition rapid prevalence assessment surveys 
using questionnaires have been conducted in Niger. The cohorts were examined before 
treatment each year. They were treated after baseline data collection and were re-treated once 
a year in their respective localities at the time of the mass treatment campaigns to ensure the 
effect of the mass drug administration could be measured. Table 3.2 shows the results of the 
cohort who completed the 3 years surveys as well as the cross-sectional surveys at the 3 time 
points of study. Following two distribution campaigns, a decline in both prevalence and most 
importantly intensity of schistosome infections was observed in all the three countries (Table 
3.2). The initial schistosome prevalence was higher in the school-aged group than in either the 
adolescent or the adult groups. In Burkina Faso the most dramatic reduction in prevalence of 
infection was observed among the school-aged population group; i.e. the baseline infection 
prevalence of 59.6% in 2004 dropped to 6.2% in 2005 and to 7.7% in 2006. In Mali, the 
decrease of observed prevalence was satisfactory; from 71.4% at baseline to 36.4% and 
28.3% after the first and second treatment rounds, respectively. However, in high 
transmission areas where the initial prevalence of infection was high, the remaining 
prevalence after two treatment rounds was still almost 50%. The effect of the treatment on 
intensity of S. haematobium infection in Mali was a reduction from 73.1 eggs/10 ml urine to 
7.6 eggs/10 ml urine and 5.6 eggs/10 ml urine one and two years after baseline screening, 
respectively. We believe that in addition to the immediate health improvements of those 
treated, the benefit of the two treatments in the school-aged population will continue into 
adulthood (Ouma et al. 2005; King, 2006). 
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Table 3.2. Prevalence and intensity of infection in children cohorts, adolescent and adult longitudinal and cross-sectional data pre- and post-treatment 
Baseline Year 1 follow-up Year 2 follow-up 
 Children 
No. of 
individuals 
examined 
Prevalence 
(95% CI) 
Mean infection 
intensity*  
(95% CI) 
No. of 
individuals 
examined 
Prevalence 
(95% CI) 
Mean 
infection 
intensity 
(95% CI) 
No. of 
individuals 
examined 
Prevalence 
(95% CI) 
Mean infection 
intensity  
(95% CI) 
Burkina Faso 783 59.6 (56.2-63.1) 94.2 (76.4-111.9) 783 6.2 (4.5-7.9) 1.0 (0.2-1.9) 783 7.7 (5.8-9.6) 6.8 (1.6-11.9) 
Mali 1399 71.4 (69.0-73.8) 73.1 (63.3-82.8) 1399 36.4 (33.9-38.9) 7.6 (6.1-9.1) 1399 28.3 (25.9-30.7) 5.6 (3.1-8.1) 
Niger 1145 75.4 (72.9-77.9) 58.7 (48.6-68.8) 1145 37.4 (34.6-40.2) 8.6 (6.4-10.8) 1145 35.7 (32.9-38.5) 13.9 (10.5-17.5) 
Adolescent and adults 
Mali (cross-
sectional data)** 197 54.8 (47.9-91.6) 15.3 (10.1-20.5) 847 41.1 (37.8-44.4) 9.4 (6.8-12.1) 534 9.7 (7.2-12.3) 0.4 (0.2-0.6) 
Niger 
(longitudinal 
data) 116 24.1 (16.3-31.9) 2.2 (1.6-3.8) 116 9.5 (4.1-14.8) 0.2 (0.0-0.6) 116 11.2 (5.4-16.9) 0.7 (0.1-1.3) 
* arithmetic mean; ** At baseline adolescents and adults have contributed data from 7 communities in Segou while at follow-up visits different people from
10 communities in Segou were recruited in these studies.
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3.5.  Maintaining the benefits of mass treatment 
3.5.1. The continuation of the treatment campaigns 
Two mass treatment campaigns do not resolve the health problems due to 
schistosomiasis. Several areas in the three West African countries still remain to be covered 
by mass treatment campaigns. This is due to the significant resources necessary to scale up 
control activities. Moreover, re-treatment is essential to keeping morbidity at low levels. The 
treatment of the target populations is of primary importance and must continue. 
The continuation of the mass treatment campaigns relies heavily on the need for free 
and/or donated drugs. SCI provided the drugs for free mass drug administration. However 
apart from the mass treatment campaigns the delivery of praziquantel is through the cost 
recovery system in the countries. In addition, SCI supported registration of several 
praziquantel manufacturers in the countries in order to encourage competitive bidding process 
which would obtain best prices during the in-country procurement process (Garba et al. 
2006). But even with the reduction of the price of praziquantel (Savioli et al. 2004), its cost 
still remains high for the budget of these three national governments and for the current cost 
recovery system. International initiatives with pharmaceutical companies, like the ivermectin, 
albendazole and the azithromycin donation programmes are essential. There is a fear of donor 
fatigue if a praziquantel donation programme is not established and if national governments 
are unable to contribute to the costs of distribution. Gabrielli et al. (2006) showed that mass 
drug distribution campaigns only cost US$ 0.32 per person treated (cost of the drug, 
management, planning, training, social mobilization and remuneration of distributor 
included). 
There is also a need to reinforce the capacities of the district health staff to ensure all the 
control activities at their level are successfully programmed and conducted with coordinated 
workshops in planning, surveillance and evaluation. In addition, it is necessary to increase the 
manpower of the district health staff with qualified personnel. This option may be difficult for 
these three West African countries in the context of Word Bank structural adjustment policies, 
which require a reduction of the number of government agents. 
One suggestion is for community structures or associations made up of the high-risk 
groups (e.g. gardening associations, fishermen groups, rice growers and women co-
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operations) to take the responsibility of the treatment under the supervision of the health 
workers. Drugs must be available at all levels of the health structure in order to treat 
individual cases free of charge. These both assume a general motivation of the target 
populations and a reinforcement of the existing community structures like the health 
committees, the irrigation scheme management committees, and other local non-
governmental organizations (NGOs) and associations. In particular, the village communities 
need to be responsible for the management of their health centres. Enhancing school health 
programmes is another way to regularly distribute drugs and such programmes could possibly 
permit more periodic treatment campaigns (every two to three years). Integration with other 
health activities could also reduce the costs and therefore encourage governments and partners 
to contribute to the financing of mass treatment campaigns. 
3.5.2. Villages targeted for control 
Due to the fact that schistosomiasis is focal (Labbo et al. 2008; Ernould et al. 2004), 
monitoring of control activities requires more precise annual evaluations, primarily at the 
village level. Such precise evaluations permit the monitoring of the long-term impact and 
effectiveness of the mass treatment campaigns and a possible reduction in the transmission. A 
reinforcement of local capacities in monitoring and evaluation is essential at all levels. It is 
misleading to think that a national coordination team alone can carry out all necessary 
surveys. This would take too much time and would require a very high data management 
capacity to ensure rapid analysis in order to formulate treatment strategies in a timely manner. 
Moreover, the district health staffs do not have the capacity or the autonomy to undertake the 
control programmes and to conduct the surveillance activities. Even when district level 
capacities exist, health agents have additional work and therefore the activities required for 
schistosomiasis control are difficult to achieve. 
Analysis of results indicates that the risk of reinfection is associated with the location of 
the village, the age of the individual and haematuria, but is not associated with the sex of the 
individual or the frequency of water contact (Satayathum et al. 2006; King, 2006). Thus a 
schistosomiasis control strategy targeted at village level seems the most logical and the 
establishment and use of a geographical information system (GIS) platform can assist the 
national programmes in targeting villages that require control interventions and defining 
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overall treatment strategies (Simoonga et al. 2009; Clements et al. 2008), but its role may be 
limited in resource poor countries. 
3.5.3. Additional control strategies 
The transmission of schistosomiasis is linked with behaviour. Long-term information, 
education and communication (IEC) campaigns could increase the knowledge of the 
populations, and thus contribute to behaviour change (Poggensee et al. 2005). Safe water 
supplies, and the construction and use of latrines, must be provided or improved (Singer and 
Castro, 2008; Asaolu and Ofoezie, 2003). It is important to remember that schistosomiasis is 
primarily found in poor communities and in countries with very limited resources. In addition, 
preventing children from bathing in infested water when temperatures reach above 40°C will 
always be difficult. Therefore, it would be deceptive to think of obtaining a good coverage of 
both safe water supplies and latrines in a short period. Thus, an increase in education and 
poverty reduction efforts are necessary for the control of schistosomiasis.  
3.5.4. Can we consider transmission control? 
Molluscicides were not used by any of the control programmes in West Africa probably 
due to cost and the fear of ecological consequences (Sturrock, 2001). Considering the weak 
impact of the mass treatment campaigns on the transmission (King, 2006), the use of 
molluscicides in small temporary ponds where fishing activities are not practised can be 
considered on a small scale (Sturrock, 2001) to contribute to transmission control.  This will 
ensure the reduction of transmission and therefore will enable the control programmes to 
adopt a more periodic treatment schedule.  Using molluscicides in these small and temporary 
ponds where fishing activities are absent can therefore be advantageous to national control 
programmes. A study in northern Cameroon (Tagougang et al. 2006) showed that in the 
sahelian zone where temporary ponds represent the main transmission system for 
schistosomiasis a reduction in snail population without causing ecological damage to fish and 
other claming plates is possible if 4 fold less the recommended dose (0,25mg/m3) of 
molluscicides is applied twice. The reduction of the molluscicide dose is more cost efficient, 
but cost effectiveness studies are still necessary.  
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3.6 .  Future: Integration of the programmes and the control of neglected 
tropical diseases 
The integration of vertical control programmes is considered as a cost effectiveness way 
to deliver a health package (Lammie et al. 2006; Brady et al. 2006). The American 
government (United States Agency for International Development) awarded a $100m USD 
grant for the integrated control of neglected tropical diseases to the company Research 
Triangle International (RTI). Burkina Faso, Mali and Niger are among the selected fast-track 
countries for implementation of this neglected tropical disease control project. This 
integration will concentrate on delivery of appropriate treatments against schistosomiasis, 
STH, trachoma, lymphatic filariasis and onchocerciasis. The main strategies of the integration 
plan are mass drug distribution, IEC and training. This grant offers the three countries a 
chance to have continued support to their national control programmes, but for how long is 
still a question. 
Integration with other existing health activities is another way to ensure the continued 
distribution of the drugs. In Niger, an integrated distribution of the polio vaccination and 
mebendazole for children under 5 was successfully completed in December 2006 when three 
million children were successfully treated against intestinal worms.  Though the under 5s are 
not considered in the WHO recommendations for schistosomiasis control (Stothard and 
Gabrielli, 2007), they represent a significant proportion of those affected (Bosompem et al. 
2004), and therefore integration of schistosomiasis control with existing health activities, such 
as national immunisation days could be a channel to reach this target. 
3.7.  Conclusion 
The long-term treatment of target populations in an integrated and decentralized way, and 
a progressive introduction of transmission control, are essential for the successful fight 
against schistosomiasis in Africa. The poverty reduction policy of increasing school 
attendance and providing safe water would ensure populations are more aware of the disease 
and therefore reduce reinfection rates. 
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4.1.  Abstract 
The burden of schistosomiasis in infants and preschool-aged children and their mothers is 
poorly known. We carried out a cross-sectional epidemiological survey in two villages in 
Niger: Falmado is endemic for Schistosoma haematobium only, whereas a mixed 
S. haematobium-S. mansoni focus has been reported from Diambala. The survey examined 
282 children (149 girls, 133 boys, average age: 2.6 years) and 224 mothers (average age: 30.1 
years). For S. haematobium diagnosis, two urine samples obtained on consecutive days were 
subjected to the standard urine filtration method. Additionally, macro- and microhaematuria 
were determined. The diagnosis of S. mansoni was based on a single stool sample with 
duplicate Kato-Katz thick smears. In Diambala, a standardised, pre-tested questionnaire was 
administered to mothers, which recorded demographic data, treatment history with 
anthelminthic drugs, household sanitation and water supply, and bathing practices for their 
children. Prevalence of egg-patent S. haematobium infections among young children and their 
mothers was respectively 50.5% and 55.6%, in Falmado, and 60.5% and 72.2% in Diambala. 
The prevalence of S. mansoni infection in Diambala was 43.8% among children and 52.1% in 
mothers. Mixed egg-patent infections of S. haematobium and S. mansoni were revealed in 
28.6% of the children and 37.3% of the mothers. Questionnaire data showed that 69.8% of the 
children were accompanied by their mothers to schistosomiasis transmission sites before they 
were one year of age, and that three-quarter of the mothers used water directly drawn from the 
irrigation canals to wash their children. To conclude, a substantive proportion of children 
below the age of five years had egg-patent schistosomiasis, inclusive of co-infection with 
S. haematobium and S. mansoni. In the context of schistosomiasis control, more attention 
should be paid on preschool-aged children and women of childbearing age, so that they can 
benefit from preventive chemotherapy, which in turn might increase effective coverage of 
those infected. 
Keywords: Schistosomiasis, Schistosoma haematobium, Schistosoma mansoni, co-
infection, infants, preschool-aged children, women, prevalence, Niger 
Chapter 4 - Schistosomiasis in infants and preschool-aged children 
55 
4.2.  Introduction 
Classified among the neglected tropical diseases (NTDs) (Molyneux et al., 2005; Hotez et 
al., 2006), schistosomiasis remains one of the most important parasitic diseases in the tropics 
and subtropics, and constitutes a major public health problem (van der Werf et al., 2003; 
Steinmann et al., 2006). Schistosomiasis is endemic in Niger, with 3-4 million people 
exposed, the majority of whom have Schistosoma haematobium infections (Garba and 
Aboubacar, 2000), but there are recent signs that S. mansoni is expanding along the Niger 
River Valley (NRV), probably due to water-resource developments (Steinmann et al., 2006). 
The main sites of transmission are the irrigated areas of the Niger River and the semi-
permanent and permanent ponds (Labbo et al., 2008). Following the World Health Assembly 
(WHA) resolution 54.19 put forth in May 2001 (WHO, 2002), Niger is implementing a 
national schistosomiasis and soil-transmitted helminthiasis control programme with the 
support of the Schistosomiasis Control Initiative (Garba et al., 2006, 2009; Fenwick et al., 
2009). The objective of this programme is to reduce morbidity due to schistosomiasis and 
soil-transmitted-helminthiasis by treating at least 75% of all school-aged children and other 
high-risk communities where the prevalence exceeds 50% with praziquantel and albendazole, 
a strategy termed ‘preventive chemotherapy’ (Savioli et al., 2004; Garba et al., 2006, 2009). 
By focusing treatment upon the school-aged population, WHA resolution 54.19 neglected 
children of preschool age, thus preventing them from benefiting from the praziquantel 
treatment given to their older peers, and hence creating a potential health inequity (Johansen 
et al., 2007; Stothard and Gabrielli, 2007). Root causes include the belief that very young 
children would not yet been exposed to infested freshwater bodies, thus an insufficient 
understanding and documentation of the extent and severity of schistosomiasis in this age 
class, and a paucity of pharmacokinetic safety data of praziquantel among young children 
(Allen et al., 2002; Geary et al., 2010). However, in endemic zones, women are frequently 
accompanied by their children, even at young age, when they go to ponds, rivers or irrigation 
canals, all of which may be contaminated with cercariae, the infective stage to humans. 
Therefore children are likely to come into contact with contaminated water at a very young 
age. Recent studies in Nigeria (Mafiana et al., 2003; Opara et al., 2007), Ghana (Bosompen et 
al., 2004) and Uganda (Odogwu et al., 2006) have shown that infection with S. haematobium 
and S. mansoni can indeed occur in very early childhood. 
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The present study pursued two objectives. First, to determine, the prevalence of 
schistosomiasis in children below the age of five years and in their mothers in a village where 
only S. haematobium occurred, and in a village where both S. haematobium and S. mansoni 
were present. The second objective was to enhance our understanding of the epidemiology of 
schistosomiasis and risk factors for an infection in early childhood. The results reported here 
shed new light on a largely neglected issue of schistosomiasis epidemiology and control and 
may therefore assist public health experts and disease control managers to devise adequate 
strategies to tackle the disease in the preschool-aged population and their mothers. 
4.3.  Materials and methods 
4.3.1.  Study area 
This cross-sectional epidemiological study was carried out in Diambala and Falmado, in 
the Western Sahel zone of Niger, in April 2007 (Fig. 4.1). The two villages have been 
selected after a survey in school-aged children has shown a high prevalence of 
schistosomiasis. Diambala (geographical coordinates: 14.313 N latitude; 1.300 W longitude) 
is located in the NRV in the department of Tillabéri, near an irrigated rice zone. The estimated 
population at-risk of schistosomiasis in this department is 193,825 people. Falmado (12.514 N 
latitude; 2.861 W longitude) is located in the department of Birni Gaouré in the valley of 
Dallol Foga, surrounded by permanent and temporary ponds with an at-risk population of 
148,833 individuals. 
An exhaustive door-to-door census conducted prior to parasitological and questionnaire 
surveys revealed a total population of 3,961 in Diambala and 676 inhabitants in Falmado. In 
Diambala, the major schistosomiasis transmission sites are the irrigation canals and the seven 
temporary ponds where favourable conditions enable the intermediate host snails to thrive. It 
is a well-known focus of mixed S. haematobium and S. mansoni and anthelminthic drugs have 
been administered prior to our study. In Falmado, rains occurring during the wet season 
ensure that both the permanent and temporary ponds surrounding the village are filled up, 
facilitating transmission of schistosomiasis. However, prior to the present study, the village of 
Falmado was never targeted for either praziquantel or albendazole treatment. We proceeded to 
an exhaustive sampling of all the households having a child of less than five years after 
census to participate to the study. 
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Fig. 4.1. Map of the study area in western Niger. 
4.3.2. Ethical consideration and treatment 
Ethical clearance was obtained from the Niger National Ethical Committee (Niamey, 
Niger) and from the NHS-LREC review board of St Mary’s Hospital, Imperial College 
(London, UK) application 03.36. In the field, the objectives of the study were explained to the 
local village chiefs and political and religious authorities who gave their consent to conduct 
the study. 
All the mothers with children under five years of age were invited to participate in the 
study. The objectives, procedures and potential risk and benefits were explained prior to data 
collection. Once the mothers gave their oral informed consent (illiteracy rate is very high, 
hence we opted for oral rather than written informed consent), their children were included in 
the study. The whole population of the two villages were treated immediately after the study 
with praziquantel (single 40 mg/kg oral dose) and albendazole (single 400 mg oral dose), 
using crushed tablets for the youngest children by the national schistosomiasis and soil-
transmitted helminthiasis control programme during their mass treatment campaign. 
Praziquantel and albendazole tablets were crushed between two spoons, diluted with water 
and given to the child by the mother generally accustomed to give drugs in this way to their 
children. Drugs administered in this way were well tolerated. 
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4.3.3.  Questionnaire survey 
A questionnaire assessing risks for early childhood schistosome infections was 
administered to participating mothers in Diambala, the village characterized by a mixed focus 
of S. haematobium and S. mansoni. We employed a standardized, pre-tested questionnaire that 
has been successfully used before (Beidou, 2006) in the local language (Zarma) by trained 
field investigators. Socio-demographic data (e.g. age, sex, profession and educational 
attainment), knowledge and attitude towards water contact patterns, means of prevention, 
water supply, availability of latrines, and recent history of treatment with anthelminthic drugs 
were collected. 
4.3.4. Parasitological survey 
Urine collection containers (and in Diambala also stool collection containers) with unique 
identifiers were handed out to the participating mothers and their young children. Each 
subject included in the study underwent two parasitological examinations of their urine on 
consecutive days. For the collection of the urine samples, from a few very young children, 
plastic potties were given out to facilitate collection of urine. Urine specimens were collected 
between 10:30 and 14:00 hours and the standard urine filtration method was employed 
(WHO, 1985). In brief, urine samples were vigorously shaken, and 10 ml were filtered using 
nucleopore filters. The filters were placed on a microscope slide, a drop of Lugol’s iodine was 
added and the slides were examined under a microscope by experienced laboratory 
technicians. The number of S. haematobium eggs per slide were counted and recorded for 
each individual separately. Additionally, urine specimens were examined for 
macrohaematuria (visible blood in urine). Only the first day urine sample was subjected to 
microhaematuria testing, using Hemastix® strip (Bayer; Leverkusen, Germany). 
A single stool specimen collected from participating mothers and their young children in 
Diambala was subjected to the Kato-Katz technique (Katz et al., 1972) with duplicate thick 
smears prepared from each sample. We also recorded the consistency of stools (liquidity and 
presence of blood). Other intestinal parasites detected under the microscope were also 
recorded. 
We classified intensity of schistosome infections according to guidelines put forth by the 
World Health Organization (WHO, 2002). For S. haematobium, we determined between light 
Chapter 4 - Schistosomiasis in infants and preschool-aged children 
59 
infection (1-49 eggs/10 ml of urine), and heavy infection (≥50 eggs/10 ml of urine). The 
intensity of S. mansoni infection was classified into light infection (1-99 eggs per gram of 
stool (EPG)), moderate infection (100-399 EPG) and heavy infection (≥400 EPG). 
4.3.5. Statistical analysis 
All data were entered into an Excel spreadsheet, transferred into EpiInfo version 6.04d 
(Centers for Disease Control and Prevention; Atlanta, USA) and analysed with the latter 
software. We calculated the various proportions of interest and made comparisons using the 
Pearson χ2 test, or the Yates’ corrected χ2 test, as appropriate. For statistical significance, we 
use a threshold of 5%. 
4.4.  Results 
4.4.1. Characteristics of study population 
Table 4.1 summarises the demographic characteristics of the studied population, stratified 
by village. Overall, 282 children and 224 mothers participated in the study. The average age 
of the whole surveyed preschool-aged children group was 2.6 years with a standard deviation 
(SD) of 1.1 years. There were more girls than boys in both villages with a sex ratio of male to 
female of 0.89. The age of the mothers ranged from 15 to 50 years, with an average of 30.1 
(SD=8.6) years. 
In Diambala, 97.8% of the surveyed children had a history of treatment with albendazole 
and 1.1% had a history of treatment with praziquantel. Almost three quarters of the mothers 
(72.3%) reported to have previously received praziquantel. In Falmado, no previous treatment 
was reported with either drug, neither in mothers nor in children. 
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Table 4.1: Characteristics of the study population in the two villages of Diambala and Falmado in 
western Niger and prior treatment history with praziquantel and albendazole. 
Characteristics Village Children 
(< 5 years) 
Mothers 
Number of participants (%) Diambala Male 84 (45.4) 
Female 101 (54.6) 
Total 185 (100) 143 
Falmado Male 49 (50.5) 
Female 48 (49.5) 
Total 97 (100) 81 
Total Male 133 (47.2) 
Female 149 (52.8) 
Total 282 (100) 224 
Mean age (SD) Diambala 2.7 (1.0) 31.4 (8.7) 
Falmado 2.6 (1.2) 27.8 (7.9) 
Total 2.6 (1.1) 30.1 (8.6) 
History of treatment with 
praziquantel in % (95% CI) 
Diambala 1.1 (0.1-3.9) 72.3 (64.2-79.5) 
Falmado 0.0 (0.0-3.7) 0.0 (0.0-4.4) 
History of treatment with 
albendazole in % (95% CI) 
Diambala 97.8 (94.5-99.4) 0.0 (0.0-2.6) 
Falmado 0.0 (0.0-3.7) 0.0 (0.0-4.4) 
4.4.2. Infection with S. haematobium 
Table 4.2 summarises the results of S. haematobium infection in both children aged 
below five years and their mothers. The prevalence of S. haematobium among children was 
60.5% in Diambala and 50.5% in Falmado. There is no difference between girls and boys 
(χ2 = 0.01, P = 0.9). The prevalence of heavy infection of S. haematobium (≥50 eggs/10 ml of 
urine) was 6.2% in the children of Falmado. The prevalence of macrohaematuria and 
microhaematuria among preschool-aged children was respectively 5.2% and 50.5% in 
Falmado, and 2.2% and 38.9% in Diambala. The prevalence of both macrohaematuria and 
microhaematuria was higher in Falmado compared to Diambala, but the difference was not 
statistically significant (χ2 = 1.00, P = 0.316 for macrohaematuria; χ2 = 3.49, P = 0.061 for 
microhaematuria). 
Among mothers, the prevalence of S. haematobium was 55.6% in Falmado and 72.2% in 
Diambala. The prevalence of heavy infection was particularly high in Falmado (8.6%). The 
prevalence of macrohaematuria and microhaematuria among mothers was respectively 8.6% 
and 61.7% in Falmado, and 2.1% and 52.4% in Diambala. 
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Table 4.2. Prevalence of S. haematobium infection and morbidity indicators among children aged 
below 5 years and their mothers in the two study villages of Diambala and Falmado, western Niger. 
Characteristics Village n Children 
(< 5 years) 
n Mothers 
S. haematobium infection 
prevalence in % (95% CI) 
Diambala 185 60.5 (53.1-
67.6) 
143 72.2 (64.2-79.4) 
Falmado 97 50.5 (39.2-
59.8) 
81 55.6 (44.1-66.6) 
Prevalence of heavy 
S. haematobium infections 
(≥50 eggs/10 ml of urine) 
in % (95% CI) 
Diambala 0.0 (0.0-1.9) 0.0 (0.0-2.5) 
Falmado 6.2 (2.3-13.0) 8.6 (3.5-17.0) 
Mean (SD) 
Diambala 4.3 (6.3) 6.8 (7.69) 
Falmado 9.4 (31.2) 12.9 (28.9) 
Macrohaematuria 
in % (95% CI) 
Diambala 2.2 (0.6-5.4) 2.1 (0.4-6.0) 
Falmado 5.2 (1.7-11.6) 8.6 (3.5-17.0) 
Microhaematuria 
in % (95% CI) 
Diambala 38.9 (31.8-
46.3) 
52.4 (43.9-60.8) 
Falmado 50.5 (40.1-
60.8) 
61.7 (50.2-72.3) 
4.4.3. Infection with S. mansoni 
The results of the infection with S. mansoni and other intestinal parasites in Diambala are 
presented in Table 4.3. Overall, the prevalence of S. mansoni was 43.8%. There was no 
statistically significant difference in infection prevalence among boys and girls. 17.3% of the 
children presented light infections (1-99 EPG), 23.8% moderate infections (100-399 EPG), 
whereas 2.7% of the children were heavily infected (≥400 EPG). The proportion of both 
liquid stools and blood in stool was 3.2%. 
In the mothers group, the prevalence of S. mansoni was 52.1%. Stratification by infection 
intensity revealed 13.4%, 29.6% and 9.2% light, moderate and heavy infections, respectively. 
The macroscopic characteristic of the stools from the mothers showed that 18.3% contained 
blood and that 2.1% were liquid. 
Chapter 4 - Schistosomiasis in infants and preschool-aged children 
62 
Table 4.3. Prevalence and intensity of S. mansoni infection, other helminth infections and stool 
consistency in children below the age of 5 years and their mothers in the village of Diambala, western 
Niger. 
Characteristics Children (< 5years) Mothers 
Number of individuals examined 185 143 
Prevalence of S. mansoni in % (95% CI) 43.8 (36.5-51.3) 52.1 (43.6-60.6) 
Prevalence of mixed infection with S. mansoni 
and S. haematobium in % (95% CI) 
28.6 (22.3-35.7) 37.3 (29.4-45.8) 
Mean infection intensity in EPG (SD) 80.7 (132.6) 151.4 (263.5) 
Infection intensity classes in % (95% CI) 
No infection 56.2 (48.7-63.5) 47.9 (39.4-56.4) 
Light infection (1-99 EPG) 17.3 (12.1-23.5) 13.4 (8.3-20.1) 
Moderate infection (100-399 EPG) 23.8 (17.8-30.6) 29.6 (22.2-37.8) 
Heavy infection (≥400 EPG) 2.7 (0.9-6.2) 9.2 (5.0-15.1) 
Liquid stools in % (95% CI) 3.2 (1.2-6.9) 2.1 (0.4-6.0) 
Blood in stool in % (95% CI) 3.2 (1.2-6.9) 18.3 (12.3-25.7) 
Enterobius vermicularis in % (95% CI) 8.6 (5.0-13.7) 2.8 (0.8-7.0) 
Hookworm in % (95% CI) 2.7 (0.9-6.2) 4.9 (2.0-9.9) 
Hymenolepis nana in % (95% CI) 0.0 (0.0-1.9) 2.1 (0.4-6.0) 
4.4.4. Co-infection with S. haematobium and S. mansoni 
In Diambala, more than a quarter (28.6%) of the preschool-aged children was co-infected 
with S. mansoni and S. haematobium. The respective prevalence of co-infection with both 
S. mansoni and S. haematobium among mothers was 37.3%. 
4.4.5. Risks factors for early childhood schistosome infections 
Table 4.4 summarises the results obtained with the questionnaire administered to the 
mothers in Diambala. The mothers knew about schistosomiasis, its symptoms, and the role of 
water contact in the transmission of the disease. Fig. 4.2a shows that the irrigation canal, 
which is the main water contact site for villagers, was also the principal source of water 
utilized by the women. The availability of latrines in the households was low (18.9%), and 
hence open defecation (“in the bush”) was practiced by four out five of the villagers (Fig. 
4.2b). 
Most of the mothers (69.8%) stated they brought infants younger than one year of age to 
the irrigation canal (Fig. 4.2c), thus children were put in contact with the transmission sites 
very early in their life. The water of the canal was used by 75.3% of the mothers to wash their 
children, while the water from the well or drilling was used by only 30.2% of the women (Fig. 
4.2d). As shown in Fig. 4.2e, three-quarter of the mothers said that they washed their children 
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directly in the canal (Fig. 4.3), and 51.3% said they used a bucket for bathing (Fig. 4.4). With 
the exception of one mother, all reported to use soap while washing their children (Fig. 4.2e). 
Table 4.4. Mothers’ knowledge and awareness of schistosomiasis in Diambala, western 
Niger (number of mothers interviewed = 147) 
Knowledge and awareness Positive responders (%) 
Know about schistosomiasis 142 (96.6) 
Know a place where one becomes infected 142 (96.6) 
Know that schistosomiasis is a water-related disease 135 (90.5) 
Know at least one symptom of schistosomiasis 140 (95.5) 
Fig. 4.2. Frequency in % of (A) water sources used by the mothers; (B) disposal sites of the human 
excreta; (C) age of the infants at first exposure to contamination sites; (D) water used to clean infants 
and preschool-aged children; and (E) cleaning practices of the infants by the mothers. 
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Fig. 4.3. A mother with her 1-year and 3-year-old children in the canal in Diambala, western 
Niger. 
Fig. 4.4. A young mother bathing their child in a small bucket, while older children are 
playing in the pond. 
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4.5.  Discussion 
This epidemiological survey in the western part of Niger has revealed that children below 
the age of five years are at significant risk of schistosomiasis. Moreover, it is also evident that 
in one of the two study villages presenting as a mixed infection focus of S. haematobium and 
S. mansoni, young children have contracted both forms of schistosomiasis. Our study 
population consisted of 282 infants and preschool-aged children, and their mothers (n = 224). 
To our knowledge, this is the largest study carried out to date for investigation of 
schistosomiasis among infants and preschool-aged children. In previous studies, Perel and 
colleagues (1985) examined 142 preschool-aged children also in Niger, Odogwu and co-
workers (2006) studied 136 young children in Uganda, whereas Mafiana et al. (2003) 
examined 209 young children, and Opara et al. (2007), another 126 preschool-aged children 
in Nigeria. Furthermore, our findings showed that co-infection with both S. haematobium and 
S. mansoni already occurs at very young age, since more than a quarter of the surveyed 
infants and preschool-aged children in Diambala were co-infected, an issue that has been 
neglected thus far. 
While we found a prevalence of S. haematobium of 50.5% and 60.5% in Falmado and 
Diambala, respectively, and a prevalence of 43.8% for S. mansoni in Diambala in our group 
of young children in western Niger, prevalence ranging from 3.9% to 71.8%, and from 7% to 
47.4% were found for S. haematobium and S. mansoni, respectively, in the other settings 
(Perel et al., 1985; Mafiana et al., 2003; Bosompen et al., 2004; Odogwu et al., 2006; Opara et 
al., 2007; Sousa-Figueiredo et al., 2008). It should be noted that the prevalence of S. mansoni 
reported by Odogwu et al. (2006) in Uganda was 47.4%, however this was only after carrying 
out a total of six Kato-Katz thick smear readings (three stool samples with duplicate Kato-
Katz examinations), while only a duplicate Kato-Katz examination was conducted in our 
study using a single stool sample. Furthermore, the Odogwu et al. (2006) study consisted of a 
sample size of only 19 preschool-aged children where such exhaustive confirmatory 
parasitological examinations were undertaken, with the remainder of the child cohort 
examined by single Kato-Katz but bolstered with urine-circulating cathodic antigen (CCA) 
rapid diagnostic test. Without doubt, we would have found a higher prevalence if we had 
carried out several Kato-Katz examinations on multiple stool samples, coupled with urine-
CCA tests. Hence the true S. mansoni prevalence in our study might be considerably higher 
than reported here, because of the lower sensitivity of a duplicate Kato-Katz thick based on a 
single stool sample when compared to multiple Kato-Katz thick smears obtained from 
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multiple stool samples (de Vlas and Gryseels, 1992; Utzinger et al., 2001; Booth et al., 2003; 
Bergquist et al., 2009). 
The high prevalence of S. mansoni both among young children and their mothers in 
Diambala reflects the expansion of intestinal schistosomiasis in the NRV upstream from 
Tillabéri. The intermediate host snail of S. mansoni, Biomphalaria pffeiferi, was found in five 
out of eight irrigated areas (Namarigoungou, Diambala, Bonféba, Toula and Daikaina) 
surveyed upstream and in the surrounding area of Tillabéri (Labbo et al., 2003). A previous 
investigation by Garba et al. (2004) found human infection with S. mansoni only in the village 
of Namarigoungou where a prevalence of 5.9% was observed. This constitutes a major health 
risk for the local population, which might be further exacerbated once the Kandadji dam 
construction is completed as noted before (Hunter et al., 1993; Tecsult, 2006). The Kandadji 
dam is located 187 km upstream of Niamey on the Niger River and the construction 
commenced in August 2008. The area for which major environmental, health and social 
impacts are predicted extends over approximately 4,500 km². The dam itself will be an earth 
embankment with a length of 8.78 km and a peak height of 231 m. The water surface is 
estimated at 282 km2 extending over a length of 60 km. The dam will be used for hydropower 
production (565 GWh) and irrigated agriculture (31,000 ha). Impoundment of the water 
reservoir will result in forced resettlement of approximately 35,000 people. The micro-
climate, which will result from the dam lake, will probably lead to an increase in the 
distribution area and the number of B. pfeiferi. Moreover, the migration phenomenon brought 
on by the arrival of workers for the dam construction and the forced resettlement of resident 
population, and also the introduction of new irrigated areas will increase the number of people 
at risk and those who will become infected (Lerer and Scudder, 1999; Steinmann et al., 2006). 
Urinary schistosomiasis is highly endemic in the two villages studied here. Indeed, the 
prevalence of S. haematobium in each village exceeded 50%, the threshold recommended for 
large-scale administration of praziquantel (WHO, 2002). To our knowledge, our study is the 
first to highlight such a high prevalence of S. haematobium in children below the age of five 
years in Niger. In a previous study conducted by Perel and colleagues (1985) in the village of 
Liboré (located near an irrigated zone of the Niger River) and in the village of Zarmeye 
(located near a temporary pond), a prevalence of 14.1% and 4.6%, respectively was found. 
In a study in Ghana, Bosompen et al. (2004) found a prevalence of 11.2% among children 
aged 2 months to 5 years with the youngest infected child only four months old, as assessed 
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by the urine sediment method. This technique is known to be less sensitive than urine 
filtration used in our study. By employing an immunological test, Bosompen and colleagues 
(2004) found a prevalence of 30% in the same study population. In a previous study carried 
out in Niger, the youngest infected child was six months old (Perel et al., 1985), as in the 
current study. In Nigeria, Opara et al. (2007) found a prevalence of 19.8% and Mafiana et al. 
(2003) found a prevalence of 71.8% in children younger than 5 years. The high prevalence 
observed in our study highlight the intense transmission of urinary schistosomiasis in the 
NRV. We did not observe a statistically significant difference between the prevalence 
according to age, even though previous studies showed infection may start at a very early age 
(Perel et al., 1985; Bosompen et al., 2004). 
Detection of 50 or more S. haematobium eggs per 10 ml of urine is regarded as an 
indicator of risk for morbidity, as is macrohaematuria (WHO, 2002), which is used by several 
control programmes as an indicator for the monitoring and for the identification of endemic 
communities warranting treatment. In Diambala, although the prevalence of infection was 
high, we did not find any heavily infected children or macrohaematuria. On the other hand, in 
Falmado, 6.2% of the children were heavily infected and 3.2% had macrohaematuria. This 
reveals that not only can the prevalence of S. haematobium be very high in the children below 
five years of age, but also that they can be heavily infected and therefore are at risk of 
developing morbidity very early in life. In Ebonyi Benue River Valley of Nigeria, Anosike et 
al. (2003) found a prevalence of 27.6% in children younger than five years. The children also 
had a very high mean arithmetic eggs count of 298.4 per 10 ml of urine. The high 
S. haematobium prevalence that we found in Falmado can be explained by the intensive 
transmission and by the fact that the village was never subjected to praziquantel 
administration prior to our study. 
In mothers of Diambala, the overall prevalence of S. mansoni was 52.1%. The prevalence 
of moderate infection and heavy infection were 29.6% and 9.2%, respectively. This reflects 
the high morbidity in women of childbearing age and justify the extension of large-scale drug 
administration campaigns to this target by WHO (Allen et al., 2002; Ajanga et al., 2006; 
Friedman et al., 2007). 
The overall prevalence of S. haematobium in mothers was 72.2% in Diambala, 
constituted by only light infections. The absence of heavy infection intensities is probably due 
to the impact of the previous mass treatment campaigns carried out by the national 
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schistosomiasis control programme. Mass treatment campaigns with praziquantel and 
albendazole, targeting all school-aged children and the total population in highly endemic 
areas, have been carried out in NRV in 2004 and 2005. Children under five years of age were 
treated with albendazole during integrated deworming and poliomyelitis vaccination 
campaigns in December 2006 for Falmado and March 2007 for Diambala with estimated 
coverage rates in excess of 90%. 
Since the main objective of the national schistosomiasis control programme is to control 
morbidity, it can therefore be concluded that a significant reduction of morbidity was obtained 
in the treated areas. In Falmado, a village that had not been targeted during the mass treatment 
campaigns, the prevalence of S. haematobium was 55.6% with a prevalence of 8.6% being 
heavy infections. 
In high schistosomiasis transmission areas, infants would be exposed to the risk of 
obvious infection, especially if they accompany their mothers to transmission sites or if they 
bathe regularly. In Diambala, 99.3% of the mothers questioned provided information on water 
contact related to their domestic activities and the exposure of their children to the risks of 
transmission. The proportion of mothers with a latrine in their house was low (17.7%), 
therefore the majority of human waste was disposed outside the village, in the bush and 
temporary ponds. The water of the irrigation canals was used for domestic activities by two-
third of the mothers. In our study the majority of the mothers (76.7%) were accompanied by 
their children to the canal or the pond and washed them with the contaminated water. Mothers 
brought their children with them because they did not have suitable guardian to watch over 
the children while they conducted their daily activities or because they planned on bathing 
their children in a bucket (51.8%) or directly in the water (52.8%) once their activities were 
complete. 
Bosompem et al. (2004) observed that 29.2% of the mothers wash their children directly 
in the irrigation canal. In our study the average time that a child spent in the water was 15 min 
(SD = 8 min). Our results are comparable with those of Odogwu et al. (2006) in Uganda 
where 71.4% of the mothers confirmed washing their children with lake water for an average 
duration of 28 min (SD = 15 min), hence considerably longer than in our study. Exposure 
time for the children when they accompanied their mothers was a determining factor in the 
transmission of schistosomiasis infection and its severity. The high rates of prevalence and 
intensity of infection found in school-aged children, the reason for which they are the priority 
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target of most control programmes, results from the fact that the infection accumulates from 
an early age. Due to this behaviour, school-aged children in hyperendemic zones are likely to 
develop severe clinical signs of schistosomiasis if they are left untreated. The harmful 
behaviour of the mothers with respect to not preventing their children from coming in contact 
with infested water could be explained by their ignorance of schistosomiasis prevention and 
transmission although in Diambala our results show that 90% of the mothers were aware that 
schistosomiasis is a water-related disease. Hence, it is possibly that the lack of accessible 
clean water combined with the necessity of taking their infants with them when performing 
their household chores could explain the persistence of such risk associated behaviour. 
The use of soap, although claimed by the majority of the mothers, did not seem to be 
convincing with regard to impeding cercariae from penetrating the unbroken skin. During our 
study, we observed mothers placing their children into the canals or in buckets for long 
periods of time for the children to play and the mothers to conduct their daily activities. The 
amount of time the children were in the contaminated water was largely sufficient for the 
child to become infected. 
In conclusion, the present study revealed the extent of S. mansoni and S. haematobium 
(co)infection in children aged less than five years in two hyper-endemic villages in Niger and 
highlights these infections as an important, yet neglected public health issue for 
schistosomiasis control. As S. mansoni is spreading in the NRV in the hydro-electric Kandadji 
dam area, it is conceivable that schistosomiasis in younger children will continue to increase, 
and thus to more accurately monitor and assess this issue, additional surveys are urgently 
needed to confirm and better quantify this geographical zone of infection. It is important to 
note that there is a persistence of risky behaviours within the study populations. More than 
80% of the women had no access to latrines and therefore disposed of their waste in nature 
and two-third of the women used the irrigation canals for both their water supply and to wash 
their children. We noticed a positive impact of the prior praziquantel administration on 
morbidity as the number of light infections was higher and in addition no severe infection was 
found in mothers in treated zones. This indicates that the high infection responsible for gross 
morbidity is preventable through regular treatment. Because of the safety of praziquantel, 
women of childbearing age should be given this drug during mass treatment campaigns and 
also on a routine basis in maternal health clinics. It is imperative that a system to determine 
where children of young age are heavily infected and then these children aged less than five 
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years should be treated during mass treatment campaigns in order to reduce or prevent the 
development of morbidity in this very young age group. The need for a suitable formulation 
of praziquantel (e.g. syrup) must be emphasised, which will help to readily administer 
praziquantel to this age group. 
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5.1.  Abstract 
The aim of this study was to assess the efficacy and safety of two closely spaced doses of 
praziquantel (PZQ) against Schistosoma haematobium and S. mansoni infection in school-
aged children, and to characterise re-infection patterns over a 12-month period. The study was 
carried out in five villages in western Niger: Falmado, Seberi and Libore (single 
S. haematobium infection foci), and Diambala and Namarigoungou (mixed S. haematobium-
S. mansoni infection foci). Parasitological examinations consisted of triplicate urine filtrations 
and triplicate Kato-Katz thick smears at each visit. Two 40 mg/kg oral doses of PZQ were 
administered 3 weeks apart. Adverse events were monitored within 4 hours after dosing by 
the survey team and 24 hours after treatment using a questionnaire. Our final study cohort 
comprised 877 children who were infected with either S. haematobium, or S. mansoni, or both 
species concurrently and received both doses of PZQ. Follow-up visits were conducted 6 
weeks, 6 months and 12 months after the first dose of PZQ. At baseline, the geometric mean 
(GM) infection intensity of S. haematobium ranged from 3.6 (Diambala) to 30.3 eggs/10 ml of 
urine (Falmado). The GM infection intensity of S. mansoni ranged from 86.7 (Diambala) to 
151.4 eggs/gram of stool (Namarigoungou). Adverse events were reported by 33% and 1.5% 
of the children after the first and second dose of PZQ, respectively. We found cure rates 
(CRs) in S. haematobium-infected children 3 weeks after the second dose of PZQ ranging 
between 49.2% (Falmado) and 98.4% (Namarigoungou) and moderate to high egg reduction 
rates (ERRs) (71.4-100%). Regarding S. mansoni, only moderate CRs and ERRs were found 
(51.7-58.8% in Diambala, 55.2-60.2% in Namarigoungou). Twelve months post-treatment, 
prevalence rates approached pre-treatment levels, but infection intensities remained low. In 
conclusion, PZQ, given in two closely spaced doses, is efficacious against S. haematobium, 
but the low ERR observed against S. mansoni raises concern about mounting PZQ tolerance. 
 
Keywords: Schistosomiasis, Schistosoma haematobium, Schistosoma mansoni, 
praziquantel, efficacy, safety, mixed infection, re-infection pattern, school-aged children, 
Niger 
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5.2.  Introduction 
Schistosomiasis, which is classified among the neglected tropical diseases (NTDs) (Hotez 
et al., 2006b; Molyneux et al., 2005; Utzinger et al., 2009), constitutes a considerable public 
health problem, particularly in Africa, where more than 95% of the cases are currently 
concentrated (Steinmann et al., 2006; Utzinger et al., 2009; Gryseels 2012). Ongoing efforts 
to re-evaluate the global burden due to schistosomiasis, taking into account also subtle 
morbidities, suggest that the burden could be as high as that owing to malaria (Hotez and 
Kamath, 2009; King and Dangerfield-Cha, 2008; Steinmann et al., 2006). In areas where 
schistosomiasis is highly endemic, the declared objective is to control morbidity (Savioli et 
al., 2009; WHO, 2002). Praziquantel (PZQ) is the drug of choice due to its good safety and 
therapeutic profile and ease of administration (single oral dose). Indeed, timely administration 
of PZQ improves the health and wellbeing of schistosome-infected people, and might prevent 
a significant proportion of HIV transmission in areas where HIV/AIDS and schistosomiasis 
co-exist (Hotez et al., 2009; Secor, 2012). 
In 2001, the World Health Assembly (WHA) put forth resolution 54.19, which called 
upon member states to regularly treat at least 75% and up to 100% of all school-aged children 
at risk of schistosomiasis (WHO, 2002). Treatment should be extended to other high-risk 
groups (e.g. fishermen or entire communities) whenever appropriate. With regard to the 
control of schistosomiasis and other helminthiases, since 2006, the World Health 
Organization (WHO) promotes a strategy phrased “preventive chemotherapy”, which relies 
on the regular administration of anthelminthic drugs to at-risk populations without prior 
diagnosis (WHO, 2006, 2010). In the meantime, several national integrated NTD control 
programmes have been launched in Africa (Kolaczinski et al., 2007; Kabatereine et al., 2010; 
Dembélé et al., 2012). These programmes are supported by international organisations such as 
the Bill & Melinda Gates Foundation, the United States Agency of International Development 
(USAID), among others. The supply of PZQ is a crucial part of this strategy (Savioli et al., 
2009; WHO, 2012). For the year 2010, for example, it has been reported that 33.5 million 
people were treated with PZQ, most of them (27.9 million) in Africa (WHO, 2012). However 
to reach the goal of WHA resolution 54.19, more than 100 million school-aged children in 
Africa alone require preventive chemotherapy with PZQ every year (Utzinger et al., 2009; 
Hotez et al., 2010; WHO, 2012). It is therefore anticipated that the use of PZQ will further 
increase in the years to come (Utzinger et al., 2009; Hotez and Pecoul, 2010; Hotez et al., 
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2010). Mounting drug pressure might increase the likelihood of resistance development, and 
hence, there is a pressing need to monitor the efficacy of PZQ (WHO, 1998; Doenhoff et al., 
2008) and to search for additional or alternative treatment strategies to prolong the useful life-
span of PZQ (Doenhoff et al., 2009; Inyang-Etoh et al., 2009; Obonyo et al.). The use of 
multiple dose regimens is among these strategies (Picquet et al., 1998; Utzinger et al., 2000; 
Tchuem Tchuenté et al., 2001; N'Goran et al., 2003; Sacko et al., 2009). Two doses of PZQ, 
spaced by a few weeks, are of particular relevance in high transmission areas, where people 
might be infected with both juvenile and adult schistosome worms. Since the activity of PZQ 
is restricted to the adult schistosomes, a first dose of the drug will not clear the juvenile 
worms, but a few weeks later, these parasites have developed into adult worms that are then 
susceptible to a second dose of PZQ (Sabah et al., 1986, Utzinger et al., 2003, Doenhoff et al., 
2008). Indeed, a recent systematic review quantified the incremental benefit of a second dose 
of PZQ, administered 2 to 8 weeks after an initial dose, for both S. haematobium and 
S. mansoni in Africa (King et al., 2011). 
 
Adverse events due to PZQ are important issues as they can jeopardize compliance rate 
(Sissoko et al., 2009; Keiser et al., 2010; Obonyo et al., 2010). Indeed, high frequency of 
adverse events after PZQ administration are often reported (Berhe et al., 1999; Keiser et al., 
2010; Lovis et al., 2012). These adverse events could be a cause of refusal of subsequent 
treatment rounds, and hence an important impediment for preventive chemotherapy 
programmes (Fleming et al., 2009). In-depth ethnographic research conducted in Uganda 
revealed that, among a host of other local dynamics, people may actively resist PZQ 
administration because of the tipping balance between adverse events and perceived benefits 
of deworming without prior diagnosis (Parker et al., 2008; Parker and Allen, 2011). 
The objectives of this study were to assess the efficacy and safety of two closely spaced 
doses of PZQ against S. haematobium and S. mansoni infections among school-aged children 
and to investigate re-infection patterns. The study was carried out in five highly endemic 
villages of Niger, two of which are characterized by the co-existence of both schistosome 
species, and we used standard protocols and quality-controlled diagnostic methods. 
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5.3.  Materials and methods 
5.3.1.  Study area 
The study was carried out in five villages in the western part of Niger in the regions of 
Dosso and Tillaberi between March 2007 and June 2008 (Fig. 5.1). Falmado (geographical 
coordinates: 12.5138° N latitude, 2.8611° W longitude) is located in the district of Boboye in 
close proximity to a permanent pond in the valley of Dallol Bosso, which is a fossil river 
running only during the rainy season. According to a census done in 2007 (before launching 
the current study), there were 677 inhabitants. The main activity of the population is farming 
(e.g. cultivation of cassava, potato and vegetables). Only S. haematobium is transmitted in the 
village, with Bulinus truncatus serving as the main intermediate host snail. Although 
malacological surveys recorded the presence of Biomphalaria pffeiferi, an important 
intermediate host snail of S. mansoni, no such infections were observed among the 
populations (unpublished data). 
Seberi (13.2944° N, 2.8611° W) and Libore (13.4027° N, 2.1902° W) are located in the 
district of Kollo, adjacent to irrigated fields of the Niger River valley. A population census 
carried out in 2001 reported total numbers of inhabitants of 1,635 and 2,464, respectively 
(National Census of the Population 2001). The main agricultural activity is rice farming with 
two harvests per year facilitated by an irrigation network established in the 1970s. 
Malacological surveys conducted in the area showed that only intermediate host snails of 
S. haematobium were present (Labbo et al., 2008). 
Diambala (14.3149° N, 1.3009° W) and Namarigoungou (14.3667° N, 1.2571° W) are 
situated upstream of Tillaberi along the Niger River. The population sizes in Diambala and 
Namarigoungou are 5,116 and 3,256, respectively. These two villages are located in an 
irrigated rice farming perimeter. Both S. haematobium and S. mansoni are transmitted in this 
area, with S. mansoni only quite recently (Labbo et al., 2003; Garba et al., 2004). 
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Fig. 5.1. Map showing the location of the five study villages in Niger where the efficacy and safety of 
two closely spaced doses of praziquantel treatments, including re-infection patterns were studied in 
2007 and 2008. 
5.3.2.  Study design 
The epidemiological design of the study presented here was a 12-month longitudinal 
cohort study after a treatment intervention. Children were orally administered PZQ at the dose 
of 40 mg/kg at baseline and 3 weeks later. Follow-up surveys were carried out 6 weeks, 6 
months and 12 months after the first dose of PZQ. Inclusion criteria were (i) acceptance to 
participate in the study; (ii) children aged 6-15 years; (iii) infection with either 
S. haematobium, or S. mansoni, or both species concurrently during baseline; and (iv) 
residency in the study villages for at least one year. 
 
5.3.3.  Ethics statement and operational considerations 
The study received approval from the national ethics committee of Niger (reference no. 
N01/2008/CCNE). The regional and district health and education authorities and the 
traditional and religious chiefs of the surveyed villages were informed of the study and kindly 
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asked to provide logistical support to our research team. The objectives and procedures of the 
study were explained to the parents or legal guardians of participating children. Due to the 
high illiteracy rate in these communities, we opted for oral rather than written informed 
consent. One month after the second dose of PZQ, preventive chemotherapy was provided by 
the national schistosomiasis and soil-transmitted helminthiasis control programme, and the 
five villages described here, were all included. At-risk populations were offered free PZQ 
(single 40 mg/kg oral dose) and albendazole (single 400 mg oral dose). Great care was taken 
not to re-treat children of our cohort. 
 
5.3.4.  Field and laboratory procedures 
Each child included in the study was invited to provide three urine samples (collected 
over three consecutive days) per survey, the baseline cross-sectional and each of the three 
follow-up surveys. Urine samples were collected between 10:30 and 14:00 hours and standard 
protocols were followed for diagnosis (WHO, 1985). In brief, urine samples were vigorously 
shaken and 10 ml were filtered using 13 mm diameter nucleopore filters. The filters were 
placed on a microscope slide, a drop of Lugol’s iodine was added, and then examined under a 
microscope by experienced laboratory technicians. The number of S. haematobium eggs per 
slide were counted and recorded for each child separately. Additionally, from children in 
Diambala and Namarigoungou, three stool samples were collected per survey over three 
consecutive days. The samples were subjected to the Kato-Katz technique with single 41.7 mg 
thick smears prepared from each sample (Katz et al., 1972). 
The laboratory examinations took place on site in Falmado, Diambala and 
Namarigoungou. For Libore and Seberi, which are located 25-40 km from Niamey, the 
samples were transferred and examined in our laboratory the same day. 
We classified intensity of schistosome infections according to WHO guidelines (WHO, 
2002). In brief, for S. haematobium, we stratified into light (1-49 eggs/10 ml of urine) and 
heavy infections (≥50 eggs/10 ml of urine). The intensity of S. mansoni infection was 
classified into light (1-99 eggs per gram of stool (EPG)), moderate (100-399 EPG) and heavy 
infections (≥400 EPG). We adhered to the following system of quality control: each day, 10 
slides from each technician were re-examined by a senior technician to check for internal 
consistency (acceptance rate: <10% of error rates). 
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5.3.5. Treatment and monitoring of adverse events 
After the baseline survey, all children were given PZQ (MED-PHARMN; batch Nb. 
06L11B) at a dose of 40 mg/kg. Children’s weight was measured with a digital scale. 
Treatment was administered early in the morning at school before children entered their class 
rooms, hence shortly after they had taken their breakfast at home. Treatment was 
accompanied by an orange juice, provided free of charge by the research team. Children were 
re-treated 3 weeks later with the same dose and batch of PZQ. 
For a period of 4 hours, children remained under medical supervision. In case vomiting 
occurred within 1 hour, children were re-dosed. Acute adverse events were recorded and 
appropriate measures taken by the study physician of our team. Twenty-four hours post-
treatment, children were invited to fill-in a questionnaire about any adverse events that 
occurred since drug administration. 
 
5.3.6.  Statistical analysis 
 
Data were entered into an Excel spreadsheet and analysed with EpiInfo 2000. Only those 
children who were found positive for S. haematobium and/or S. mansoni at the baseline cross-
sectional survey and had taken PZQ twice were considered for analysis (per-protocol 
analysis). 
PZQ efficacy was assessed by determining both the cure rate (CR) and the egg reduction 
rate (ERR). The CR is defined as the proportion of individuals infected either with 
S. haematobium or S. mansoni at baseline who became egg-negative 6 weeks after the first 
dosing. The CR 6 months after the first dose of PZQ was also determined. ERR was defined 
as the percentage reduction of the geometric mean (GM) egg counts for the positive 
individuals. The GM was calculated as the antilogarithm of the mean of the log-transformed 
egg counts only for the positive individuals. Our data also allowed characterising re-infection 
patterns, i.e. the proportion of children who were egg-negative 6 weeks after the first dosing 
but became egg-positive 6 and 12 months post-treatment. 
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P-values <0.05 were considered to indicate statistical significance. We compared 
proportions using the Pearson χ2 with Yates correction as appropriate. GM egg counts among 
different groups were compared using ANOVA. 
 
5.4.  Results 
5.4.1.  Study profile and compliance 
Fig. 5.2 shows the study profile, including the numbers of children participating at the 
various follow-up time points, stratified by village. Overall, 1,558 children of school-age were 
enrolled in the baseline cross-sectional survey. These children provide urine samples alone or 
both urine and stool samples in the mixed S. haematobium-S. mansoni transmission foci. The 
baseline parasitological screening revealed the highest prevalence of S. haematobium in 
Falmado (99.0%) followed by Libore (93.9%). A considerably lower prevalence was found in 
Namarigoungou (46.5%). 
The overall prevalence of S. mansoni was 66.2% in Namarigoungou and 62.4% in 
Diambala. The prevalence of mixed S. haematobium-S. mansoni infection was 41.6% in 
Diambala and 35.3% in Namarigoungou. According to the baseline survey, the total number 
of children with a Schistosoma infection was 1,205 (77.4% of the initially screened children). 
A total of 877 children received both doses of PZQ and were followed-up at 6 weeks, 6 
months and 12 months post-treatment. 
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Fig. 5.2. Survey profile chart comprising the number of children included, Schistosoma haematobium 
(Sh) and S. mansoni (Sm) prevalences at the baseline cross-sectional survey, the treatment rate and the 
attendance rate 6 weeks (W6), 6 months (M6) and 12 months (M12) after the first dose of two closely 
spaced doses of praziquantel. 
 
The characteristics of the children (number, sex and age) who were retained for the final 
analysis are summarised in Table 5.1. Stratified by village, between 150 (Falmado) and 223 
(Namarigoungou) children participated. There were more girls than boys with a sex ratio 
female:male of 1.2. The average age was 9.3 years with a range of 6 to 16 years. The 
youngest average age was noted in Falmado (8.2 years), while in Diambala the average age 
was 9.9 years. 
The compliance rates at the various follow-up surveys varied and we observed 
considerable differences from one village to another (Fig. 5.2). A particularly low compliance 
rate occurred 6 weeks after the first dose of PZQ (52.1%), which coincided with the long 
school holidays. Compliance at the 6 and 12 months post-treatment follow-ups were 79.4% 
and 82.3%, respectively. 
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Table 5.1. Characteristics of the surveyed school-aged children in five study villages in Niger in early 2007. 
 
Characteristics Single S. haematobium transmission foci  Mixed S. haematobium-S. mansoni transmission foci Overall total 
 Libore Seberi Falmado Total  Namarigoungou Diambala Total  
No. of children examined 163 161 150 474  223 180 403 877 
No. (%) of girls 77 (47.2) 87 (54.0) 90 (60.0) 254 (53.6)  128 (57.4) 99 (55.0) 227 (56.3) 481 (54.8) 
No. (%) of boys 86 (52.8) 74 (46.0) 60 (40.0) 220 (46.4)  95 (42.6) 81 (45.0) 176 (43.7) 396 (45.2) 
Mean age (SD) in years 9.0 (1.8) 9.0 (1.9) 8.2 (2.9) 9.1 (2.2)  9.3 (1.9) 9.9 (2.0) 9.6 (1.9) 9.3 (2.1) 
SD, standard deviation 
Table 5.2. Number (%) of acute adverse events (AEs) within 4 hours and solicited AEs (within 4-24 hours) reported by school-aged children (n=874) after the 
first and second dose of praziquantel (PZQ), spaced by 3 weeks, in a study carried out in five villages in Niger in 2007 
 
Adverse event No. (%) of AEs after the first dose of PZQ  No. (%) of AEs after the second dose of PZQ 
 Acute AEs Solicited AEs  Acute AEs Solicited AEs 
Abdominal pain 119 (13.6) 29 (3.3)  4 (0.5) 0 
Sleepiness 38 (4.4) 0  0 0 
Headache 32 (3.7) 2 (0.2)  2 (0.2) 0 
Itching 26 (3.0) 0  0 0 
Vomiting 26 (3.0) 6 (0.7)  6 (0.7) 0 
Skin rash 18 (2.1) 12 (1.4)  0 0 
Nausea 15 (1.7) 1 (0.1)  0 0 
Asthma 7 (0.8) 3 (0.3)  0 0 
Dizziness 5 (0.6) 0  0 0 
Haematuria 2 (0.2) 0  0 0 
Fever 0 1 (0.1)  1 (0.1) 0 
Total 288 (33.0) 54 (6.2)  13 1.5) 0 
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5.4.2.  Safety of PZQ 
Acute (within 4 hours) and solicited (within 4-24 hours) adverse events after the first and 
second dose of PZQ are shown in Table 5.2. As expected, the frequency of adverse events 
was higher after administration of the first dose of PZQ than the second one. Most of the 
adverse events occurred within 4 hours after PZQ administration; there were 288 acute 
adverse events versus 54 solicited adverse events after the first dose of PZQ. The respective 
numbers after the second dose dropped to 13 and nil. Abdominal pain was the most common 
adverse event (13.6% after the first dose of PZQ), followed by sleepiness (4.4%) and 
headache (3.7%). 
 
5.4.2.1.  Efficacy of PZQ against S. haematobium 
The efficacy of PZQ against S. haematobium infection determined 6 weeks and 6 months 
after the first dose of PZQ are shown in Table 5.3. In the single S. haematobium transmission 
foci, the GM egg counts at baseline varied from 4.9 (Seberi) to 30.3 eggs/10 ml of urine 
(Falmado). The prevalence of heavy infections (≥50 eggs/10 ml of urine) in these two villages 
was 5.6% and 38.8%, respectively. In Diambala and Namarigoungou, the two villages where 
S. mansoni co-exists, the GM of S. haematobium was 3.6 and 4.0 eggs/10 ml of urine, 
respectively. 
At the first follow-up time point, i.e. 6 weeks after the first and 3 weeks after the second 
dose of PZQ, CRs in Namarigoungou and Diambala were 98.4% and 96.0%, respectively. In 
the single S. haematobium transmission foci, the CRs were considerably lower, varying 
between 49.2% (Falmado) and 58.9% (Seberi). Among children who were still infected after 
these two closely spaced PZQ doses, infections were all of low intensity (<50 eggs/10 ml of 
urine). ERRs in the single S. mansoni transmission foci varied between 71.4% (Seberi) and 
92.1% (Falmado). 
Six months post-treatment, the observed CRs were higher in Namarigoungou and 
Diambala (both 100%) than in Seberi (82.5%), Falmado (57.7%) and Libore (42.0%). The 
GM egg counts had decreased to 2.8 eggs/10 ml of urine in Falmado. However, two of the 
treated children (1.5%) still presented with a heavy infection. 
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Table 5.3: Efficacy of two closely spaced doses of praziquantel (PZQ) against S. haematobium in five villages of Niger determined 6 weeks and 6 months 
after the first dose of PZQ and re-infection rates at 6 and 12 months post-treatment. 
 Single S. haematobium transmission foci  Mixed S. haematobium-S. mansoni transmission foci 
 Libore Seberi Falmado Total P-value  Namarigoungou Diambala Total P-value 
Before treatment           
No. of infected children treated with 
PZQ 
163 161 150 474   133 136 269  
No. (%) of children ≥50 eggs/10 ml of 
urine 
50 (30.7) 9 (5.6) 57 (38.8) 116 (24.5) <0.001  0 (0.0) 1 (0.7) 1 (0.4) n.a. 
GM egg count per 10 ml of urine (SD) 18.8 (5.3) 4.9 (3.8) 30.3 (3.5) 13.9 (5.1) <0.001  4.0 (2.3) 3.6 (2.4) 3.7 (2.3) 0.055 
6 weeks post-treatment           
No. of children examined 61 56 122 239   63 75 138  
No of children cured (CR in %) 34 (55.7) 33 (58.9) 60 (49.2) 127 (53.1) 0.430  62 (98.4) 72 (96.0) 134 (97.1) 0.740 
No. of children ≥50 eggs/10 ml of urine 0 0 0 0   0 0 0  
GM egg count/10 ml of urine (SD) 2.1 (2.5) 1.4 (1.7) 2.4 (1.5) 2.1 (2.5) 0.001  - - -  
ERR in % 88.2 71.4 92.1 84.9 <0.001  100.0 100.0 100.0 n.a. 
6 months post-treatment           
No. of children examined 100 160 130 390   95 110 205  
No of children cured (CR in %) 42 (42.0) 132 (82.5) 75 (57.7) 248 (63.6) <0.001  95 (100.0) 110 (100.0) 205 (100.0) n.a. 
No. (%) of children ≥50 eggs/10 ml of 
urine 
0 0 2 (1.5) 2 (0.5)   - - -  
GM egg count/10 ml of urine (SD) 2.5 (2.8) 1.4 (1.7) 2.8 (3.0) 2.3 (2.8) <0.001  - - -  
ERR in % 86.7 71.4 90.8 83.5 <0.001  100.0 100.0 100.0 n.a. 
No. of children reinfected/surveyed (%) 17/24 (70.8) 2/33 (6.1) 25/54 
(46.3) 
44/111 
(39.6) 
<0.001  0.0 0.0 0.0 n.a. 
12 months post-treatment           
No. of children examined 134 148 134 416   107 88 195  
No. (%) of children positive 125 (93.3) 79 (53.4) 83 (61.9) 287 (69.0) <0.001  0 (0.0) 5 (5.7) 5 (2.6) 0.041 
No. (%) of children ≥50 eggs/10 ml of 
urine 
15 (11.2) 1 (0.7) 2 (1.5) 18 (4.3) <0.001  0 (0.0) 0 (0.0) 0 (0.0) n.a. 
GM egg count/10 ml of urine (SD) 6.0 (4.8) 2.1 (2.6) 1.9 (2.9) 3.2 (4.1) <0.001  - 1.9 (1.7) 1.5 (1.7) n.a. 
ERR (in %) 68.1 57.1 93.7 76.9 <0.001  100.0    
No. of children reinfected/surveyed (%) 27/28 (96.4) 12/28 (42.9) 27/53 
(50.9) 
66/109 
(60.6) 
<0.001  0/53 (0.0) 4/49 (8.2) 4/102 (3.9) 0.107 
CR, cure rate; ERR, egg reduction rate; GM, geometric mean; n.a., not assessed; SD, standard deviation. 
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5.4.2.2. Efficacy of PZQ against S. mansoni 
The efficacy of two closely spaced doses of PZQ against S. mansoni infection in the two 
villages where both S. haematobium and S. mansoni co-exist are summarised in Table 5.4. At 
baseline, the level of S. mansoni infection was significantly higher in Namarigoungou than in 
Diambala (GM faecal egg counts: 151.4 EPG vs. 86.7 EPG, P <0.001). The prevalence of 
light infections (1-99 EPG) was 49.3% in Diambala and 27.5% in Namarigoungou. 
Two closely spaced doses of PZQ yielded similar CRs against S. mansoni: 60.2% in 
Namarigoungou and 58.8% in Diambala, as determined at the 6-week follow-up. The ERRs in 
the two villages were also comparable: 55.2% and 51.7%, respectively. Six months post-
treatment, the apparent CR in Diambala remained at the same level (59.0%), while it had 
dropped to 24.2% in Namarigoungou. However, no heavy S. mansoni infections (≥400 EPG) 
were observed in either village. The 6-month ERRs among infected children were 70.3% in 
Namarigoungou and 69.7% in Diambala. 
 
.
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Table 5.4: Efficacy of two closely spaced praziquantel (PZQ) doses administered to school-aged children infected with S. mansoni in two villages of Niger 
determined 6 weeks and 6 months after the first dose of PZQ and re-infection levels at 6 and 12 months post-treatment follow-up surveys. 
 Diambala Namarigoungou Total P-value 
Before treatment     
 No. of infected children treated with PZQ 140 193 333  
 No. (%) of children with light infection (1-99 EPG) 69 (49.3) 53 (27.5) 122 (36.6) <0.001 
 No. (%) of children with moderate infection (100-399 EPG) 61 (43.6) 116 (60.1) 177 (53.2) 0.003 
 No. (%) of children with heavy infection (≥400 EPG) 10 (7.1) 24 (12.4) 34 (10.2) 0.115 
 GM egg count/g of stool (SD) 86.7 (2.4) 151.4 (2.7) 124.9 (2.7) <0.001 
6 weeks post-treatment     
 No. of children examined 80 103 183  
 No of children cured (CR in %) 47 (58.8) 62 (60.2) 109 (59.6) 0.843 
 No. (%) of children with light infection (1-99 EPG) 30 (37.5) 29 (28.2) 59 (32.2) 0.180 
 No. (%) of children with moderate infection (100-399 EPG) 3 (3.8) 11 (10.7) 14 (7.7) 0.080 
 No. (%) of children with heavy infection (≥400 EPG) 0 (0.0) 1 (1.0) 1 (0.5) n.a. 
 GM egg count/g of stool (SD) 41.9 (2.3) 67.9 (2.5) 54.8 (2.5) <0.001 
 ERR in % 51.7 55.2 56.1 0.582 
6 months post-treatment     
 No. of children examined 117 149 266  
 No of children cured (CR in %) 69 (59.0) 36 (24.2) 105 (39.5) <0.001 
 No. (%) of children with light infection (1-99 EPG) 43 (36.8) 88 (59.1) 131 (49.2) <0.001 
 No. (%) of children with moderate infection (100-399 EPG) 5 (4.3) 25 (16.8) 30 (11.3) 0.001 
 No. (%) of children with heavy infection (≥400 EPG) 0 (0.0) 0 (0.0) 0 (0.0) n.a. 
 GM egg count/g of stool (SD) 26.3 (2.6) 44.9 (2.9) 38.3 (2.9) <0.001 
 ERR in % 69.7 70.3 69.3 0.946 
 No. of children reinfected/surveyed (%) 16/42 (38.1) 40/54 (74.1) 56/96 (63.4) <0.001 
12 months post-treatment     
 No. of children examined 104 158 262  
 No. (%) of children with no infection 48 (46.2) 42 (26.6) 90 (34.4) 0.001 
 1-99 EPG (%) 48 (46.2) 96 (60.8) 144 (55.0) 0.020 
 100-399 EPG (%) 7 (6.7) 19 (12.0) 26 (9.9) 0.161 
 ≥400 EPG (%) 1 (1.0) 1 (0.6) 2 (0.8) n.a. 
 GM egg count/g of stool (SD) 43.6 (2.8) 46.1 (2.6) 45.3 (2.6) <0.001 
 ERR in % 49.7 69.6 63.7 0.001 
 No. of children reinfected/surveyed (%) 24/39 (61.5) 35/54 (64.8) 59/93 (63.4) 0.746 
CR, cure rate; EPG, eggs per gram of stool; ERR, egg reduction rate; GM, geometric mean; n.a., not assessed; SD, standard deviation.
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5.4.2.3. Efficacy of PZQ in mixed versus single S. haematobium and S. mansoni 
infections 
The data presented here were only from the two villages (Namarigoungou and Diambala) 
with S. haematobium and S. mansoni co-exist. Table 5.5 shows the efficacy of two closely 
spaced PZQ doses against S. haematobium in the two villages were S. haematobium and 
S. mansoni are co-endemic. At baseline, the GM infection intensity of S. haematobium was 
higher in children concurrently infected with S mansoni than a S. haematobium mono-
infection (3.9 vs. 3.2; P =0.032). At the 6-week treatment follow-up, the GM infection 
intensity of S. haematobium was still higher in those children concurrently infected with 
S. mansoni than the S. haematobium mono-infected ones (2.1 vs. 1.0, P <0.001), owing to a 
significantly different ERR. At the 6-month treatment follow-up, all investigated children 
were apparently cured, and hence no differences observed regardless of whether children had 
a mono- or co-infection at baseline. 
With regard to efficacy of two closely spaced doses of PZQ against S. mansoni in the 
mixed transmission villages, at baseline, the prevalence of heavy S. mansoni infections (≥400 
EPG) was 12.1% in the co-infected subjects and 7.5% in those presenting a single S. mansoni 
infection, with no statistically significant difference between the two groups (Table 6). The 
GM faecal egg count was significantly higher in the co-infected children compared to the 
single S. mansoni-infected children (2.8 vs. 2.5, P <0.001). Six weeks post-treatment, the CR 
was similar between the two groups: 56.7% in co-infected children and 63.3% in those 
infected with S. mansoni singly (P = 0.370). ERRs were also comparable: 53.4% in co-
infected and 60.0% in the single-infected subjects (Table 5.6). Six months after the 
administration of two doses of PZQ, the CR was 40.0% in the co-infected subjects and 38.6% 
in the single-infected children. No heavy infections were observed in either group. Similar 
ERRs were observed: 69.3% in the mixed infections and 69.4% in the group singly infected 
with S. mansoni. 
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Table 5.5: Efficacy of two closely spaced doses of praziquantel (PZQ) against S. haematobium in two villages of Niger where both S. haematobium and 
S. mansoni co-exist (Namarigoungou and Diambala), as determined 6 weeks and 6 months after the first dose of PZQ. Data are stratified by children with 
single S. haematobium or mixed S. haematobium-S. mansoni infection. Re-infection patterns at 6 and 12 months post-treatment are also shown 
 
Characteristics Total S. haematobium 
mono-infection 
S. haematobium-
S. mansoni mixed 
infection 
P-value 
Before treatment     
 No. of S. haematobium-infected children 269 70 199  
 No. (%) of children ≥50 eggs/10 ml of urine 1 (0.4) 0 (0.0) 1 (0.5) n.a. 
 GM egg count/10 ml of urine (SD) 3.7 (2.3) 3.2 (2.2) 3.9 (2.4) 0.032 
6 weeks post-treatment     
 No. of children examined 138 34 104  
 No of children cured (CR in %) 134 (97.1) 32 (94.1) 102 (98.1) 0.223 
 No. (%) of children ≥50 eggs/10 ml of urine 0 (0.0) 0 (0.0) 0 (0.0 ) n.a. 
 GM egg count/10 ml of urine (SD) 2.1 (1) 1.0 (1) 2.1 (1) <0.001 
 ERR in % 43.2 68.8 46.2 0.029 
6 months post treatment     
 No. of children examined 205 39 166  
 No of children cured (CR in %) 205 (100.0) 39 (100.0) 166 (100.0) n.a. 
 No. (%) of children ≥50 eggs/10 ml of urine 0 (0.0) 0 (0.0) 0 (0.0) n.a. 
 GM egg count/10 ml of urine (SD) 0.0 - -  
 ERR in % 100.0 100.0 100.0 n.a. 
No. of children re-infected/surveyed (%) 0/269 (0.0) 0/39 (0.0) 0/166 (0.0) n.a 
12 months post treatment     
 No. of children examined 195 42 153  
 No. (%) of children ≥50 eggs/10 ml of urine 0 (0.0) 0 (0.0) 0 (0.0) n.a. 
 GM egg count/10 ml of urine (SD) 1.9 (2.1) 2.0 (1.0) 1.9 (2.3) 0.687 
 ERR in % 48.6 37.5 51.3 0.139 
 No. of children re-infected/surveyed (%) 4/99 (4.0) 1/19 (5.3) 3/80 (3.8)  
CR, cure rate; ERR, egg reduction rate; GM, geometric mean; n.a., not assessed; SD, standard deviation. 
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Table 5.6: Efficacy of two closely spaced doses of praziquantel (PZQ) against S. mansoni in two villages of Niger where both S. mansoni and S. haematobium 
co-exist (Namarigoungou and Diambala), as determined 6 weeks and 6 months after the first dose of PZQ. Data are stratified by children with single 
S. mansoni or mixed S. mansoni-S. haematobium infection. Re-infection patterns at 6 and 12 months post-treatment are also shown. 
Characteristics Overall 
 S. mansoni 
S. mansoni mono-
infection 
S. mansoni-
S. haematobium mixed 
infection 
P-value 
Before treatment     
 No. of S. mansoni-infected children 333 134 199  
 No. (%) of children with light infection (1-99 EPG) 122 (36.6) 50 (37.3) 72 (36.2) 0.833 
 No. (%) of children with moderate infection (100-399 EPG) 177 (53.2) 74 (55.2) 103 (51.8) 0.534 
 No. (%) of children with heavy infection (≥400 EPG) 34 (10.2) 10 (7.5) 24 (12.1) 0.174 
 GM egg count/g of stool (SD) 124.9 (2.7) 123.4 (2.5) 125.9 (2.8) <0.001 
6 weeks post-treatment     
 No. of children examined 185 79 104  
 No of children cured (CR in %) 109 (59.6) 50 (63.3) 59 (56.7) 0.370 
 No. (%) of children with light infection (1-99 EPG) 59 (32.2) 26 (32.9) 33 (31.7) 0.866 
 No. (%) of children with moderate infection (100-399 EPG) 14 (7.7) 2 (2.5) 12 (11.5) 0.023 
 No. (%) of children with heavy infection (≥400 EPG) 1 (0.0) 1 (1.3) 0 (0.0)  
 GM egg count/g of stool (SD) 54.8 (2.5) 49.3  (2.4) 58.7 (2.5) <0.001 
 ERR in % 56.1 60.0 53.4 0.446 
6 months post treatment     
 No. of children examined 266 101 165  
 No of children cured (CR in %) 105 (39.5) 39 (38.6) 66 (40.0) 0.822 
 No. (%) of children with light infection (1-99 EPG) 131 (49.2) 50 (45.5) 81 (49.1) 0.574 
 No. (%) of children with moderate infection (100-399 EPG) 30 (11.3) 12 (11.9) 18 (10.9) 0.808 
 No. (%) of children with heavy infection (≥400 EPG) 0 (0.0) 0 (0.0) 0 (0.0)  
 GM egg count/g of stool (SD) 38.3 (2.9) 37.7 (3.1) 38.7 (2.8) <0.001 
 ERR in % 69.3 69.4 69.3 0.970 
 No. of children re-infected/surveyed (%) 56/96 (63.4) 25/28 (89.3) 31/58 (60.8) 0.006 
12 months post treatment     
 No. of children examined 262 109 153  
 No of children cured (CR in %) 90 (34.4) 39 (35.8) 51 (33.3) 0.681 
 No. (%) of children with light infection (1-99 EPG) 144 (55.0) 57 (52.3) 87 (56.9) 0.464 
 No. (%) of children with moderate infection (100-399 EPG) 26 (9.9) 12 (11.0) 14 (9.2) 0.620 
 No. (%) of children with heavy infection (≥400 EPG) 2 (0.8) 1 (0.9) 1 (0.7)  
 GM egg count/g of stool (SD) 45.3 (2.6) 48.7 (2.6) 43.1 (2.6) <0.001 
 ERR in % 63.7 60.5 65.8 0.365 
 No. of children re-infected/surveyed (%) 59/93 (63.4) 30/42 (71.4) 29/51 (56.9) 0.147 
CR, cure rate; EPG, eggs per gram of stool; ERR, egg reduction rate; GM, geometric mean; SD, standard deviation.
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5.4.3 Re-infection patterns 
Patterns of re-infection with S. haematobium in the single transmission foci showed 
strong idiosyncrasies from one village to another. While only 6.1% of the surveyed children 
Seberi were re-infected 6 months after two closely spaced PZQ doses, the respective 
prevalences in Falmado and Libore were 46.3% and 70.8% (Table 3). In the two villages 
where both S. haematobium and S. mansoni co-exist, no re-infection with S. haematobium 
was observed among 205 children who were present at the 6-month follow-up (76.2% of the 
children included). Twelve months post-treatment, 27 out of 28 children surveyed in Libore 
were re-infected with S. haematobium (96.4%). In Falmado, at this post-treatment follow-up, 
half of the children surveyed were re-infected (50.9%), and only a slightly lower prevalence 
was found in Seberi (42.9%). The prevalence of heavy infections (≥50 eggs/10 ml of urine) at 
the 12-month follow-up varied between 0.7% (Seberi; the village with the lowest baseline 
infection prevalence) and 11.2% (Libore; the village with the highest baseline infection 
prevalence). 
In the S. haematobium-S. mansoni mixed transmission foci, the overall prevalence of 
S. haematobium was 2.6% among the 195 children (72.4% of the subjects included) who were 
re-examined 12 months post-treatment. No re-infection occurred in Namarigoungou and only 
four out of 49 children surveyed were re-infected in Diambala (8.2%). There were no heavy 
S. haematobium infections at the 12-month follow-up. The re-infection rate of those children 
who were negative 6 weeks after treatment was 8.2% in Diambala (Table 5.3). 
With regard to S. mansoni re-infection patterns, 12 months after PZQ administration, we 
observed infection prevalences of 53.8% in Diambala and 73.4% in Namarigoungou and 
respective GM faecal egg counts of 43.6 EPG and 46.1 EPG (Table 5.4). Heavy infections 
(≥400 EPG) were found in two children (0.8%). Almost two third of the children surveyed 
were re-infected with S. mansoni at this 12-months post-treatment follow-up (61.5% in 
Diambala and 64.8% in Namarigoungou). As can be seen in Table 5.6, the prevalence of 
S. mansoni at the 12-month post-treatment follow-up was similar between children who were 
infected with S. mansoni only (64.2%) and those with a S. mansoni-S. haematobium co-
infection at baseline (66.7%). Moreover, the GM S. mansoni faecal egg counts at the 12-
month follow-up in the two groups were similar (48.7 EPG vs. 43.1 EPG). Approximately two 
third of the children were re-infected with S. mansoni at the 12-month post-treatment follow-
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up (63.4%), with a slightly higher prevalence among those children who had a S. mansoni 
mono-infection at baseline (71.4%) compared with those who were co-infected at baseline 
(56.9%), but the difference showed no statistical significance (P = 0.147). 
5.5.  Discussion 
Our study is among the few investigations assessing the efficacy and safety of two 
closely spaced doses of PZQ (40 mg/kg each, given 3 weeks apart) against schistosomiasis. 
Such a strategy has been proposed as a means of improving PZQ effectiveness (Tchuem 
Tchuenté et al., 2001; King et al., 2011). Indeed young developing stages of schistosomes (i.e. 
schistosomula) are largely refractory to PZQ. However, administering a second dose of PZQ 
several weeks later should kill these parasites as they have matured (Doenhoff et al., 2008). 
Our study was conducted in the western part of Niger, one of the most intense schistosomiasis 
transmission zones encountered in West Africa. While S. haematobium is the principal 
schistosome species, there are also mixed S. haematobium-S. mansoni foci affecting already 
preschool-aged children (Tchuem Tchuenté et al., 2004; Garba et al., 2010). 
The overall compliance rate over the 12-month course of the study was acceptable with 
the exception of the 6-week post-treatment follow-up, which coincided with the long school 
holidays. Our final compliance rate 12 months after the first dose of PZQ (82.3%) was 
comparable to rates observed in Côte d’Ivoire, which ranged from 70% to 83% in four 
villages (N'Goran et al., 2001). In a study carried out in Cameroon, the 6-week post-treatment 
participation rate was 87%. However, due to changes in the school calendar, it dropped to 
41% another 3 weeks later when schools were on vacation (Tchuem Tchuenté et al., 2004). 
In terms of efficacy, we found moderate CRs 6 weeks post-treatment against 
S. haematobium in the single transmission foci (49.2-58.9%), and moderate-to-high ERRs 
(71.4-92.1%). Interestingly, considerably higher CRs were observed against S. haematobium 
in the mixed infection foci (96.0-98.4%) and ERRs approaching 100%. These observations 
point to the importance of monitoring PZQ efficacy in single and mixed Schistosoma 
transmission foci (Gouvras et al., 2012). Importantly though, the CRs observed in the single 
S. haematobium transmission foci are lower than the CR reported in a previous study (Garba 
et al., 2001), i.e. 68% 6 weeks after a single 40 mg/kg oral dose of PZQ, although the GM egg 
count at baseline was similar (35 eggs/10 ml of urine). Moreover, the ERR was higher in the 
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previous study using a single dose of PZQ (98.8% vs. 84.9% in the current study with a two-
dose regimen). While these findings might point to mounting PZQ tolerance, care is indicated 
because of the low 6-week compliance rate in the present study (approximately 50%). Sacko 
and colleagues, in a study conducted in two villages in Mali, assessed the efficacy of two 
closely spaced doses of PZQ (40 mg/kg each, given 2 weeks apart). Three months post-
treatment, CRs of 46.0% (Koulikoro) and 56.8% (Silengue) were obtained, hence similar to 
our findings in the Niger River valley (Sacko et al., 2009). CRs and ERRs are associated with 
pre-treatment infection intensity, as shown in previous studies (Olds et al., 1999; Utzinger et 
al., 2000; Gryseels et al., 2001; N'Goran et al., 2003). Tchuem Tchuenté and colleagues in 
Cameroon, adhering to the same treatment protocol as in the present study, obtained a higher 
CR (82.1%) and ERR (98.7%) (Tchuem Tchuenté et al., 2004). However, the baseline 
infection intensity was lower in the Cameroon study (19 eggs/10 ml of urine) compared to the 
present study (30 eggs/10 ml of urine in Falmado). N’Goran and colleagues also obtained 
higher CRs and ERRs among school-aged children in south-central Côte d’Ivoire (N'Goran et 
al., 2003) with similar pre-treatment infection intensity (23.8 eggs/10 ml of urine and 29.4% 
excreting ≥50 eggs/10 ml of urine). The post-treatment evaluation was done 3 weeks after the 
second dose of PZQ, but the interval between the two PZQ doses was 4 weeks while in the 
current study in Niger and the investigation done in Cameroon (Tchuem Tchuenté et al., 
2004), it was 1 week shorter. The observed CR in the aforementioned Côte d’Ivoire study was 
93% and the ERR was 96.6%. Midzi and colleagues in Zimbabwe administered two doses of 
40 mg/kg PZQ with an interval of 6 weeks in a highly endemic area for S. haematobium 
(33.8% of the children excreting ≥50 eggs/10 ml of urine) (Midzi et al., 2008). Drug efficacy 
evaluation in our study was undertaken 3 weeks after the second dose and showed high CR 
(88.5%) and ERR (98.2%). We speculate that the time interval between two doses of PZQ 
should be somewhat longer than 3 weeks as investigated in Niger (current study) and 
Cameroon (Tchuem Tchuenté et al., 2004), as the research conducted in Côte d’Ivoire 
(interval: 4 weeks) (N’Goran et al., 2003) and Zimbabwe (interval: 6 weeks) (Midzi et al., 
2008) showed higher efficacy. Moreover, we conjecture that the 3-week interval between the 
second dosing and drug efficacy evaluation might have been too short, as it might have still 
detected the tail of egg excretion (Danso-Appiah et al., 2009). This issue might explain the 
apparent improvement of the results at the 6-month post-treatment follow-up. To clarify this 
issue, we propose a study, where a cohort of individuals infected with S. haematobium is 
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followed-up weekly for at least 2 months after a single 40 mg/kg oral dose of PZQ, similar to 
a recent study done for S. mansoni (Scherrer et al., 2009). 
With regard to S. mansoni, only moderate CRs (58.8-60.2%) and ERRs (51.7-55.2%) 
were observed after two closely spaced doses of PZQ. The overall GM faecal egg count of 
those children who remained infected was 54.8 EPG 3 weeks after the second dose of PZQ. 
The current study represents the first investigation to assess the efficacy of PZQ against 
S. mansoni in this emerging focus of Niger, where only S. haematobium was present 10 years 
ago (Garba et al., 2004). No apparent improvements were observed in terms of CR and ERR 
at the 6-month post-treatment follow-up. A similarly low CR (58.1%) and ERR (56.2%) was 
observed in Ndombo, Senegal, after two 40 mg/kg PZQ doses given 4 weeks apart (Tchuem 
Tchuenté et al., 2001). The GM faecal egg count in this Senegal study was approximately 3-
fold higher than in our study. However, only 43 individuals were included in the Senegal 
study, and hence care is indicated when interpreting those results. In a larger study carried out 
in an emerging and high-intensity S. mansoni focus in the Senegal River valley, Piquet and 
colleagues reported an overall CR of 76.1% and an ERR of 88.1% after administration of two 
40 mg/kg doses of PZQ spaced by 4 weeks (Picquet et al., 1998). The GM faecal egg count 
was considerably higher than in the current study conducted in Niger (478 EPG vs. 125 EPG). 
In Côte d’Ivoire, two doses of PZQ (60 mg/kg given as split dose of 30 mg/kg within 3 hours 
plus a second dose of 40 mg/kg 5 weeks later) administered to S. mansoni-infected school-
aged children resulted in a CR of 89.7% and an ERR of 92.5%. In this Côte d’Ivoire study, 
the pre-treatment GM faecal egg count was 161 EPG (Utzinger et al., 2000). In Uganda, 
Kabatereine et al. administrated two doses of PZQ 6 weeks apart in an area highly endemic 
for S. mansoni near Lake Albert (GM egg count >250 EPG), which resulted in CR and ERR 6 
weeks after the second dosing of 69.1% and 99.6%, respectively (Kabatereine et al., 2003). 
The low CRs and ERRs against S. mansoni following two closely spaced doses of PZQ 
reported here is of concern and we recommend follow-up studies that include molecular 
methods that might help to elucidate strain-specific sensitivity/tolerance to PZQ. 
Interestingly, the treatment efficacy against S. haematobium and S. mansoni showed no 
statistically significant difference when comparing children with a single species or a mixed 
species infection, although samples sizes were arguable small. Previous studies have shown 
that treatment efficacy is influenced by pre-treatment infection intensity, and the current study 
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suggest that additional research is warranted to elucidate the potential role of the host’s co-
infection status pre-treatment. 
Re-infection patterns of schistosomiasis are governed by multiple factors, such as local 
ecology and epidemiology (e.g. temporary or permanent water bodies), human water-contact 
patterns, pre-treatment infection intensity and schistosome species (Kahama et al., 1999; 
Ernould et al., 2004). In general, re-infection with S. mansoni occurs more rapidly than 
S. heamatobium, as observed in several studies in mixed infection foci (Daffalla and Fenwick, 
1982; Ernould et al., 2004). N’Goran et al. followed a cohort of schoolchildren over a 24-
month period in four villages of south-central Côte d’Ivoire, which allowed detailed 
investigation of re-infection patterns with S. haematobium (N'Goran et al., 2001). The CR in 
the Côte d’Ivoire study, using a single 40 mg/kg dose of PZQ, was acceptable (82% 4 weeks 
post-treatment). Six months post-treatment, the observed prevalence was 63% in Taabo 
Village (GM egg count 0.4 eggs/10 ml of urine), 49% in Batera (GM egg count 3.2 eggs/10 
ml of urine), 14% in Bodo (GM egg count 1.4 eggs/10 ml of urine) and 10% in Assinzé (GM 
egg count 1.6 eggs/10 ml of urine). At the 12-month follow-up, the prevalence reached pre-
treatment level (85%) in Taabo Village, but remained low in the other three settings. In the 
present study, re-infection with S. haematobium was higher along the Niger River where 
transmission is permanent than in villages located in close proximity to temporary ponds 
where the transmission is seasonal although the pre-treatment infection intensities were 
comparable. 
In the current study, we monitored adverse events, both acute (within 4 hours) and 
solicited (within 24 hours), following PZQ administration. Three issues are worth 
highlighting. First, no severe adverse events were observed. Second, adverse events were 
transient; most of them had disappeared within the 4-24 hours post-treatment window. Third, 
adverse events were more frequent after the first dose of PZQ compared to the second one 3 
weeks later. Indeed, while 32.9% of the treated children reported mild and transient adverse 
events after the first dose of PZQ, only 1.5% did so after the second dose. Twenty-four hours 
after administration of a single 40 mg/kg oral dose of PZQ in an area endemic for S. mansoni 
in western Côte d’Ivoire, Raso and colleagues observed adverse events in 12.5% of the 
participants (Raso et al., 2004). Another study carried out in south-central Côte d’Ivoire, 
where S. haematobium is endemic, reported adverse events among 33.3% and 13.3% of 
children after the first and second dose of PZQ, respectively (N'Goran et al., 2001). Our study 
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therefore confirms that PZQ-related adverse events are associated with pre-treatment infection 
intensity. 
Abdominal pain, nausea and headache were the most frequent symptoms in the current 
study, as well as in previous investigations. Considerably higher frequencies of adverse events 
were reported in Kenya (Olds et al., 1999) and Ethiopia (Berhe et al., 1999). Briefly, in 
Kenya, 88% of individuals infected with S. mansoni and 65% of participants infected with 
S. haematobium reported adverse events, most of which occurred 4-6 hours after PZQ 
administration (Olds et al., 1999). In Ethiopia, the frequency of adverse events 4-6 hours post-
treatment was 14.7%, whereas 91.5% of the participants reported adverse events within 24 
hours, mainly abdominal pain and diarrhoea (Berhe et al., 1999). However, no mention of the 
feeding status of the participants prior to treatment was made. There is growing consensus 
that food intake prior to PZQ administration can lower the frequency and severity of adverse 
events, and hence improve acceptance of the treatment by community members. 
In conclusion, two 40 mg/kg oral doses of PZQ given 3 weeks apart are efficacious 
against S. haematobium in a highly endemic area of western Niger. However, low CRs and 
ERRs were observed against S. mansoni in the two mixed-infection villages. Our findings 
raise concern about mounting PZQ tolerance against S. mansoni, and hence warrant detailed 
follow-up studies, including laboratory investigations and rigorous monitoring of PZQ 
efficacy within the frame of the national schistosomiasis and other NTD control programmes. 
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6.1.  Abstract 
Given the characteristic age-prevalence curve of Schistosoma infection, preventive 
chemotherapy with praziquantel is primarily targeted at school-aged children, whilst, in 
highly endemic areas, other high-risk groups might be included for regular treatment. 
Nevertheless, schistosomiasis can affect children well before they reach school-age, but this 
population group is usually excluded from preventive chemotherapy. We assessed the safety 
and efficacy of praziquantel syrup (Epiquantel®) in preschool-aged children in three villages 
of Niger. Children aged ≤72 months provided multiple urine and stool samples that were 
microscopically examined using standard protocols. Schistosoma-positive children were 
treated with praziquantel syrup at a dose of 40 mg/kg after a meal of millet porridge. Children 
remained under medical supervision for four hours and adverse events were recorded. 
Additionally, a questionnaire was administrated to the mothers/guardians 24 hours post-
treatment for further probing of adverse events. Treatment efficacy was evaluated three and 
six weeks post-treatment using multiple stool and urine samples. A third of the 243 treated 
children reported adverse events within four hours, whilst a further 6.2% reported adverse 
events upon probing 24 hours post-treatment. Abdominal pain, bloody diarrhoea and 
sleepiness were the most common adverse events, but these were transient and self-limiting. 
Praziquantel syrup showed moderate-to-high efficacy against S. haematobium with egg 
reduction rates of 69.4% and 71.2% three and six weeks post-treatment and cure rates of 
85.7% (95% confidence interval (CI) 79.7-90.5%) and 94.9% (95% CI 90.5-97.6%), 
respectively. Considerably lower cure and egg reduction rates were observed against 
S. mansoni (e.g. cure rate at 6-week post-treatment follow-up was only 50.6% (95% CI 39.9-
61.2%). Concluding, praziquantel syrup is well tolerated in preschool-aged children with 
moderate-to-high efficacy against S. haematobium, but considerably lower efficacy against 
Chapter 6 - Safety and efficacy of praziquantel syrup 
 
109 
 
S. mansoni in Niger. A larger study is warranted to investigate the observed differences in 
species-specific susceptibilities and to assess operational issues and community-effectiveness. 
 
Keywords: Praziquantel, syrup formulation; Safety; Efficacy; Preschool-aged children; 
schistosomiasis; Schistosoma mansoni; Schistosoma haematobium; Niger 
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6.2.  Introduction 
Human schistosomiasis continues to constitute a major public health problem, 
particularly in sub-Saharan Africa (Utzinger et al., 2009; Gray et al., 2011; Rollinson et al., 
2012). Patent Schistosoma infection is characterised by the presence of parasite eggs in urine 
(Schistosoma haematobium) or faeces (Schistosoma mansoni and other species). The long-
term consequences of Schistosoma infection are bladder and liver fibrosis, portal 
hypertension, kidney failure and cancer of the bladder (Gray et al., 2011; Gryseels, 2012). 
Moreover, S. haematobium can cause genital bleeding, extra uterine pregnancies, and sterility 
in women and might enhance the risk of HIV transmission (Stoever et al., 2009; Kjetland et 
al., 2012). 
In Niger, it is currently estimated that between 1.7 and 4.5 million people are at risk of 
schistosomiasis (Schur et al., 2011). The main transmission areas are concentrated within 
irrigated fields of the Niger River valley (Garba et al., 2006). In certain villages, the 
prevalence of infection can exceed 90% in school-aged children (Garba et al., 2010b). Since 
2004, a national programme for the control of schistosomiasis and soil-transmitted 
helminthiasis was implemented by the Ministry of Health. In line with recommendations by 
the World Health Organization (WHO), the main objective is to reduce morbidity due to 
schistosomiasis and soil-transmitted helminthiasis by regularly treating at least 75% of 
school-aged children and other high-risk groups where the prevalence of infection exceeds 
50% (WHO, 2002; Garba et al., 2006). By focusing the treatment primarily on the school-
aged population, this strategy excludes younger children from praziquantel-based preventive 
chemotherapy. However, previous studies have shown that in highly endemic areas, women 
are accompanied by their young children when they spend time at water contact points where 
schistosomiasis transmission takes place (Stothard and Gabrielli, 2007; Garba et al., 2010a). 
Indeed, several studies carried out in Niger and elsewhere in Africa showed high prevalence 
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of Schistosoma infection in preschool-aged children (Garba et al., 2010a; Dabo et al., 2011; 
Stothard et al., 2011; Coulibaly et al., 2012; Ekpo et al., 2012). For example, in the villages of 
Falmado and Diambala in western Niger, we found S. haematobium prevalence of 50.5% and 
60.5%, respectively, in children below the age of 5 years. Worryingly, one 6-month-old child 
already exhibited a patent infection. Moreover, in Diambala where S. haematobium and 
S. mansoni co-exist, the prevalence of S. mansoni in the same group of children was 43.8%, 
whereas 28.6% of the children had a mixed S. haematobium-S. mansoni infection (Garba et 
al., 2010a). 
Praziquantel is widely used. Indeed, an estimated 33.5 million treatments were 
administered in 2010 alone (WHO, 2012). In general, praziquantel is well tolerated and can be 
used in pregnant and lactating women (Olds, 2003). Hence, the WHO extended its 
recommendations to also treat pregnant and lactating women (Savioli et al., 2009). It is 
therefore conceivable that infants are in contact with praziquantel by the intermediary of the 
mother’s milk when lactating mothers are treated (Olds, 2003). However, the lack of 
information on morbidity, safety and efficacy of praziquantel in preschool-aged children are 
important reasons evoked for non-integration of this age group in preventive chemotherapy 
control programmes (Stothard and Gabrielli, 2007). The absence of an adapted oral 
formulation for the youngest children (e.g. syrup) is an additional reason for the non-inclusion 
of this age group in preventive chemotherapy (WHO, 2007; Keiser et al., 2011). Indeed the 
use of tablets to deworm young children, especially those aged below 2 to 3 years, might lead 
to chocking, which has resulted in fatalities during large-scale deworming campaigns, as 
reported from Ethiopia and Madagascar (Yewale and Dharmapalan, 2012). Recent studies 
focussing on the epidemiology and control of schistosomiasis in preschool-aged children used 
crushed praziquantel tablets, mixed with water or a juice, before oral administration (Odogwu 
et al., 2006; Sousa-Figueiredo et al., 2009; Garba et al., 2010a; Coulibaly et al., 2012). 
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Administration of crushed praziquantel tablets was efficacious and well tolerated (adverse 
events were mainly mild and self-limiting, disappearing within a few hours). 
In Egypt, where praziquantel syrup (Epiquantel®) is available, children under the age of 5 
years have been treated with this formulation. However, limited information exists on safety 
and efficacy. Hence, the WHO provided different Ministries of Health and research groups 
with a syrup formulation to assess its safety, efficacy and compliance issues. A study carried 
out in Uganda found that praziquantel syrup was equally efficacious than crushed 
praziquantel tablets among children below the age of 5 years (cure and egg reduction rates 
were above 80% and similar in both groups) with no difference in adverse events and non-
compliance profiles (Navaratnam et al., 2012). The objective of the current study was to 
assess the safety and efficacy of Epiquantel® in preschool-aged children in Niger in order to 
provide additional evidence for the treatment of this age group with praziquantel as part of the 
ongoing preventive chemotherapy control programmes implemented in highly endemic areas. 
 
6.3.  Materials and methods 
6.3.1.  Study design and investigational drug 
We present an analytical intervention study aiming to assess the safety and efficacy of 
praziquantel syrup in preschool-aged children infected with S. haematobium and/or 
S. mansoni. In this cohort study, children with patent Schistosoma infection were treated and 
followed-up 3 and 6 weeks post-treatment. 
The investigational drug is Epiquantel® (batch no. 087684), an oral suspension of 
praziquantel presented in a 15 ml bottle with a total dose of 1,800 mg. The syrup is 
manufactured by Egyptian International Pharmaceutical Industries Co. (EIPICO). 
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6.3.2.  Study sites 
 
The study was carried out in three villages of Niger: Ndounga, Bonfeba and Zamakoira. 
Ndounga (geographical coordinates 13°21’34.9” N latitude and 2°14’51” E longitude) is 
located in the department of Kollo (Tillabéri region), approximately 20 km east of the capital 
town Niamey, and is situated in close proximity to an irrigated rice perimeter. Other crops 
produced here are millet, groundnut and beans. Water is supplied via several individual wells, 
drilling and a small drinkable water conveyance. There are three schools and a health centre 
in Ndounga. The only human schistosome species present is S. haematobium. A pre-selection 
survey conducted in March 2010 in school-aged children found a very high prevalence of 
83.3%. A door-to-door census carried out by our team in early 2010 revealed a population of 
1,207 inhabitants. Large-scale administration of praziquantel has been carried out in 2004, 
2005, 2007 and 2009 by the Ministry of Health, usually reaching high coverage. 
Bonfeba (14°22’32.52” N, 1°12’43.19” E) is located 45 km in the west of Tillabéri. 
During our March 2010 census, we determined the population at 2,106 inhabitants. The 
economic activity is mainly based on rice cultivation, fishing and livestock rearing. Irrigation 
canals have been identified as the main transmission sites for schistosomiasis. A pre-survey 
carried out in school-aged children in March 2010 found a prevalence of 66.7% for 
S. mansoni and 21.1% for S. haematobium. There are three primary schools and one health 
centre. Water supply is poor; indeed, the village counts only one drilling. Preventive 
chemotherapy using praziquantel has been implemented between 1997 and 2000 by the Niger 
River Valley Bilharzia Control Project (Garba and Alarou, 2000) and again in 2004, 2005, 
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2007 and 2009 by the national control programme supported by the Schistosomiasis Control 
Initiative (Fenwick et al., 2009). 
Zamakoira (13°42’36.72” N, 1°43’10.56” E) is located in Kollo department. Our March 
2010 census revealed a population of 1,140 people. The main activities of the population are 
irrigated rice farming with two production cycles per year. Additionally, in the rainy season, 
millet is cultivated. The village has one primary school and one health centre. The main water 
sources are a small river crossing the village and two pumps. A survey carried out in May 
2010 found a prevalence of 42.5% for S. haematobium among school-aged children. The 
village received preventive chemotherapy with praziquantel at the same time as Bonfeba. 
 
6.3.3.  Study population 
After completing village censuses in March 2010, we invited all the mothers/guardians 
who had been registered with children aged ≤72 months to participate in our study. The 
following inclusion criteria were employed: (i) age ≤72 months; (ii) living in the village for at 
least six months prior to the start of the study; (iii) written informed consent form signed by 
parents or guardians; (iv) infected with S. haematobium, or S. mansoni or both species 
concurrently; (v) good health as determined by a medical doctor; (vi) no anthelminthic 
treatment one month before the start of the study; and (vii) no participation in any other 
clinical trial. 
 
6.3.4.  Procedures 
6.3.4.1.  Questionnaire survey and clinical examination 
The exact age of the children, their medical background and medication history were 
obtained from the health booklet of the children. For children presenting without this health 
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booklet, a questionnaire was administrated to the mothers/guardians to collect this essential 
set of information. 
A clinical examination was performed by a physician to assess the general health status 
of the child. Based on these findings, it was decided whether or not a child could be included 
in the praziquantel syrup safety and efficacy study. For participating children, their weight 
was determined using a digital scale (nearest 0.1 kg) and their axillary temperature 
determined with a digital thermometer (nearest 0.01 °C). 
6.3.4.2.  Parasitological examination of urine and stool samples 
Eligible children were invited to provide three urine samples over consecutive days in 
each of the three cross-sectional surveys that were processed using standard protocols. In 
brief, urine samples were collected between 10:30 and 14:00 hours and subjected to a 
filtration method. Urine samples were vigorously shaken and 10 ml were filtered using 13-
mm diameter Nucleopore filters. The filters were placed on microscope slides, a drop of 
Lugol’s iodine added, before examination under a microscope by experienced laboratory 
technicians. The number of S. haematobium eggs per slide was counted and recorded for each 
child separately. 
Three stool samples were collected over consecutive days at baseline in all three villages 
and for the two follow-ups only in Bonfeba (sole village where S. mansoni occurs) and 
subjected to the Kato-Katz technique. We prepared 41.7 mg thick smears from each stool 
sample (Katz et al., 1972). 
Intensity of schistosome infections were classified according to WHO guidelines (WHO, 
2002). Hence, for S. haematobium, intensity was stratified into light (1-49 eggs/10 ml of 
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urine) and heavy infections (≥50 eggs/10 ml of urine). The intensity of S. mansoni infection 
was classified as light (1-99 eggs per gram of stool (EPG), and moderate/heavy infection 
(≥100 EPG). 
 
6.3.4.3.  Treatment and assessment of adverse events 
A dose of 40 mg/kg of praziquantel was administered to children identified with patent 
Schistosoma infection. All children were given a millet-based wafer and porridge prior to 
treatment, in order to enhance praziquantel bioavailability (Castro et al., 2000). 
Praziquantel syrup bottles were vigorously shacked to homogenize the solution. The 
exact quantity of medicine was taken with a millilitre scale pipette (Figure 6.1a). The dose 
was then diluted with bottled water in a cup and given to the children by their 
mothers/guardians (Figure 6.1b). In case vomiting occurred within one hour of drug 
administration, a second dose was administered. Children remained under medical 
supervision for a period of four hours. Acute adverse events were recorded and appropriate 
measures taken by the study physician. After this 4-hour direct surveillance period, 
mothers/guardians and their children were allowed to return home. Mothers/guardians were 
encouraged to report adverse events that occurred within 24 hours post-treatment. 
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Fig. 6.1. Dosing the required amount (40 mg/kg) of praziquantel syrup (A) and administration of the 
syrup by the child’s mother (B) 
 
6.3.5.  Ethical consideration 
Authorization to undertake the study was obtained from the national ethics committee of 
Niger (no. 07/2010/CCEN). Village authorities and local health authorities were informed 
about the study. The objectives, procedures, potential risk and benefits were explained in the 
local language, using lay terms, to all the mothers/guardians. Written informed consent was 
obtained from all the participating mothers/guardians. It was emphasised that participation 
was voluntary, and hence children could be withdrawn from the study without further 
obligation. At the end of the study, all participating children were again treated with 
praziquantel syrup at 40 mg/kg. 
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6.3.6.  Statistical analysis 
Data were collected on paper forms and double-entered and analysed using EpiInfo 
version 3.5.3 (Centers for Disease Control and Prevention; Atlanta, USA). Only those 
children who were found positive for S. haematobium and/or S. mansoni at the baseline cross-
sectional survey and who were given praziquantel syrup were considered for analysis (per-
protocol analysis). 
The proportion of children experiencing adverse events within four hours (assessed by 
the study physician) and within 24 hours (reported by mothers/guardians) was calculated. 
Cure rate (CR) and egg reduction rate (ERR) 3 and 6 weeks post-treatment were the primary 
efficacy measures. CR was defined as the proportion of individuals infected either with 
S. haematobium or S. mansoni at baseline who became egg-negative 3 or 6 weeks after the 
treatment. ERR was defined as the percentage reduction of the geometric mean egg count for 
the positive individuals. The geometric mean was calculated as the antilogarithm of the mean 
of the log-transformed egg counts only for Schistosoma-positive individuals. 
P-values <0.05 were considered to indicate statistical significance. We compared 
proportions using Pearson’s χ2 with Yates correction. Geometric mean egg counts among 
different groups were compared using Anova or Kruskal-Wallis test, as appropriate. 
 
6.4.  Results 
6.4.1.  Characteristics of the study population 
Overall, 243 children met our inclusion criteria, i.e. they were ≤72 months of age, lived in 
the village for at least 6 months before the study, had written informed consent by 
parents/guardians, were infected with either S. haematobium, or S. mansoni or both species 
concurrently, they were of good general health, did not receive anthelminthic treatment within 
Chapter 6 - Safety and efficacy of praziquantel syrup 
 
119 
 
the past month and did not participate in other trials, and hence they were treated with 
praziquantel syrup. The largest group of children came from Bonfeba, the village where 
S. haematobium and S. mansoni co-exist (43.2%). There were significantly more boys than 
girls (138 versus 105, χ2=4.45, p=0.035). The mean age of the children was of 41 months 
(standard deviation (SD), 16 months) ranging from 1 to 67 months. The mean weight of the 
children was 12.6 kg (range, 5.1-18.2 kg). The number of children with a S. haematobium 
mono-infection was 147, while 78 had a S. mansoni mono-infection. Eighteen children were 
identified with mixed infections. 
 
Table 6.1 
Characteristics of the surveyed preschool-aged children, stratified by study setting 
Village Female Male Total 
Bonfeba  48 (45.7%) 57 (54.3%) 105 
Ndounga  24 (42.9%) 32 (57.1%) 56 
Zamakoira  33 (40.2%) 49 (59.8%) 82 
Total  105 (43.2%) 138 (56.8%) 243 
 
6.4.2.  Safety of praziquantel syrup 
No serious adverse events were observed throughout the study. The overall proportion of 
children experiencing at least one adverse event after treatment was 34.2%. Most of the 
adverse events occurred within four hours after drug administration (32.5%), while the 
proportion of adverse events 24 hours post-treatment was considerably lower (6.2%). We 
found no difference in the occurrence of adverse events in relation to age (χ2=0.11, p=0.991 
for the occurrence of at least one adverse event). 
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Table 6.2 
Frequency (%) of adverse events among preschool-aged children in Niger treated with praziquantel 
syrup, according to the time of occurrence stratified by children’s age 
1-23 
months 
24-35 
months 
36-59 
months 
60-67 
months 
Total 
Number  included 33 35 120 55 243 
Adverse events (within 4 hours post-
treatment) 
36.4% 34.3% 30.8% 32.7% 32.5% 
Adverse events (between 4 and 24 
hours post-treatment) 
3.0% 8.6% 5.0% 9.1% 6.2% 
At least one adverse event 36.4% 34.3% 33.3% 34.5% 34.2% 
The most common adverse event was abdominal pain (30.6%), followed by bloody 
diarrhoea (16.2%) and sleepiness (15.3%). The proportion of children vomiting was 7.1%. 
Three out of the 18 reported bloody diarrhoeal episodes occurred within four hours post-
treatment, as reported to the study physician. Thirteen children reported fever, all occurring 
within the first four hours post-treatment. 
6.4.3.  Efficacy of praziquantel syrup against S. haematobium 
The results of the efficacy of praziquantel syrup against S. haematobium are summarised 
in Tables 6.3 and 6.4. At baseline, 165 children were infected with S. haematobium, most of 
them with light intensities (1-49 eggs/10 ml of urine), whereas 12.7% showed heavy 
infections (≥50 eggs/10ml of urine). In Bonfeba, all of the S. haematobium infections were of 
light intensity. The proportion of heavy infections was higher in Ndounga (17.9%) than in 
Zamakoira (13.4%) with no statistically significant difference (χ2=0.36, p=0.549). The 
infection intensity varied significantly according to village (Anova, F=6.52, p=0.001). The 
overall geometric mean egg count per child was 5.8 eggs/10 ml of urine. A higher geometric 
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mean egg count was found in Ndounga (9.2 eggs/10 ml of urine) compare to Zamakoira (5.5 
eggs/10 ml of urine). The baseline geometric mean egg count and the proportion of heavy 
infection was higher among children aged ≥60 months that their younger counterparts (Table 
6.4), but no significant difference was observed between these two age classes (Anova, 
F=0.57, p=0.63). There was also no difference in the infection intensity between sex (χ2=1.02, 
p=0.310) during the baseline cross-sectional survey. 
Three weeks post-treatment, the overall CR against S. haematobium was 85.7% (95% 
confidence interval (CI) 79.7-90.5%) (Table 6.3). It was 100% in Bonfeba, 80.8% in Ndounga 
and 84.1% in Zamakoira. The overall geometric mean ERR was 69.4%, ranging between 
61.0% (Zamakoira) and 100% (Bonfeba). 
Six weeks after treatment, observed CRs were slightly higher in all the three villages. The 
global CR was 94.9% (95% CI 90.5-97.6%). It was 100% in Bonfeba, 97.6% in Zamakoira 
and 88.2% in Ndounga. The overall geometric mean ERR was 76.6% with a geometric mean 
egg count of 1.4 eggs/10 ml of urine. 
 
Chapter 6 - Safety and efficacy of praziquantel syrup 
 
122 
 
 
Table 6.3  
Efficacy of praziquantel syrup against S. haematobium infection in preschool-aged children in Niger 
stratified by setting 
 
 
Characteristics Study setting Total 
 Bonfeba Ndounga Zamakoira  
Baseline     
 Number (%) of children 
included 
27 (16.1) 56 (33.3) 82 (50.6) 165 (100.0) 
 Number (%) of children with 
light infection (1-49 eggs/10 ml of 
urine) 
27 (100) 46 (82.1) 71 (86.6) 144 (87.3) 
 Number (%) of children with 
heavy infection (≥50 eggs/10 ml of 
urine) 
0 (0.0) 10 (17.9) 11 (13.4) 21 (12.7) 
 Geometric mean egg count per 
10 ml of urine 
2.3 9.2 5.2 5.6 
Three weeks post-treatment    
 Number (%) of children 
examined 
27 (100.0) 52 (92.9) 82 (100.0) 161 (97.6) 
 Number of children cured (CR, 
%) 
27 (100.0) 42 (80.8) 69 (84.1) 138 (85.7) 
 Geometric mean egg count per 
10 ml of urine 
0.0 1.5 2.0 1.7 
 Geometric mean egg reduction 
rate (ERR, %) 
100.0 83.6 61.0 69.4 
Six weeks post-treatment    
 Number (%) of children 
examined 
25 (92.6) 51(91.1) 81 (98.8) 157 (95.2) 
 Number (%) of children cured 
(CR, %) 
25 (100.0) 45 (88.2) 79 (97.5) 149 (94.9) 
 Geometric mean egg count per 
10 ml of urine 
0.0 1.5 1.0 1.4 
 Geometric mean egg reduction 
rate (ERR, %) 
100.0 83.6 80.8 71.2 
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Table 6.4 
Efficacy of praziquatel against S. haematobium in preschool-aged children in Niger, stratified 
by age 
Characteristics Age (months) Total 
 1-23 24-35 36-59 60-67  
Baseline      
 Number (%) of children 
included 
21 (12.7) 26 (15.8) 83 (50.3) 35 (21.2) 165 (100.0) 
 Light infection (1-49 
eggs/10 ml of urine) 
20 (95.2) 23 (88.5) 75 (90.4) 26 (74.3) 144 (87.3) 
 Heavy infection (≥50 
eggs/10ml of urine) 
1 (4.8) 3 (11.5) 8 (9.6) 9 (25.7) 21 (12.7) 
 Geometric mean egg 
count per 10 ml of urine 
2.24 4.29 5.28 12.98 5.55 
Three weeks post-
treatment 
     
 Number (%) of children 
examined 
21 (100.0) 24 (92.3) 82 (98.8) 34 (97.1) 161 (97.6) 
 Number (%) of children 
cured (CR, %)  
18 (85.7) 23 (95.8) 70 (85.4) 27 (79.4) 138 (85.7) 
 Geometric mean egg 
count per 10 ml of urine 
1.4 3.0 1.7 1.7 1.7 
 Geometric mean egg 
count reduction rate 
(ERR, %) 
37.1 30.1 67.2 86.9 69.4 
Six weeks post-treatment      
 Number (%) of children 
examined 
19 (90.5) 24 (92.3) 81 (97.6) 33 (94.3) 157 (95.2) 
 Number of children cured 
(CR, %) 
18 (94.7) 23 (95.8) 76 (93.8) 32 (97.0) 149 (94.9) 
 Geometric mean egg 
count per 10 ml of urine 
1.0 1.0 1.6 1.0 1.4 
 Geometric mean egg 
reduction rate (ERR, %) 
55.4 76.7 68.9 92.3 71.2 
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6.4.4.  Efficacy of praziquantel syrup against S. mansoni 
The results of the efficacy of praziquantel syrup against S. mansoni are summarised in 
Table 6.5. At baseline, 96 children were infected with S. mansoni. Most of the infections were 
of light intensity (61.5%). Children aged 1-23 months showed the highest proportion of light 
infection, while children aged 36-59 months had the highest proportion of moderate and 
heavy infection (46.8%). The overall geometric mean egg count was 71.8 EPG. 
Three weeks post-treatment, the overall CR was 75.0% (95% CI: 65.1-83.2%) with a 
geometric mean ERR of 66.7%. The CR was higher in children aged 1-23 months compared 
to their older counterparts (83.3% versus 66.7%). 
Six weeks after treatment, a considerably lower overall CR was determined (50.6%, 95% 
CI 39.9-61.2%) but it remained stable in the youngest children (90.0% in children aged 1-23 
months). The geometric mean ERR six weeks post-treatment was low (18.5%). 
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Table 6.5 
Efficacy of praziquantel against S. mansoni in preschool-aged children in Niger, stratified by 
age 
Characteristics Age (months) Total 
1-23 24-35 36-59 60-67 
Baseline 
Number (%) of children 
included 
14 (14.6) 12 (12.5) 47 (48.9) 23 (24.0) 96 (100.0) 
Number (%) of children 
with light infection (1-
99 EPG) 
12 (85.7) 8 (66.7) 25 (53.2) 14 (60.9) 59 (61.5) 
Number (%) of children 
with moderate and 
heavy infection (≥100 
EPG) 
2 (14.3) 4(33.3) 22(46.8) 9 (39.1) 37 (38.5) 
Geometric mean egg 
count (EPG) 
44.6 64.4 73.2 97.7 71.8 
Three weeks post-
treatment 
Number (%) of children 
examined 
12 (85.7) 12 (100.0) 43 (91.5) 21(91.3) 88 (91.7) 
Number of children cured 
(CR, %) 
10 (83.3) 7 (58.3) 35 (81.4) 14 (66.7) 66 (75.0) 
Geometric mean egg 
count (EPG) 
13.9 53.3 21.8 18.2 23.9 
Geometric mean egg 
reduction rate (ERR, %) 
68.9 17.2 70.2 81.3 66.7 
Six weeks post-
treatment 
Number (%) of children 
examined 
10 (71.4) 10 (83.3) 43(91.5) 20 (86.9) 83 (86.5) 
Number of children cured 
(CR, %) 
9 (90.0) 3(30.0) 22 (51.2) 8 (40.0) 42(50.6) 
Geometric mean egg 
count (EPG) 
24.0 74.0 51.1 69.1 58.5 
Geometric mean egg 
reduction rate (ERR, %) 
46.2 -14.9 30.2 29.2 18.5 
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6.4.5.  Comparison of treatment efficacy according to Schistosoma species 
We found significantly higher CRs of praziquantel syrup against S. haematobium compared to 
S. mansoni. At the 3-week post-treatment follow-up, the respective CRs against 
S. haematobium and S. mansoni were 85.7% and 75.0%, owing to a statistically significant 
difference (χ2=4.41, p=0.018). At the 6-week post-treatment follow-up, the difference 
between the CRs against S. haematobium and S. mansoni were even more pronounced (94.9% 
versus 50.6%; χ2=65.58, p<0.001). 
6.5.  Discussion 
Inclusion of preschool-aged children in preventive chemotherapy against schistosomiasis 
might be justified in specific high-risk areas (e.g. settings in close proximity to large dams and 
irrigation systems), as infection prevalence and morbidity in this age group might already be 
considerable. Severe morbidity due to schistosomiasis results from an accumulation of 
infections and consequently high worm loads, and hence timely treatment of young children 
might prevent the development of irreversible morbid sequelae. Bloody diarrhoea due to 
S. mansoni and haematuria due to S. haematobium may cause anaemia, malnutrition and 
delayed physical and cognitive development in young children (Gray et al., 2011; Gryseels, 
2012). These negative consequences might be avoided by early treatment with praziquantel. 
Moreover, with a shift from morbidity control to transmission interruption and ultimately 
local elimination (King et al., 2006; Bergquist et al., 2009; Stothard et al., 2009; Rollinson et 
al., 2012), the inclusion of preschool-aged children into preventive chemotherapy campaigns 
must be considered, alongside improvement of sanitation, clean water and hygiene behaviour 
to curb transmission (Utzinger et al., 2009). 
However, the extent and impact of schistosomiasis in preschool-aged children remains to 
be further elucidated. Additionally, there is a paucity of quality data on the safety and efficacy 
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of praziquantel in preschool-aged children (Keiser et al., 2011), and a syrup formulation has 
only been available in Egypt. These are reasons that might explain why young children are 
currently excluded from preventive chemotherapy. With the exception of a recent paper 
pertaining to the safety and efficacy of praziquantel syrup against S. mansoni in a group of 
preschool-aged children in Uganda (Navaratnam et al., 2012), preceding work determined the 
efficacy of crushed praziquantel tablets administered to preschool-aged children. In these 
studies, investigators usually used 600-mg tablets of praziquantel, crushed them between two 
spoons and mixed the powder with water or a juice to mask the bitter taste of the drug before 
administration (Doenhoff et al., 2008; Meyer et al., 2009). This approach is not only time 
consuming, but some brands of praziquantel tablets are difficult to cut into two, three or four 
pieces in order to obtain the appropriate dosage of 40 mg/kg. Of note, 600-mg praziquantel 
tablets are the most widely used formulation deployed by national control programmes 
(Doenhoff et al., 2008), whereas tablets of lower dose (e.g. 100 or 200 mg) are rarely used. 
Epiquantel® is a syrup brand produced and used in Egypt since 1998 (Talaat and Miller, 
1998). The use of a downward extended dose-pole can help integrated preschool-aged 
children into preventive chemotherapy (Sousa-Figueiredo et al., 2012). 
Reviewing the literature, we conjecture that our sample size comprising 243 
Schistosoma-infected preschool-aged children is one of the largest focusing on the safety and 
efficacy of praziquantel syrup in this age group. In two previous studies done in Uganda, there 
were 155 (Odogwu et al., 2006) and 1,124 preschool-aged children included (Navaratnam et 
al., 2012), with S. mansoni prevalences of 7% and 26%, respectively. In the latter study, 
however, not all the children treated were infected. In another study in Nigeria, a sample of 
167 preschool-aged children with an infection prevalence of 58.1% was included (Ekpo et al., 
2010). Relatively large sample sizes were also included in Mali (Dabo et al., 2011) (n=338 
children) and in another study in Uganda (Sousa-Figueiredo et al., 2009) (n=363 children). 
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Our baseline survey, using a reasonably sensitive diagnostic approach with triplicate urine 
filtration and triplicate Kato-Katz thick smear examinations revealed that 12.7% of the 
children harboured a heavy S. haematobium infection (≥50 eggs/10 ml of urine), while 38.5% 
of the children infected with S. mansoni showed a moderate or heavy infection (≥100 EPG). 
Administration of praziquantel syrup was relatively straightforward. The precise syrup 
dose was taken with a pipette and poured in a small cup delivered with the Epiquantel® box 
and given to the mothers so that they could administer the drug to their children (Figure 6.1). 
As the syrup has a viscous consistency, the cup must be rinsed with water before use by the 
next child. We did not observe any immediate severe adverse events, such as false route or 
coughing. However, a third of the children experienced adverse events, most of which 
appeared within four hours and resolved within 24 hours. Indeed, while 32.5% of the treated 
children reported adverse events within four hours post-treatment, only 6.2% reported adverse 
events between four and 24 hours post-treatment. In a previous study administering two doses 
of praziquantel (standard tablets) within three weeks (40 mg/kg each) to school-aged children 
in Niger (Garba et al., 2012), the frequency of adverse events was similar (32.9%). Previous 
observations of abdominal pain, bloody diarrhoea and sleepiness being the most common 
adverse events in schoolchildren corroborate with findings reported here in preschool-aged 
children. In contrast, in Uganda, fewer adverse events were reported after praziquantel 
treatment in S. mansoni-infected preschool-aged children (2.6% reported feeling ill 24 hours 
post-treatment) (Sousa-Figueiredo et al., 2009). Importantly though, not all of the children 
were infected; the prevalence of infection was 44.3% with a geometric mean egg count of 6.1 
EPG. In another study carried out in Uganda where a low infection prevalence of S. mansoni 
was observed, no adverse events were recorded within 24 hours post-treatment (Odogwu et 
al., 2006). In our study, by design, only Schistosoma-infected children were included and the 
geometric mean egg count was more than 10-fold higher (72.1 EPG). 
Chapter 6 - Safety and efficacy of praziquantel syrup 
129 
In a recent study done in Mali, few adverse events were reported 24 hours post-treatment 
(3.3%) when using crushed praziquantel tablets in two villages where the S. haematobium 
prevalence was comparable to our study (i.e. 15.7% of heavy infection among children aged 
≤5 years) (Dabo et al., 2011). The most frequent adverse events were sleepiness, dizziness 
and diarrhoea. In our study, children were fed before treatment, which enhances 
bioavailability of praziquantel (Castro et al., 2000). However, no mention of the feeding status 
of the participants prior to treatment was recorded in Uganda and Mali. In a recent multicentre 
praziquantel efficacy and safety trial among children aged 10-19 years (Olliaro et al., 2011), 
high frequencies of adverse events (78%) were reported within four hours, where results 
varied from one site to another from 66% to 92%. Praziquantel was administrated after food 
intake. In a study in Zimbabwe (Midzi et al., 2008), 54.3% of children reported single adverse 
events, whereas 11% reported two or more adverse events concurrently within 24 hours after 
administration of praziquantel at the standard dose of 40 mg/kg. Praziquantel was given with 
food and adverse events were actively probed by the survey team 24 hours after treatment. It 
is now commonly admitted that food intake prior to praziquantel not only enhances 
bioavailability, but also lowers the frequency and severity of adverse events. The difference in 
the higher proportion of adverse events we found might also stem from the fact that, in our 
study, children were closely monitored by a research team and clinicians within four hours 
after treatment. In some of the previous studies, mothers were asked to report any adverse 
events occurring within 24 hours post-treatment. Since adverse events are mainly transient, 
mothers might not have seen the necessity to report adverse events to the research team. 
Indeed, active probing for adverse events results in higher rates of reported adverse events 
(Olliaro et al., 2011). 
Against S. mansoni, the CR and ERR were considerably lower compared to the results 
obtained with S. haematobium. We observed CRs of 75.0% and 50.6% after 3 and 6 weeks 
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post-treatment, respectively. While an ERR of 66.7% was found 3 weeks post-treatment, a 
much lower ERR of only 18.5% was observed at the 6 weeks post-treatment follow-up. In 
contrast, in Uganda, CR and ERR of 100% were observed after treating children <5 years of 
age with crushed praziquantel tablets at the same dose of 40 mg/kg (Sousa-Figueiredo et al., 
2009). However these results have to be interpreted with caution, as the number of children 
with a confirmed S. mansoni infection in Uganda was low (i.e. only 28 children). Moreover, 
in the multicentre praziquantel trial against S. mansoni carried out in Brazil, Mauritania and 
Tanzania, high CRs (91.6-99.4%) and ERRs (89.2-91.9%) were observed (Olliaro et al., 
2011). Of note, baseline geometric mean egg counts (278.3-813.5 EPG) were considerably 
higher than in the present study. In a previous study conducted in Niger, we observed a 
similar moderate response of S. mansoni to praziquantel (Garba et al., 2012). The CRs and 
ERRs were 51.7-58.8% in Diambala and 55.2-60.2% in Namarigoungou after two closely 
spaced doses of praziquantel, each given at 40 mg/kg to school-aged children. We speculate 
that the low response to praziquantel might be due to the high S. mansoni reinfection rates in 
this zone where the population is highly susceptible to the infection due to the emergence of 
S. mansoni (Garba et al., 2004). Six-month post-treatment reinfection rates of 38.1% 
(Diambala) and 74.1% (Namarigoungou) were observed in two villages located near our study 
site. Another reason could be the lower bioavailability of Epiquantel®. A study has shown a 
lower dissolution of Epiquantel® and Bilharzid®, compare to other brands of praziquantel 
resulting in a reduced efficacy against S. mansoni-infected mice (Botros et al., 2011). 
In conclusion, treatment of children aged ≤72 months with praziquantel syrup is operationally 
feasible. Although adverse events occurred in about one-third of the children, these were mild 
and transient. Epiquantel® resulted in moderate-to-high efficacy against S. haematobium, but 
considerably lower CR and ERR were found against S. mansoni, particularly at the 6-week 
post-treatment follow-up. The latter observation warrants further follow-up investigations. 
Chapter 6 - Safety and efficacy of praziquantel syrup 
131 
Moreover, financial implications of using a syrup formulation rather than tablets should be 
studied, alongside an individual diagnosis-treatment approach versus blanket treatment. In the 
interim, we suggest that, in areas where schistosomiasis remains highly endemic, preschool-
aged children should be considered for inclusion in preventive chemotherapy, using crushed 
praziquantel tablets or, where available, syrup formulation. 
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7.1. Abstract 
Background 
In 2004 Niger established a large scale schistosomiasis and soil-transmitted helminths 
control programme targeting school age children aged 5-14 years and adults. In two years 4.3 
million treatments were delivered in 40 districts using school based and community 
distribution. 
Method and Findings 
Four districts were surveyed in 2006 to estimate the economic cost per district, per 
treatment and per schistosomiasis infection averted. The study compares the costs of 
treatment at start up and in a subsequent year, identifies the allocation of costs by activity, 
input and organisation, and assesses the cost of treatment. The cost of delivery provided by 
teachers is compared to cost of delivery by community distributers (CDD). 
The total economic cost of the programme including programmatic, national and local 
government costs and international support in four study districts, over two years, was US$ 
456,718; an economic cost/treatment of $0.58. The full economic delivery cost of school 
based treatment in 2005/06 was $0.76, and for community distribution was $0.46. Including 
only the programme costs the figures are $0.47 and $0.41 respectively. Differences at sub-
district are more marked. This is partly explained by the fact that a CDD treats 5.8 people for 
every one treated in school. 
The range in cost effectiveness for both direct and direct and indirect treatments is 
quantified and the need to develop and refine such estimates is emphasised 
Conclusions 
The relative cost effectiveness of school and community delivery differs by country 
according to the composition of the population treated, the numbers targeted and treated at 
school and in the community, the cost and frequency of training teachers and CDDs. Options 
analysis of technical and implementation alternatives including a financial analysis should 
form part of the programme design process. 
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7.2.  Author Summary 
Schistosomiasis and soil-transmitted helminth control programmes are important, 
relatively low cost means to improve the health of those affected, in particular rural school 
age children. It can also reduce schistosomiasis related morbidity in their later lives. The 
paper presents information on the implementation and costs of a large scale national 
programme in Niger.  
The total economic cost per treatment was $0.58. This includes programme, government 
and international costs. Two systems, school based and community delivery were used to treat 
children and targeted adults. Contrary to findings in some countries we find that school based 
delivery is less cost effective than community delivery. This is due to the low proportion of 
the population targeted and treated by the school based system.  
Treating adults as well as children increased the numbers treated and reduced the overall 
cost per treatment. Prevalence and infection is higher in children than adults and overall 
effectiveness in terms of infection averted is affected. The cost per infection averted is 
assessed for direct treatment and direct and indirect treatment effects. The study expands the 
evidence available for decision makers involved in programme planning and design, funding 
and implementation. 
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7.3.  Introduction  
Schistosomiasis is one of the most prevalent chronic infectious diseases found world-
wide and is associated with anaemia, chronic pain, diarrhoea, and under nutrition. It is 
recognised as a major public health problem in many rural areas, particularly in school-age 
children. With affordable and sustained control measures morbidity and transmission can be 
decreased. 
Robust studies on the implementation of large scale control of schistosomiasis and soil 
transmitted helminths (STH) are required to strengthen the evidence base on the cost-
effectiveness and affordability of such investment [1]–[3]. In particular, evidence on 
effectiveness is needed to support the strategic planning for expanded treatment and global 
coverage as well as for national vertical and integrated Neglected Tropical Disease (NTD) 
programmes. The objectives of this study are to identify: the cost of the Mass Drug 
Administration (MDA) programme; the cost per person treated; and the costs of treatment as 
delivered by school based staff and community distributers. 
A number of studies have identified the costs of targeted and MDA for schistosomiasis 
control [4]–[9]. These have, with the exception of [4], [9], provided empirical evidence of 
school based approaches. This paper provides the cost of MDA treatment and compares the 
costs of the school and community based distribution systems used. It assesses the evidence 
from other MDA programmes taking account of factors such as the level of school enrolment, 
coverage levels to consider the general guidelines that can be taken from these works 
 
7.4. Description of the programme for mass drug administration in Niger  
In 2004 Niger established a national programme to control schistosomiasis and soil-
transmitted helminths (PNLBG) supported by the Schistosomiasis Control Initiative (SCI), 
funded by the Bill and Melinda Gates foundation [10]. Its objective in line with Resolution 
WHA54.19 was to treat 75% of school age children at risk of infection and in communities 
where prevalence is over 50% to also treat at risk adults. The purpose being to reduce the 
morbidity related to schistosomiasis infection to a level at which it would not constitute a 
public health problem [11]. 
Chapter 7 - Cost of treatment 
 
141 
 
The primary school net enrolment rate (NER) in 2004 in Niger was 41% (UNESCO UIS 
global education database Table 7.5, Enrolment ratios by International Standard Classification 
of Education (ISCED) level), lower in rural areas; and considerably less than the rate of 68% 
for Sub Saharan Africa (SSA). To achieve high treatment coverage in targeted school age 
children and at risk adults two treatment strategies, school-based and community-based 
distribution, were established. Treatment for S. haematobium was provided every two years in 
most endemic areas, and annually in high prevalence areas to reduce initial levels. School-
based distribution was provided by trained teachers who distributed the drugs to students in 
the schools. Children not attending school could receive treatment either in the schools or 
from the Community Drug Distributor (CDD) at home or at another fixed treatment location. 
The MDA programme was established and rolled out over 2 years from April 2004 across 
40 districts in all 7 regions of the country, including the capital city Niamey. The programme 
activities were implemented progressively commencing in the Tilaberi and Dosso regions. In 
2004/05, 1,627,828 treatments were delivered in 22 districts and in 2005/06 2,683,121 
treatments were delivered in 40 districts. Figure 7.1 outlines the main MDA programme 
activities. 
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Figure 7.1. The main steps in the MDA programme. Figure 7.1 presents the component 
activities of the MDA process. Activities mainly occurring in the first year are shown as well 
as annual activities. 
 
Initial meetings and agreement of the programme with the regional and district 
administrations were followed by a prevalence survey and mapping to prioritise areas for 
MDA. A national workshop and practical field sessions to develop capacity in the diagnosis 
of schistosomiasis was organised. Further capacity-building workshops and training for staff 
in organisation, management and implementation of MDA was provided to key district health 
and educational inspectorate staff in an initial national workshop. These staff then trained 
clinic staff, health workers and head teachers though district meetings. Training was provided 
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on the calculation of drug requirements, drug distribution organisation, the management of 
side effects and the reporting of results. Community and school-based drug distributors were 
trained in the use of dose poles (to determine drug dosage), and the completion of treatment 
forms. 
The national programme developed, piloted, printed and delivered information, education 
and communication (IEC) materials for distribution to the districts. These materials included 
posters and a booklet for use in schools and communities as well as technical sheets for those 
administering the drugs. Drugs were procured centrally by SCI on behalf of countries which 
SCI supported in West and East Africa [12]. The drugs were sent directly from the National 
store to the districts. The districts and inspectorates repacked the drugs and IEC material for 
distribution to or collection by clinics and schools. Social mobilisation activities were 
undertaken at various administrative levels. National radio and television broadcasts were 
undertaken in three local languages and in French, organised by the PNLBG; local radio 
broadcasts were organised by the districts; village criers were organised by clinics to inform 
communities about the logistics of the MDA. 
A rally to launch the campaign was undertaken and organised by an host region; it 
involved a day of speeches, dance and hospitality supported by national, regional and 
programme dignitaries and was broadcast on national radio and television. 
Treatments were delivered at schools by teachers; CDDs provided treatment by going 
from door to door and at other fixed points supervised by clinic, district and regional staff. 
Technical and management support and supervision were provided to the districts by national 
staff. 
At the end of the MDA unused drugs and monitoring reports were collected by national 
staff. A one day post MDA evaluation meeting was held in each participating region attended 
by national, regional and district staff. A summary of the partner roles and responsibilities is 
identified in Table 7.1. 
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Table 7.1. Roles and responsibilities in the Niger schistosomiasis and STH MDA. 
 
 
7.5. Methods  
A protocol for the cost and resource use study was agreed with Niger Ministries of Health 
and Education at national and local government level. Written informed consent to participate 
in the programme longitudinal surveillance and monitoring research was obtained from the 
children's parents or guardians, or head teachers according to the study protocol approved by 
St Mary Research Ethics Committee of Imperial College, UK, 2003, (EC No 03.36, R&D No: 
03/SB/003E) and amended 2005 St Mary's (REC Ref: AM2003). 
This was a retrospective study which covered a two year period from April 2004 to May 
2006, including the first and second years of MDA and related programme activities in four 
health districts. 
All data on first year costs at national, regional, district, and sub district levels were taken 
from the PNLBG accounts and receipts and records of staff missions or activities. Second 
year cost data for national and regional level activities were taken from receipts. District and 
sub district, school and community MDA resource use data for 2005 were collected in June 
2006 through a retrospective survey. The four health districts: Kollo, Tera, Tilaberi, (Tilaberi 
region) and Gaya (Dosso region) are all located in the Niger River Valley, and were in the 
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first phase of implementation. The control programme had previously established sites for 
longitudinal monitoring of prevalence and morbidity in these districts. 
The cost survey was designed to collect data on the time taken and resources used by 
district and sub district health staff, and by the education inspectorate and school staff in the 
2005 MDA delivery. Questionnaires were designed and tested, and a 2 day training workshop 
was undertaken in 2006 to familiarise and train the schistosomiasis MDA district co-
ordinators, responsible for the data collection. 
The questionnaires covered the usage of: vehicles, fuel and other equipment and materials 
used in the MDA and in training, time spent in different activities by staff at regional, district, 
and clinic level, payments made to CDDs, and for local services. Survey data on 2005 MDA 
delivery costs were verified with PNLBG receipts. Drug usage was obtained from district and 
from PNLBG records. Coverage figures were obtained from district treatment registers and 
the national annual treatment summary. 
Longitudinal surveillance and monitoring data were obtained from records of the Centre 
de Recherche Medicale et Sanitaire (CERMES) and from the PNLBG register of activities 
and receipts. 
 
7.5.1. Determination of the economic cost of treatment 
The study examines the economic costs of the MDA programme in its first and second 
years. The economic costs include the full value of the resources used. Where this is not 
adequately represented by the financial or market cost, an opportunity cost is used (see Table 
7.S4). The main cost elements include: the programme specific expenditure; the opportunity 
cost or value of government contributions related to in-kind costs of using local government 
staff and vehicles and the value of CDD's time (taken as the daily agricultural labour rate); 
and the international costs of programme co-ordination, reporting and technical support. 
Programme costs include directly incurred capital costs; recurrent costs; and variable 
costs. Capital costs incurred by the programme included central level purchase of Information 
Technology (IT), medical and laboratory equipment and other electrical and mechanical 
goods and furniture used to equip the PNLBG office including the purchase of four 4×4 
vehicles for PNLBG (Table 7.S1). Capital costs were annualised over their useful lives (Table 
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7.S2) using a discount rate of 3%. This represents the annual cost of owning and operating an 
asset over its lifespan. 
Programme recurrent costs including staff costs, office and vehicle running costs, and 
programme variable costs were collected from the programme records, accounts and receipts. 
These costs were apportioned in relation to the time spent by programme staff on MDA 
activities and the proportion of that time allocated to study areas. 
Variable costs related to perdiems, materials and services incurred in relation to the 
programme activities. Centralised activities (e.g. organisation and provision of national 
training for all district technicians, planning and organisation) and regional activities (e.g. 
MDA launch) were equally apportioned in relation to the number of districts in the MDA and 
share of the four study districts. Location specific activity costs such as supervision, mapping, 
central delivery of drugs to districts were allocated on the basis of costs incurred in the study 
districts. 
Sentinel monitoring informs the national treatment strategy. The costs of sentinel site 
monitoring were apportioned to the study districts on the basis of study area treatments 
relative to national treatments. 
Government staff costs were based on salary costs collected through questionnaire and 
the Government salary grid. District and sub district vehicle usage was calculated from 
questionnaire returns and costed using hire rates. These values are estimated to reflect the 
opportunity cost of using the resources for the MDA rather than for an alternative activity. 
Costs were collated and classified by three levels of organisation (national, regional & 
district, or community), type of activity (training, support & supervision, baseline & 
monitoring, reporting, evaluation, advocacy, mobilisation & IEC) and cost type (fuel, 
transport, materials, services, drugs, per diems, temporary contracts and office related 
recurrent costs). 
Prices are in constant 2005 terms (Table 7.S4). Foreign exchange was converted at the 
fixed rate of CFA 655/Euro and $1.244/Euro (http://www.federalreserve.gov/release/January 
2 2009). Discounted economic analysis was undertaken using discount rate of 3% in line with 
World Bank rates [13]. The cost of a treatment includes both albendazole and praziquantel. 
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7.5.2.  School based and community delivery system cost calculation 
Community and school based delivery was and is practised nationally. The costs incurred 
by the two systems were equally attributed at national, regional and district level. It is at sub 
district level that the systems differ in the organisation and implementation of the delivery 
activities. The school and sub district delivery services used a partial analysis which took 
account of these cost components only. 
The cost of delivery using a CDD and of using a teacher was calculated. These costs 
included per diems and travel allowances for CDD and head teacher training; allowances for 
delivery (applicable only for CDD), health clinic staff costs for CDD selection (per diems and 
fuel) and supervision (fuel only). The training of one or more teachers and their supervision in 
schools was undertaken by the school head, no financial cost was incurred. Joint activity costs 
of the district health and education inspectorate (training, drug repacking, drug delivery to sub 
districts and schools and supervision) would be incurred despite the system. These have not 
been included in the partial analysis but an allowance has been estimated to allow 
comparability with other MDA programmes. 
 
7.5.3.  Cost effectiveness analysis  
The effectiveness of treatment was calculated as the difference between the population 
with schistosomiasis infection at baseline and follow-up survey. The prevalence rates used are 
from a longitudinal health impact study (Nadine Seward (2007) Niger Three Years Data 
Analysis, SCI internal report (unpublished)). 
To assess the effectiveness of the programme's direct and direct and indirect treatment 
effects an assessment of the impact in the treated population and in the targeted population 
was made. Treatment costs were calculated as the number of treatments in each year 
multiplied by the full economic cost in 2004/5 and in 2005/6. 
Eight schools and four communities located in areas highly endemic for schistosomiasis 
took part in a longitudinal health impact study. The study used baseline and longitudinal 
follow-up surveys one year post treatment to monitor: parasitological indicators (prevalence 
and intensity of helminth disease examining stool and urine samples following standard 
procedures using kato katz and filtration methods [14]); morbidity indicators (anaemia and 
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associated pathology of schistosomiasis, assessed by ultrasound examination following 
standard protocols developed by WHO) and general indicators of height and weight. The 
baseline survey enrolled 1659 children from 8 different schools in 3 regions prior to the first 
MDA campaigns of 2004 and 2005. The number of children enrolled from each school ranged 
from 179 to 299; with almost equal numbers of children in age groups of 7, 8 & 11 years old. 
Of those recruited 1193 (72%) were followed-up successfully at year 1 and year 2 surveys. 
Adults and adolescents were monitored in 4 sites in a single region. A total of 484 adolescents 
and adults were recruited at baseline. Of these, 143 (30%) were followed-up successfully at 
both year 1 and year 2 surveys. The sample size was estimated using the same criteria as 
described in [15]. 
The surveyed sites mirror the MDA treatment and represent MDA performance in 
targeted populations taking into account the treated and untreated participants in proportion to 
the MDA coverage. Any indirect effect of reduced infection in untreated pupils resulting from 
changes in the force of infection is reflected in the intensity of infection [16] which is related 
to prevalence ([17] provides more detail). To assess the wider impacts on the community, 
untreated first year students were monitored in the schools. Adults and adolescents were 
monitored at four sites. 
 
7.6.  Results 
7.6.1.  Total economic costs of treatment 
The total economic cost of the programme including programme specific expenditure, 
national and local government costs and international technical support and programme co-
ordination in four study districts, over two years, was US$ 456,718 (Table 7.2); an economic 
cost per treatment of $0.58. Excluding international costs, the programme and government 
expenditure was $0.54 per treatment. The programme expenditure per treatment was $0.44. 
The average drugs cost was $0.28 per treatment. The numbers treated in these two years 
totalled 818,562 (781,883, discounted at 3%). 
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Table 7.2: Discounted economic cost of the MDA programme for April 2004 to March 2006 
in 4 districts (2005 prices) 
 
 
 
The distribution of costs between the programme, the government and international 
support are shown in Table 7.2. Drugs accounted for 49% of the total economic cost (65% of 
programme expenditure), variable costs accounted for 19% of the economic cost (26% of 
programme expenditure). Overall there was little difference in the total economic cost of the 
programme in the four districts between the first and second years. However the total 
economic cost per treatment in the first year was $0.68 and in the second year was $0.51. Cost 
differences are shown in Table 7.3 and discussed below 
Table 7.3: Annual economic cost of the MDA programme in four districts (2005 prices) 
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Excluding the MDA drug costs, the economic cost of the programme in the four districts 
in the second year was 29% less costly than the first year and treated 25% more people. 
Higher costs in the first year of the programme are seen in programme costs and international 
support. Three factors contribute to this. The cost of the initial start up activities incurred in 
the first year only. The activities involved advocacy, development of IEC materials, 
prevalence surveys and data collection for planning and the establishment of monitoring and 
evaluation (M&E) activities, in particular the longitudinal monitoring sites (illustrated in 
figures 7.2 and 7.3), and repair and maintenance of the national office. In the second year the 
programme was scaled up. This reduced the apportioned share of recurrent and capital 
programme costs and international costs allocated to the study area. In 2004/05 22 districts 
were treated and in 2005/06 40 districts were treated. Within the study area the population 
treated in the second year which was 25% more than those treated in the first year 
 
 
Figure 7.2: 2004/05 Variable costs by activity in 4 districts (2005 prices). Total variable cost was 
$51,970 in the 4 districts. This includes start up costs involving advocacy, the prevalence baseline, 
development of IEC materials and establishing monitoring sites. At sub district level, planning and 
organisation is undertaken at the same time as training 
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Figure 7.3. 2005/06 Variable costs by activity in 4 districts (2005 prices). Total variable cost was 
$40,318 in the 4 districts. At sub district level, planning and organisation is undertaken at the same 
time as training. Compared with the previous year, 25% more people were treated. 
 
The distribution of variable expenditure (excluding drugs) by activity in the study area is 
presented in Figures 7.2 and 7.3. These show the relatively large proportion of expenditure on 
training and on MDA delivery. It also highlights activities mainly undertaken at 
establishment. Total programme variable costs in 2004/05 were $ 51,970 and in 2005/06 were 
$ 40,318, 22% less than those in the first year. 
M&E costs include costs of process monitoring in 2004/5, annual district and regional 
evaluations and programme health impact monitoring undertaken through the National 
sentinel sites. These costs amounted to an average of 13% of variable costs over the 2 years. 
Table 7.4 presents the average allocation of cost by category (capital, recurrent and variable) 
and type of input. Labour related costs (salary plus per diems) and vehicle and fuel costs 
account for 64% and 19% of all costs excluding drugs 
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Table 7.4: Programme and government MDA costs (2004/06) allocated by cost category 
 
Sensitivity analysis was undertaken on major cost items. A 10% increase in the cost of 
drugs would result in a 4.9% increase in the total economic cost of treatment ($456,718), and 
a 6.5% increase in the current programme cost ($342,226). A 10% increase in perdiems and 
allowances would result in a 1.1% increase in the total economic cost of treatment, or a 1.5% 
increase in the programme cost, a 4.2% increase in the programme cost excluding drug costs. 
A 10% increase in wages and salaries would result in a 1.5% increase in the economic cost of 
treatment. It would impact most on the government sector and distributer opportunity costs 
increasing costs by 7.7%. The increase on the programme cost would be 0.2%. The sensitivity 
of total economic cost to a saving in teacher training costs was explored. This assumed 
community distributers would undertake the school treatments for the same fixed allowance. 
Savings in teacher training allowances are assumed, but not the economic cost of their time 
which would still be required to support distributers in school based treatment. Any savings in 
teacher time would be offset by the increased opportunity cost of time for community 
distributers. The impact of the net saving on the total economic cost would be 2.9%. This is 
equivalent to a saving of 4.1% in the programme cost. This provides an approximate scale of 
magnitude within which to assess comparative costs of sub district delivery systems below.  
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7.6.2.  Cost of community based and school based delivery systems 
Sub district costs (i.e. clinic, school and community costs) account for the largest portion 
of the economic cost by administrative level. This is 23% of the total economic cost (based on 
Table 7.2); so, it is important to understand the allocation and usage. 
Sub district variable programme costs include head teacher and CDD per diems for 
training and CDD payments for distribution. Sub district government costs include the 
opportunity cost for the use of motorbikes (11%) and labour (89%). The opportunity cost of 
labour is principally accounted for by the time of the teacher and head teachers (61%), of the 
clinic staff in supervision (20%) and CDD time for training and distribution (19%). 
Table 7.5 presents the characteristics and costs of sub district delivery. The economic cost 
per school based treatment and per CDD treatment delivered was $0.36 (range $0.26–$0.55) 
and $0.06 (range $0.04–$0.07) respectively. The programme cost per school based treatment 
and per CDD treatment delivered was $0.09 (range $0.07–$0.15) and $0.03 (range from 
$0.03–0.04) respectively. 
The full economic delivery cost of school based treatment in 2005/06 was $0.76, and 
community treatment was $0.46. If only programme costs are included this figures are $0.47 
and $0.41 respectively. 
The difference in costs is in part explained by the fact that a CDD delivers 5.8 treatments 
for every one delivered in school. On average each CDD delivered 407 treatments while each 
school delivered 70. 
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Table 7.5: Characteristics and cost of community and school based delivery in 4 districts 
2005/06 
 
 
Chapter 7 - Cost of treatment 
 
155 
 
7.6.3.  Cost effectiveness of treatment  
Over the 2 treatment cycles 530,300 treatments were provided to an estimated 317,549 
adults and 288,262 treatments were provided to 241,218 children in the study areas in the 
regions of Dosso and Tilaberi. Coverage in the target population in Gaya, Dosso was 78% in 
both years, and was 69% and 71% in the three districts monitored in Tilaberi. 
Two estimates of the cost of treatment per case of infection averted (Table 7.6) are 
presented. One includes only the direct impacts of treatment and the other includes the direct 
and indirect impacts of treatment. They provide minimum and maximum limits of the true 
value. This is discussed further in the next section 
 
Table 7.6: Cost per infection of schistosomiasis averted for children and adults in four 
districts of Niger 
 
 
Including only the direct impacts on the treated population the average cost per infection 
averted in treated children in the 4 districts over the two years was $1.10. Of the 317,549 
adults treated in a single round the cost per infection averted was $4.4 and over two rounds it 
is estimated to be $6.5. The overall cost per infection averted in the treated population of 
children and adults is calculated as $2.5. 
If indirect treatment effects are included the average cost per infection averted in targeted 
(treated and untreated) children in the 4 districts over the two years was $0.78. Of the 446,180 
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adults targeted in a single round the cost per infection averted was $3.08 and over two rounds 
it is estimated to be $4.6. The overall cost per infection averted in the targeted population of 
children and adults is calculated as $1.78. 
The higher cost of infection averted in adults reflects the lower base prevalence rate. The 
longitudinal adult cohort followed up over the 2 year period suffered high drop-out rates and 
its composition was significant different at the 0.05 significance level. Males in particular 
those who were infected with S. haematobium infection were more difficult to retain at 
follow-up. The resulting cohort of 116 adults had a lower proportion of males, and had a 
lower base rate of infection (24.1%, (95% CI:16.35–31.93)) as compared with the original 
baseline sample (39.62% (95%CI:35.23–44.01)). To avoid this issue the results for the sample 
monitored at the first year follow up are used and it is conservatively assumed that the 
prevalence in the second follow up did not change. 
 
7.7.  Discussion  
The cost per treatment and prevalence figures relate to the study sample of four districts 
located in the Niger River Valley. This was and is an area of high disease prevalence and high 
population density relative to other parts of the country. The costs per person treated may be 
higher in lower density and more remote areas. Likewise the cost per infection averted will be 
greater in sub populations with lower changes in prevalence. 
The cost study relied on the survey work for details of district and sub district resource 
use. As the survey was undertaken almost a year after the MDA, it may have been affected by 
recall bias. A further limitation of the study is the delay in final analysis. This limited follow-
up work; the recent MDA's confuse recall and some key people have changed positions and 
locations. However, the issues raised by the study analysis are still relevant and worthy of 
further investigation. 
One of the strengths of the study is the availability and use of MDA health impact 
monitoring results to assess programme effectiveness. Cost effectiveness studies are often 
obliged to use trials data concerned with the efficacy of treatment [3] rather than programme 
effectiveness as monitored in Niger. This potentially allows us to capture direct and indirect 
treatment effects as identified by Miguel and Kremer [18] and French et al [16]. Both identify 
direct and indirect effects of treatment in terms of the reduced transmission of Schistosoma 
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mansoni in children in the community including children not treated. The direct and indirect 
impact quantified here represents a best case or maximum impact. Further work based on 
intensity and force of infection based on the work of French et al [16] is required to refine and 
triangulate the estimate. Estimating only the direct effects of treatment in the treated 
population provides a conservative estimate of infection averted. Due to the definition of 
prevalence used in the study and the data available, the prevalence estimate in the treated 
population is under estimated (and consequently cost per treatment is overestimated). The true 
value of the infections averted is believed to be between these two estimates. There is a 40–
42% difference in the cost per infection averted between the “best” and worst case scenarios. 
However the magnitude of difference underlines the importance of refining the method and 
developing more robust estimates. 
The most effective means of delivering helminth treatment to school age children has 
been debated in various papers. The Partnership for Child Development (PCD) [6] provided 
evidence from Ghana and Tanzania on the cost of large scale treatment in schools and the 
potential savings in using the existing school infrastructure for treatment. For many recipients, 
access to the more numerous schools is more convenient than attending more distant health 
facilities [19]. However, where school enrolment is low and particular groups (for example 
girls or the poorest children) are under-represented, there is a need for additional methods of 
reaching target populations [7]. Studies in Tanzania [20] and Uganda [21] have examined the 
effectiveness of Community Directed Treatment (ComDT) and school based treatment in 
terms of coverage for enrolled and non enrolled children. In Tanzania coverage in both 
systems was similar, whilst in Uganda coverage rates under ComDT was higher; the 
associated costs are not discussed. 
The evidence on the cost effectiveness of three recent large scale helminth MDA studies 
in Sub-Saharan Africa is summarised in Table 7.7. This presents the characteristics: treatment 
strategies, distribution methods, coverage levels, activities costed, study duration and the 
number of treatments rounds provided. Each of these affects the cost and technical 
effectiveness of the programme. 
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Table 7.7. Comparison of MDA costs of three vertical helminth control programmes in 
Sub Saharan Africa 
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Prevalence and mapping data facilitate treatment prioritisation of endemic areas. This 
reduces the numbers treated, easing pressure on constrained budgets, but allows the option, to 
treat targeted at risk adults. Niger and Uganda used a targeted approach. Burkino Faso 
undertook a blanket approach and treated all school children in the first treatment. 
Burkina Faso has the lowest financial cost per treatment but excludes start up, mapping 
and M&E costs included in the studies (see Table 7.7); it also has the highest coverage. 
Coverage is a key factor in determining costs per treatment; in particular capital and recurrent 
costs. Children accounted for all treatments in Burkina Faso and 53% of treatments in the 
Niger study. Niger's targeted strategy reduced the numbers of children requiring treatment. 
This eased the budget constraint allowing the targeted treatment of adults, and increased the 
scale economies of the programme. 
Niger and Uganda provide a measure of the effectiveness of treatment. Infections averted 
are used based on anaemia in Uganda and schistosomiasis in Niger. The use of a technical 
measure of effectiveness provides the opportunity to assess, both ex-ante and ex-post the 
potential cost effectiveness of alternative strategies. 
The sub-district school based delivery cost per treatment is similar between Niger and 
Burkina Faso (a difference of 10%). Uganda district school based delivery costs (allowing for 
central programme costs) are almost 45% greater than Niger's. The reason for this is not clear. 
It may be that central costs are included in activities other than “programme costs” Sub 
district community delivery cost per treatment in Niger are significantly lower than Burkina 
Faso due to the high numbers targeted and treated. The low levels of enrolment, low school 
numbers targeted and lower coverage rates all add to the relative cost per person of the Niger 
school based system. 
The cost per person treated can be reduced either by increasing national coverage or by 
an improvement in resource efficiency. Alternative means of school based implementation are 
available and school based treatment can be delivered by teachers, health workers or CDDs, 
training may or not be required annually. However the differences in delivery will impact on 
treatment acceptability [19] and coverage, collaboration and motivation as well as the variable 
costs. 
The distribution of programme costs in Niger, suggest cost savings would have greatest 
impact in drugs and training. Drugs are a major component of the treatment cost and account 
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for almost half of the economic cost in the current study, between 27%–46% per district of the 
economic cost in Uganda and 69% of the financial cost in Burkina Faso. The central 
procurement (undertaken in 2004/06 by SCI) improved the buyer's market power, described 
by Fenwick and Thompson [12]. On average 3.1 praziquantel tablets and 1.4 albendazole 
tablets were consumed per treatment in the current study. Using an estimate of actual against 
planned praziquantel usage (3.5 tablets/adult and 2.5 tablets/child), gave an average difference 
of 6% with a range of −4% to 23% across the four districts. The average rate is considerably 
more than the wastage rate of 1% assumed in [5]. This range shows a considerable 
discrepancy between districts and emphasises the importance of robust drug monitoring and 
reporting system. 
Targeted treatment of at risk adults in high endemic areas is used in Niger and Uganda in 
line with WHO guidelines. As the cost per infection averted in adults was 3.5 greater than for 
a child, it is important to understand the economic value of adult treatment. One approach is 
to assess the direct benefits in terms of impact on adult productivity and the value of this 
productivity. USAID Famine Early Warning System Network (FEWS-NET): Niger 
Livelihoods Profiles, provide a useful description of livelihood profiles in these areas. Two 
studies, with agricultural production comparable to that in the Niger study, report the impact 
of schistosomiasis on agricultural labour productivity [22], [23]. The impact of 
schistosomiasis treatment on family labour in paddy rice growing systems in Mali [22] found 
that health is improved due to schistosomiasis treatment. As a result the time available for 
farm work by family workers increased by 69 days/ha. Much of this time was invested in the 
cultivation of additional non irrigated land, (0.47 ha) (if it is assumed a family has 7-10 
members, the average improvement / person would be 10-7 days.). The days of family farm 
labour lost due to schistosomiasis and other parasitic and non parasitic infections was assessed 
in rain fed farm systems in Benue State, Nigeria [23]. In these systems 46% of time lost due 
to illness was related to schistosomiasis, an average loss of 18.7 working days per adult. The 
cost per adult of infection averted in Niger in the first round is estimated here as $4.3 (Table 
6) equivalent to 3 days of labour (based on the agricultural day rate ($1.4) in 2005, a year of 
famine) or 2.3 days (based on rate of $1.9 in a normal year). This indicates the potential 
economic net gain from adult treatment. The gain could be greater depending on adult rates of 
re-infection and consequent treatment need. 
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7.8.  Conclusion  
The cost of treatment per person is driven by the scale of treatment. The strategy, in 
Niger, to include targeted adults as well as school age children has increased the treatment 
numbers and reduced the cost per person treated and increased effectiveness. A conservative 
estimate of cost effectiveness over 2 years for the treated population is estimated to be $1.1 
per infection averted for children and $6.5 for adults. 
This study used a targeted treatment strategy; 53% of treatments were to children, but 
only 16% of the population treated received school based treatment. Under these conditions 
community based treatment was more cost effective than school based treatment. In Burkina 
Faso, only school age children were treated; 40% of these received school based treatment); 
the school based system was more cost effective per treatment. However, the school and 
community based distribution systems serve overlapping groups in the population; and was 
designed to facilitate access to treatment for different groups and support a coverage rate of 
75% or more in target populations. Any improvement in either system must be the result of 
improved resource use or increased coverage at the district and programme level if the change 
is not to impact on the effectiveness of the other system. 
In designing cost effective and sustainable programmes factors relating to: the treatment 
strategy, the demographic mix of the population served, system acceptability to stakeholders 
and the coverage rate need to be taken into account along with logistic issues such as health 
staff availability. Economic and financial assessment of alternative implementation plans 
should be undertaken for the project or programme design. This would support decision 
makers and programme managers, provide financial evidence in planning discussions and 
negotiations and potentially reduce the need for programme changes to improve cost 
effectiveness. 
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7.11.  Supporting information 
Table 7.S1 Summary of principal programme unit costs * Average dose 1.4 tablets Albendazole, 3.1 
tablets Praziquantel includes adult & child consumption and wastage 
 
Category Input  Units  Unit Cost $ 
Minimum  Maximum 
Capital Items  Office building Annualised cost 11,342  
 Project vehicle Purchase cost  24,669 48,251 
 Computer  Purchase cost  1,500  
 Photocopier  Purchase cost  5,104  
Salaries   
 National Co-ordinator  per month  417  
 Central Technical Staff  per month  125 330 
 Central Administrative staff per month  125 220 
 Driver  per month  110  
 District & Regional Health 
 District & Regional Staff  216 340 
 Clinic Head Nurse  per month  136 216 
 Certified Nurse per month  93  
 Community Health Worker per month  38 66 
 Distributer  per month  38 95 
 District & Regional Education 
 Inspectorate Staff  per month  244 309 
 Teachers - civil servant  per month  171 227 
 Teacher -contracted  per month  75 100 
Allowances  Central Technical Staff  per day 19 28 
 District Staff per day 19  
 Training participant  per session  5  
 Community distributer  
per local 
distribution  5  
 Driver  per day 5  
Consumables  Phone cards  per card  1.9  
 IEC poster per unit  0.1  
 Technical sheets  per unit  0.1  
 Treatment register  per unit  0.2  
 Dose poles  per unit  2.8  
 Radio broadcast per broadcast  18.9  
 Albendazole  per dose * 0.04  
 Praziquantel  per dose * 0.24  
 Hire rate / 4x4 (in district) per day  70.9  
 Hire rate / motor bike  per day  9.5  
 Fuel  per litre  1.1  
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Table 7.S2: Life of Capital assets 
 
Asset  Category   Years of life 
Electrical and mechanical goods   5 and 10 
Furniture   10 
IT equipment 5 
Medical equipment  short life   5 
Medical equipment  medium life   10 
Phone   10 
Vehicles   5 
 
Table 7.S3: Mean prevalence and confidence limits of base line and follow up surveys in study areas. 
Table S3 provides further detail of the mean and 95% confidence intervals used to estimate the cases 
averted in estimating the costs per case averted. In Gaya, Dosso region the prevalence rates are higher 
in the second follow up compared with the first. The reason is not known, but may relate to difference 
in coverage in the surveyed school. Coverage is available at district level, and sub district data is 
collated at district level, but is difficult to obtain retrospectively. The followed up for children over the 
two years was high (81%). 
 
Region/year 95% Confidence Interval 
Tilaberi (7-15 yrs) Mean Lower Upper  
Base line 93.33% 90.95% 95.72%  
Follow Up 1 45.48% 40.71% 50.24%  
Follow Up 2 33.57% 29.06% 38.09%  
Dosso (7-15 yrs)  
Base line 72.37% 66.56% 78.17%  
Follow Up 1 13.60% 9.15% 18.05%  
Follow Up 2 19.30% 14.18% 24.42%  
Adults      
Base line 34.12 % 28.30% 39.94%  
Follow Up 1 18.43 % 13.67% 23.19%  
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Table 7.S4: Glossary of terms 
 
Term Meaning 
Annualise This is the cost per year of owning and operating an asset over 
its entire lifespan, sometimes called the equivalent annual cost 
Constant prices A value from which the overall effect of general price inflation 
has been removed, also known as real prices.  
Discounting A mechanism by which values which occur in future years are 
weighted (set by the discount rate) to ensure that the time value of 
money is taken into account.  
Discount rate The economic opportunity cost of capital or the economic rate 
of return on alternative marginal projects or investments. 
Financial prices These are the actual prices at which inputs are bought and 
outputs sold and are used in financial analysis. In economic 
analysis, where prices are distorted due to market or government 
failure, it is necessary to impute the price that reflects the real 
economic value of an input or output.  The opportunity cost may be 
used to reflect this value.  
Net primary school 
enrolment (NER) 
Enrolment of the official age group for a given level of 
education expressed as a percentage of the corresponding 
population. 
Opportunity cost: The benefit or value that could have been gained from an 
alternative use of the same resource. 
Present value Sum of one or more annual discounted values  
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8. Discussion and conclusion 
The most important findings of this PhD thesis pertaining to the epidemiology and 
control of schistosomiasis in sub-Saharan Africa can be summarized as follows: 
• We found considerable prevalence and morbidity due to schistosomiasis in infants 
and preschool-aged children in selected villages of Niger. In one setting, these 
young children harboured S. haematobium and S. mansoni and, a non negligible 
proportion of them, were co-infected. 
• Mother’s behaviour (i.e. taking young children to open freshwater sites where they 
are washed and bathed) is a key risk factor for children to become infected at an 
early age. 
• Praziquantel is safe and efficacious in S. haematobium infection inducing high cure 
and egg reduction rates in school-aged children. Two closely spaced doses of 40 
mg/kg of praziquantel (given at a 3-week interval) showed good tolerance and 
efficacy against S. haematobium. 
• In preschool-aged children, praziquantel syrup is well tolerated and efficacious 
against S. haematobium at the standard dose of 40 mg/kg. 
• Treatment of preschool-aged children with praziquantel syrup was shown to be 
operationally feasible. 
• Against S. mansoni praziquantel showed moderate-to-low cure and egg reduction 
rates at the standard dose of 40 mg/kg. Two closely spaced doses of 40 mg/kg of 
praziquantel to school-aged children and treatment of preschool-aged children 
showed reasonable cure and egg reduction rates. 
• The average overall cost per person treated for schistosomiasis and soil-transmitted 
helminthiasis, including the cost of the drugs, is US$ 0.58. 
 
8.1. Challenges for sustainable schistosomiasis control in sub-Saharan 
Africa 
Sustainability of control interventions is essential to reach the goal of long-term 
morbidity reduction and eventually elimination of schistosomiasis, a disease that is intimately 
linked to poverty (WHO, 2002; King, 2010). Social and economic development, and hence 
improving the quality of life and wellbeing, is the ultimate solution to schistosomiasis control 
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as we have witnessed in Japan, St. Lucia and other Caribbean Islands, People’s Republic in 
China, Korea and partially in Egypt (Webbe, 1987; Tanaka and Tsuji, 1997; Utzinger et al., 
2005). Increasing the education level by sending children to school as far as possible are key 
factors in promoting early behavioural changes, which in turn will improve health (Miguel 
and Kremer, 2004). Provision of safe water and improved sanitation facilities and their use by 
the population will support changes in behaviour towards water contact patterns and reduce 
environmental contamination (Jordan and Unrau, 1978; Jordan et al., 1982; Utzinger et al., 
2003). However since independence, progress in several African countries in theses domains 
remained slow (http://hdr.undp.org/en/reports/global/hdr2010) because of lack of resources or 
merely insufficient political commitment (Zhang et al., 2011). Meanwhile, PCT is the only 
proved safe and low-cost strategy to have a rapid impact on schistosomiasis (Molyneux et al., 
2005; Fenwick et al., 2009). PCT strategy involving integrated control of several diseases is 
an excellent mean to move forward the control of schistosomiasis (Molyneux et al., 2005; 
Hotez et al., 2006; Utzinger and de Savigny, 2006; Hotez, 2009). By taking advantage of a 
single drug delivery system and the same distribution channel (e.g. community drug 
distributors or school teachers), MDA cost are considerably reduced. This led to an increase 
of the countries implementing PCT in sub-Saharan Africa with international support (Savioli 
et al., 2009). Free drug donation programmes and involvement of big funding agencies 
(USAID, DFID, BMGF) gave a strong boost to the control supported by a continuous strong 
advocacy campaign (Hotez et al., 2007; Linehan et al., 2011; Zoerhoff et al., 2011). 
New reports suggest that the progress made in recent years may slow down. Among other 
reasons, there might be drug shortages. For example, in 2010, Hotez and colleagues have 
alerted the scientific community that there might be PZQ tablet shortage, should treatment 
target put forth by WHA be met (Hotez et al., 2010). Indeed, the PZQ need would be 1 billion 
tablets per year in order to treat 400 million individuals through PCT. In 2011, this PZQ 
treatment shortage has become a reality 
(http://www.who.int/neglected_diseases/schistosomiasis_WHO_calls_for_action/en/index.ht
ml), resulting in MDA campaigns postponed on the ground because of late delivery of drugs. 
This shortage occurs while highly populated countries where schistosomiasis remain highly 
endemic (e.g. Nigeria and Ethiopia) have not yet started to implement nationwide control. The 
PZQ production is not following the need and this will become a major stumbling block to the 
further scaling-up of the control of schistosomiasis. Hence, there is an urgent need to increase 
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the production to fulfil the treatment gap created by the increasing number of countries 
implementing control (Reich, 1998). 
Another limiting factor is the strong dependence of these control programmes from 
external donors. Only few African countries make major investments in the control of NTDs. 
However, international donor support usually is just for a couple of years, so increasing the 
part of health budget to NTD control is important (Zhang et al., 2011). Our study has shown 
that the cost per person treated is US$ 0.58 including the cost of the drug. This cost was US$ 
0.54 in Uganda (Brooker et al., 2008) and much lower in a study in Burkina Faso, where it is 
only US$ 0.32 (Gabrielli et al., 2006). With the current advocacy towards drug companies, if 
more PZQ is eventually produced and donated, this cost will be just reduced to operational 
costs that might be more readily handled by the countries if there is sufficient political will. 
 
8.2. Maintaining the reduction of morbidity achieved 
Several years of PCT implementation have led to a considerable reduction of 
schistosomiasis endemicity in many countries to prevalence level below a pre-set 10% 
threshold where MDA is not required any longer according to current WHO guidelines 
(Kabatereine et al., 2007; Toure et al., 2008). Nevertheless, some hot spots with continued 
high transmission remain. In such circumstances, the question arises whether countries should 
continue or stop their MDA campaigns. Stopping MDA is risky, particularly in the absence of 
sound surveillance systems and where access to clean water and improved sanitations remain 
elusive. Health systems are often not ready to manage the necessary minimum essential 
activities at the district level, such as diagnosis, epidemiological surveys, decision to treat, and 
other related issues (Utzinger et al., 2009). Experience with interruption of control activities 
has shown rapid resurgence, when MDA is stopped without any activities and maintenance, 
and hence morbidity quickly comes back to pre-intervention levels (Daffalla and Fenwick, 
1982; Wagatsuma et al., 1999; Scrimgeour et al., 2001; Gray et al., 2011). Resurgence of 
schistosomiasis should by all means be avoided. Hence, before stopping MDA, control should 
be decentralized at district and drug widely available, so that district management teams will 
be ready to take the lead for further activities, such as identification and mapping of 
remaining hot spots that warrant PCT, integration of diagnostic and treatment in routine 
activities of the health facilities, and establishment of community-based surveillance. There is 
a need of continued capacity building and development of operational tools and guidelines at 
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all possible levels. Meanwhile, since a schistosomiasis vaccine is still not available and no 
proven strategy for long-term maintenance of PCT programmes is in place, it is currently 
recommended to continue MDA, and hence to keep taking the PZQ tablets (Hagan et al., 
2004). Cost studies aiming to compare the cost-effectiveness of a continued MDA and an 
increased mapping with target treatment will be helpful to choose the most economic 
approach to sustaining control efforts. Another issue that warrants further scientific inquiry is 
the minimum coverage rate of MDA to have an impact on transmission (King et al., 2006) 
and how to deal with systematic non-compliance for repeated rounds of MDA (Parker et al., 
2008). 
 
8.3. Monitoring the efficacy of PZQ 
This thesis also raised the issue of PZQ efficacy, the only drug currently used for 
morbidity control of schistosomiasis with a huge predictive increase of its use in sub-Saharan 
Africa in the years to come. Monitoring the efficacy and safety of PZQ is an important issue 
to ascertain that the drug will remain effective and that the objective of reducing and 
consolidating the morbidity will be reached (WHO, 2002; Albonico et al., 2004). Generally, 
PZQ has shown high efficacy against S. haematobium at the recommended dose of 40 mg/kg 
with extremely high ERR and moderate-to-high cure rates (Danso-Appiah et al., 2009). 
Recently a multicentre trial carried out in Brazil, Mauritania, Tanzania and the Philippines, 
confirmed the high efficacy of PZQ against S. mansoni and S. japonicum at the standard dose 
of 40 mg/kg, and hence it was concluded that it is not necessary to increase the dose to 60 
mg/kg (Olliaro et al., 2011). However, in our study, only moderate efficacy was observed 
against S. mansoni even with two closely spaced doses of 40mg/kg given 3 weeks apart. 
Similar observation have been made in Senegal (Tchuem Tchuente et al., 2001), Côte 
d’Ivoire, (Raso et al., 2004) and Uganda (Kabatereine et al., 2003). We therefore recommend 
continued monitoring of PZQ efficacy. More elaborated and standardized study protocols 
(Danso-Appiah et al., 2009), including drug quality assessment (Botros et al., 2011) are 
required, as well as a treatment strategy scheme with two rounds of MDA in highly endemic 
areas or reducing the treatment frequency to once every second year. SCORE is currently 
investigating different treatment schemes, including treatment holidays, in different countries 
of sub-Saharan Africa. 
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8.4. Including preschool-aged children in PCT 
Including preschool-aged children in PCT must be considered, since several studies have 
shown high infection prevalence and morbidity in this age group (Ekpo et al., 2010; Garba et 
al., 2010; Dabo et al., 2011; Stothard et al., 2011). All people needing PZQ should have 
access to the drug and no community group should be left out. Thus, including preschool-
aged children is justified from public health and equity points of view and will allow reducing 
the treatment gap which might also have an effect on transmission control (Johansen et al., 
2007; Stothard et al., 2011). While MDA have reduced the prevalence of schistosomiasis to 
less than 10% in school-aged children in several countries implementing PCT, it is not 
reasonable to keep the preschool-aged children untreated and let them be an important 
reservoir of transmission in the community. Recent studies not only showed that PZQ is safe 
and efficacious in preschool-aged children, but also developed and proposed a dose-pole for 
easy treatment of young children during MDA (Sousa-Figueiredo et al., 2009, 2010; Mutapi 
et al., 2011). However this dose pole needs to be further validated in other settings. The 
current PhD thesis showed that PZQ syrup is safe and efficacious. Logistic concerns about the 
introduction of syrup in MDA come mainly from the management of the volume of drug and, 
consequently, the cost of transport and storage. 
Another issue is the need of paediatric scale to weight preschool-aged children, but this 
could be solved if the proposed dose-pole is further validated in other settings. Experiences in 
countries endemic for trachoma where Zithromax® syrup is distributed proved that 
distribution of syrup during MDA is indeed feasible. Additional studies are underway in Mali, 
Burkina Faso and Niger and, thus far, no major problems have been raised (Zoerhoff et al., 
2011). Zithromax® syrup bottles are considerably larger than the one used for PZQ and 
contain dry powder, which needs to be mixed with clean water before administration. Storage 
problems have been observed at country level and in some districts because of the large 
volume of the syrup. In the case of PZQ syrup, however, the volume is certainly much lower 
considering the fact that PZQ bottles are smaller than the ones currently used for zithromax®, 
and also because of the limited target of the syrup, which determine the quantity of drug. 
Schistosomiasis is focal in endemic communities, while the distribution of trachoma drug is 
district-wide for all the children. However, before including the syrup in MDA, there is a need 
to improve the bioavailability of the PZQ syrup. Meanwhile, crushed tablet which have a 
similar efficacy with syrup can continue to be used. 
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9. Research needs 
This PhD thesis identified a number of research needs, which are offered for 
consideration. We believe that addressing some of these identified needs will contribute to 
further enhance and reinforcement of the control of schistosomiasis in sub-Saharan Africa. 
• Laboratory and field studies to investigate the low susceptibility of S. mansoni to PZQ 
are necessary. These studies should have robust protocols and focuses on genetic 
studies of the S. mansoni strains as well in vivo and vitro efficacy tests. 
• Large-scale studies (at district level) of MDA including administration of PZQ syrup 
should be undertake to identify all the details of the operations issues that will be 
raised by the introduction of PZQ syrup in PCT. 
• Cost and epidemiologic studies aiming to compare the effectiveness of a continued 
MDA and an increased mapping with target treatment should be conducted in order to 
choose the best economic and morbidity control approach to maintain the reduction of 
morbidity achieved. 
• Studies aiming to determine the minimum coverage rate of MDA to have an impact on 
transmission are important to deal with systematic non compliance for repeated rounds 
of MDAs. 
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